v0.5.1: disable apply_patch in agents prone to append-mode failures

Root cause: apply_patch finds anchor lines in read-cached file state,
but file may have been modified between read and patch, causing stalls.

Changes:
- dr-verifier: disable apply_patch AND edit; force read-then-write protocol for evidence file appends
- dr-analyst: document write-preferred protocol for sources.jsonl appends
- dr-polisher: disable apply_patch; keep edit for small string replacements
- dr-editor-in-chief / dr-translator: disable apply_patch

Recovery procedure documented in dr-verifier for write failures.

.opencode/agents/dr-analyst.md

@@ -114,9 +114,18 @@ Write to `projects/<slug>/phase2/evidence/chXX-evidence.md` (English).
 
 ### Step 7: Write to Files
 
-- Draft: `projects/<slug>/phase2/drafts/chXX.md` (English)
+**File writing protocol (v0.5.1)** — prefer `write` over `edit`/`apply_patch` for these files, because they are created fresh by you:
-- Evidence matrix: `projects/<slug>/phase2/evidence/chXX-evidence.md` (English)
+
-- New sources appended: `projects/<slug>/phase2/sources.jsonl`
+- Draft: `projects/<slug>/phase2/drafts/chXX.md` (English) — use `write` to create
+- Evidence matrix: `projects/<slug>/phase2/evidence/chXX-evidence.md` (English) — use `write` to create
+- Sources: `projects/<slug>/phase2/sources.jsonl` — read current content, append new source lines in memory, then `write` the full new content (do NOT use `apply_patch` to append JSONL lines — it often fails on whitespace matching)
+
+**If you need to revise a file you already wrote in this session** (e.g., after a self-check you want to extend a section):
+1. `read` the file to get current content
+2. Compose the new full content in memory
+3. `write` the full content (overwrites atomically)
+
+Do NOT use `apply_patch` to append content. This has caused task stalls in production (v0.4 lessons).
 
 ### Step 8: Report Back
 

.opencode/agents/dr-editor-in-chief.md

@@ -7,6 +7,7 @@ tools:
   read: true
   write: true
   edit: true
+  apply_patch: false
   bash: true
   skill: true
   task: true

.opencode/agents/dr-polisher.md

@@ -7,6 +7,8 @@ temperature: 0.4
 tools:
   read: true
   edit: true
+  write: true
+  apply_patch: false
   bash: true
   skill: true
 permission:
@@ -22,6 +24,17 @@ permission:
     "*": deny
 ---
 
+## File Writing Protocol (v0.5.1)
+
+- `edit` tool is OK for **small, precise string replacements** (e.g., replacing a禁用词 like "赋能" → "帮助"). These are safe because the search string is short and unique.
+- `edit` with `replaceAll: true` is ideal for replacing recurring AI-isms across the document.
+- **Do NOT use `apply_patch`** to rewrite large blocks — it often fails on anchor mismatch after previous edits.
+- **If you need to rewrite a large block** (e.g., restructure a whole paragraph), use the read-then-write protocol:
+  1. `read` the file
+  2. Compose full new content in memory
+  3. `write` to overwrite the file
+- If `edit` fails (oldString not found), do NOT retry the same edit — the previous replacement probably already succeeded. Re-read the file to confirm.
+
 # 角色：dr-polisher — 中文润色与输出卫生
 
 你是生物医药报告的中文编辑。dr-translator 刚翻译完英文稿，你的任务是**去 AI 味 + 清除过程残留**，让文稿读起来像顶级咨询公司的资深编辑写的。

.opencode/agents/dr-translator.md

@@ -8,6 +8,7 @@ tools:
   read: true
   write: true
   edit: true
+  apply_patch: false
   bash: true
   skill: true
 permission:

.opencode/agents/dr-verifier.md

@@ -6,7 +6,9 @@ model: zenmux/openai/gpt-5.4
 temperature: 0.2
 tools:
   read: true
-  edit: true
+  write: true
+  edit: false
+  apply_patch: false
   webfetch: true
   skill: true
 permission:
@@ -26,11 +28,25 @@ You are the "devil's advocate" of the Deep Research system. Your job is **active
 
 You run on GPT-5.4 (not Claude) specifically to provide independent cross-model verification and avoid same-source bias with dr-analyst (Claude Sonnet).
 
+## CRITICAL: File Writing Protocol (v0.5.1)
+
+**DO NOT USE `apply_patch` OR `edit` TOOLS ON EVIDENCE FILES.**
+
+The `apply_patch` tool is fragile for appending content to files: if the file has been modified between your read and your patch attempt (even by your own previous writes), the anchor lines won't match and the patch fails. This bug has caused multiple task stalls.
+
+**Use this protocol instead — "read-then-rewrite"**:
+
+1. **Read** the full current content of `chXX-evidence.md` using the `read` tool.
+2. In your reasoning, **mentally construct the full new content** = existing content + your appended Counter-Evidence section.
+3. **Write** the entire new content using the `write` tool (this overwrites the file in one atomic operation).
+4. **Never** call `apply_patch` or `edit` as a fallback if write fails. Instead: re-read, re-append, write again.
+
+The `edit` and `apply_patch` tools are disabled for this agent in v0.5.1.
+
 ## Required Skills
 
 1. `search-strategy` — Source prioritization
 2. `source-quality` — Scoring standards
-3. `humanizer-cn` — Writing style (§1-26 English side)
 
 ## Core Workflow
 
@@ -38,9 +54,15 @@ dr-pm assigns you:
 - Chapter draft path: `projects/<slug>/phase2/drafts/chXX.md`
 - Evidence matrix path: `projects/<slug>/phase2/evidence/chXX-evidence.md`
 
-### Step 1: Read the Chapter
+### Step 1: Read the Chapter and Current Evidence
 
-Extract all core claims (statements with `[src_xxx]` annotations).
+Read **both** files in full:
+- `projects/<slug>/phase2/drafts/chXX.md` (to extract claims)
+- `projects/<slug>/phase2/evidence/chXX-evidence.md` (current state, you will append to this)
+
+Keep the exact text of `chXX-evidence.md` in your context — you will need it verbatim in Step 5.
+
+Extract all core claims from the draft (statements with `[src_xxx]` annotations).
 
 ### Step 2: Counter-Evidence Search
 
@@ -50,22 +72,28 @@ For each core claim, search:
 - `"<claim keyword>" criticism OR opposing`
 - Chinese equivalents: `<关键词> 质疑 OR 争议 OR 失败`
 
+Run 3-5 webfetch queries per claim, prioritizing Tier 1-2 sources.
+
 ### Step 3: Data Sanity Check
 
 Verify all numbers in the chapter:
 - Order of magnitude reasonable (market size, success rate within industry norms)
 - Time logic consistent
-- Cross-chapter data consistency (check against framework.md)
+- Cross-chapter data consistency (read framework.md to check)
 
 ### Step 4: Backfill Unverified Claims
 
-For claims marked `[Unverified: only X source(s)]`, try to find a second independent source. If successful, add to evidence matrix. If still unable, keep the flag.
+For claims marked `[Unverified: only X source(s)]`, search for a second independent source. Note findings for Step 5.
 
-### Step 5: Write Verification Output
+### Step 5: Write Verification Output (CRITICAL — use write tool, not apply_patch)
 
-**Append** to `projects/<slug>/phase2/evidence/chXX-evidence.md` at the end:
+**Compose the full new file content in memory**:
+
+```
+<existing content of chXX-evidence.md, unchanged, from Step 1>
+
+---
 
-```markdown
 ## Counter-Evidence Review (by dr-verifier, GPT-5.4)
 
 ### Verification Summary
@@ -76,15 +104,23 @@ For claims marked `[Unverified: only X source(s)]`, try to find a second indepen
 
 ### Counter-Evidence Details
 
-#### On Claim C01: <short summary of the challenged claim>
+#### CE01 — <short judgment title>
-- Counter-evidence: <content>
+<2-3 paragraphs of counter-evidence discussion>
 - Source: [src_xxx] | Tier X | Score X
-- Recommendation: keep claim with caveat / revise wording / delete claim
+- Handling: keep with caveat / revise wording / delete claim
+
+#### CE02 — ...
 
 [If critical challenge exists:]
 🚨 CRITICAL: <explain why this counter-evidence could overturn the chapter's core judgment>
 ```
 
+**Then call `write` tool ONCE with the complete new content** to overwrite `projects/<slug>/phase2/evidence/chXX-evidence.md`.
+
+**If the Counter-Evidence Review section already exists in the file** (e.g., you're running a second round on the same chapter):
+- Do NOT add a second Counter-Evidence Review section
+- Instead, skip this chapter and report back: "Chapter already has Counter-Evidence Review. Skipping."
+
 ### Step 6: Report Back
 
 Return to dr-pm:
@@ -94,16 +130,38 @@ Core claims reviewed: X
 Counter-evidence found: X
 Unverified claims backfilled: X
 CRITICAL challenges: X (flagged in evidence file)
-File updated: phase2/evidence/chXX-evidence.md
+File updated: phase2/evidence/chXX-evidence.md (N lines → M lines)
 ```
 
 ---
 
+## If `write` fails
+
+Do NOT retry with `apply_patch` or `edit` (those tools are disabled for this agent anyway).
+
+Recovery procedure:
+1. Re-read `chXX-evidence.md` to see the current state
+2. Check if your Counter-Evidence section is already in the file — if yes, you're done, just report back
+3. If not, recompose the full content (existing + your append) and try `write` again
+4. If `write` fails 3 times in a row, report back with:
+   ```
+   WRITE FAILURE: Ch X
+   Attempts: 3
+   Last error: <error message>
+   Current evidence file state: <first 200 chars>
+   My intended Counter-Evidence content: <paste it here>
+   ```
+   This gives dr-pm visibility and the human can manually intervene.
+
+---
+
 ## Hard Rules
 
 1. ✅ Never edit chapter draft (chXX.md), only evidence file (chXX-evidence.md)
-2. ✅ Never filter out counter-evidence just to protect the chapter's conclusion
+2. ✅ Never use `apply_patch` or `edit` on evidence file — always `read` then `write` full content
-3. ✅ Flag CRITICAL when counter-evidence could overturn core judgment
+3. ✅ Never filter out counter-evidence just to protect the chapter's conclusion
-4. ✅ Chinese keyword searches mandatory for China-market claims
+4. ✅ Flag CRITICAL when counter-evidence could overturn core judgment
-5. ❌ Never delegate to other agents
+5. ✅ Chinese keyword searches mandatory for China-market claims
-6. ❌ Never fabricate counter-evidence
+6. ✅ If Counter-Evidence section already exists, skip (don't double-append)
+7. ❌ Never delegate to other agents
+8. ❌ Never fabricate counter-evidence

projects/dual-target-rnai-pipeline-2026/manifest.json

@@ -0,0 +1,282 @@
+{
+  "slug": "dual-target-rnai-pipeline-2026",
+  "topic": "双靶点RNAi药物研发进展和国内外在研管线",
+  "report_title": "双靶点 RNAi 药物工艺图谱与上游供应链机会研究",
+  "report_subtitle": "近 5 年全球在研管线的合成、偶联与酶催化技术路径解构（2021–2026）",
+  "author": "Deep Research 系统",
+  "date": "2026-04-21",
+  "version": "1.0",
+  "type": "综述",
+  "confidentiality": "机密 | 仅供内部决策使用",
+  "audience": "研发团队（上游供应链 / 工业用酶 / 无细胞表达 / 固定化酶催化方向）",
+  "time_range": "近 5 年（2021-01 至 2026-04）",
+  "geography": "全球对比（中美欧日为主）",
+  "core_questions": [
+    "近 5 年全球与中国在研的双靶点 RNAi 药物管线有哪些？分别采用何种靶点组合、技术平台与开发阶段？",
+    "双靶点 siRNA 的分子设计路径（串联/偶联/cocktail/多价支架）有哪些？各自工艺差异与关键壁垒是什么？",
+    "双靶点 siRNA 的合成工艺（固相/液相/酶法/无细胞表达）和偶联化学（GalNAc、多价簇、支架连接）在各家管线中的实现方式有何不同？",
+    "序列合成、偶联化学、纯化等环节上，上游供应链（工业用酶原料、固定化酶催化、无细胞表达体系、亚磷酰胺单体、GalNAc 配体、固相载体等）存在哪些国产替代与卡位机会？",
+    "从工艺复杂度与规模化成本角度，哪些双靶点 RNAi 技术路线最有可能率先走向商业化？对应的上游供应机会窗口与切入点是什么？"
+  ],
+  "comparison_targets": [
+    "Alnylam Pharmaceuticals",
+    "Arrowhead Pharmaceuticals",
+    "Silence Therapeutics",
+    "Dicerna / Novo Nordisk",
+    "Ionis (siRNA 相关项目)",
+    "瑞博生物 (Ribo Life Science)",
+    "舶望制药 (Argo Biopharma)",
+    "大睿生物 (Sirnaomics / Da Rui)",
+    "圣诺制药 (Sirnaomics)",
+    "悦康药业 / 君圣泰 / 石药 / 恒瑞 等国内 siRNA 玩家",
+    "双靶点 siRNA cocktail 与多价 siRNA 支架相关项目"
+  ],
+  "exclusions": [
+    "不展开讨论具体适应症的临床有效性与安全性细节（临床进度仅作为管线标签使用）",
+    "不涉及 mRNA / ASO / saRNA / 基因编辑等非 siRNA 模态的工艺细节（仅在对比位置点到为止）",
+    "不做市场容量 / 销售预测 / 估值分析（报告面向上游供应链而非投资人）",
+    "不展开疾病机制与药理学讨论"
+  ],
+  "word_budget_mode": "auto",
+  "target_words_zh": 21000,
+  "target_words_en": 15000,
+  "min_words_zh": 17000,
+  "min_words_en": 12000,
+  "disclaimer": "本报告基于公开信息与 AI 辅助研究生成，仅供参考，不构成投资或医疗建议。",
+  "work_language": "en",
+  "output_language": "zh",
+  "phase1": {
+    "status": "approved",
+    "approved": true,
+    "approved_at": "2026-04-21T05:42:34Z",
+    "approved_note": "User implicitly approved by executing /dr-research",
+    "framework_path": "projects/dual-target-rnai-pipeline-2026/phase1/framework.md",
+    "initial_scan_path": "projects/dual-target-rnai-pipeline-2026/phase1/initial-scan.md",
+    "initial_scan_index_path": "projects/dual-target-rnai-pipeline-2026/phase1/initial-scan-index.md",
+    "chapter_count": 10,
+    "revision_note": "v2: 按用户反馈重构 — 拆出 Ch6 (固定化酶) 与 Ch7 (QC 酶) 独立章；Ch9 改为 FDA/NMPA/ICH 针对性监管分析（BIOSECURE 仅一句话背景）；字数升档至 15000 EN / 21000 ZH；每章增 Technical Hooks 字段便于专家判断真假机会；初扫 63 条信源输出为 initial-scan-index.md 供 Phase 2 pickup。",
+    "central_thesis_en": "The true competitive frontier of dual-target RNAi is not the second siRNA strand but the manufacturing stack beneath it — multivalent GalNAc assembly, enzymatic ligation, immobilized biocatalysis, and the quietly scarce GMP-grade QC enzymes are the choke points. Four upstream nodes (specialty phosphoramidite monomers, high-load solid supports, immobilized glycosyl-transfer biocatalysis, QC enzymes) concentrate most of the opportunity for suppliers who can simultaneously meet NMPA 2026 chemoenzymatic guidance and FDA/ICH Q11-Q13 expectations.",
+    "central_thesis_zh": "双靶点 RNAi 的真正竞争前沿不是'加一条 siRNA 链'，而是其下的制造栈 — 多价 GalNAc 组装、酶法连接、固定化生物催化，以及常被忽视却持续短缺的 GMP 级 QC 酶。机会集中在四个上游环节：专用亚磷酰胺单体、高载量固相载体、固定化糖基转移/酯化生物催化、寡核苷酸 QC 酶；能同时满足中国 NMPA 2026 化学酶连指导原则与 FDA/ICH Q11-Q13 体系要求的供应商，将获取最大的结构性红利。",
+    "chapter_quotas_en": [
+      {
+        "index": 1,
+        "title_en": "Why the Second Strand Matters Less Than the Stack Beneath It",
+        "title_zh": "双靶点的真正战场不在'加第二条链'，而在其下的制造栈",
+        "en_words": 1050,
+        "priority": "intro"
+      },
+      {
+        "index": 2,
+        "title_en": "Dual-Target Design Space Has Already Bifurcated into Four Paradigms, Each with a Different Process Signature",
+        "title_zh": "双靶点设计空间已分化为四种范式，每种都带出一条工艺签名",
+        "en_words": 1500,
+        "priority": "P0"
+      },
+      {
+        "index": 3,
+        "title_en": "The Global Pipeline Is Denser than the Headlines Suggest, but China Is Adding Assets Faster than Anyone Else",
+        "title_zh": "全球管线比头条更密，但中国正在以最快速度堆积资产",
+        "en_words": 1500,
+        "priority": "P0"
+      },
+      {
+        "index": 4,
+        "title_en": "Solid-Phase Remains the Default, but the Competitive Edge Is Shifting to Liquid-Phase and Enzymatic Ligation",
+        "title_zh": "固相合成仍是默认路线，但竞争优势正在向液相与酶法连接迁移",
+        "en_words": 1800,
+        "priority": "P0"
+      },
+      {
+        "index": 5,
+        "title_en": "Multivalent GalNAc Cluster Chemistry: How the Industry Assembles Three-to-Seven Sugars onto a Single Oligo",
+        "title_zh": "多价 GalNAc 簇化学：行业如何把 3-7 个糖装到同一条寡核苷酸上",
+        "en_words": 1800,
+        "priority": "P0"
+      },
+      {
+        "index": 6,
+        "title_en": "Immobilized Biocatalysis Enters the GalNAc-Conjugation Pipeline — From Lab Curiosity to GMP Candidate",
+        "title_zh": "固定化生物催化进入 GalNAc 偶联流水线 — 从实验室新奇到 GMP 候选",
+        "en_words": 1650,
+        "priority": "P0"
+      },
+      {
+        "index": 7,
+        "title_en": "QC Enzymes and Process-Analytical Biocatalysts: The Quietly Scarce Third Pillar",
+        "title_zh": "QC 酶与工艺分析用生物催化剂：被忽视却紧缺的第三支柱",
+        "en_words": 1500,
+        "priority": "P0"
+      },
+      {
+        "index": 8,
+        "title_en": "Four Upstream Choke Points Define the Opportunity Map",
+        "title_zh": "四个上游咽喉点定义了机会图谱",
+        "en_words": 1650,
+        "priority": "P0"
+      },
+      {
+        "index": 9,
+        "title_en": "Regulatory Vectors Reshaping the Supply Chain: NMPA Chemoenzymatic Guidance, FDA Oligonucleotide CMC Signals, ICH Q11/Q13",
+        "title_zh": "重塑供应链的监管向量：NMPA 化学酶连指导原则、FDA 寡核苷酸 CMC 信号、ICH Q11/Q13",
+        "en_words": 1200,
+        "priority": "P1"
+      },
+      {
+        "index": 10,
+        "title_en": "Conclusions and Upstream Action Priorities, with Technical Thresholds",
+        "title_zh": "结论与上游行动优先级（附技术门槛）",
+        "en_words": 1350,
+        "priority": "conclusion"
+      }
+    ],
+    "total_en_quota": 15000,
+    "total_zh_quota_est": 21000,
+    "source_count": 63,
+    "source_tier_distribution": {
+      "tier_1": 27,
+      "tier_2": 36
+    },
+    "phase2_search_gaps": [
+      "FDA 寡核苷酸 CMC 指导原则原文",
+      "ICH Q3D Cu PDE 具体数值（原文）",
+      "ICH Q13 continuous manufacturing 对寡核苷酸酶法合成的适用性",
+      "Vazyme / Yeasen / Sangon 等国内 QC 酶产品线与 GMP 认证状态",
+      "瑞博 / 舶望 / 圣因 / 必贝特 CNIPA 中文专利说明书",
+      "TIDES 2024-2025 会议摘要（Codexis ECO / Nitto CPOS / Hongene 工艺披露）",
+      "GreenLight Biosciences 当前资产归属状态"
+    ]
+  },
+  "phase2": {
+    "status": "in_progress",
+    "started_at": "2026-04-21T05:42:34Z",
+    "current_batch": 2,
+    "batches": [
+      {
+        "batch": 1,
+        "chapters": [
+          1
+        ],
+        "note": "Intro chapter — solo"
+      },
+      {
+        "batch": 2,
+        "chapters": [
+          2,
+          3,
+          4
+        ],
+        "note": "Design paradigms + Pipeline + Synthesis"
+      },
+      {
+        "batch": 3,
+        "chapters": [
+          5,
+          6,
+          7
+        ],
+        "note": "GalNAc chemistry + Immobilized biocatalysis + QC enzymes"
+      },
+      {
+        "batch": 4,
+        "chapters": [
+          8,
+          9
+        ],
+        "note": "Choke points + Regulatory"
+      },
+      {
+        "batch": 5,
+        "chapters": [
+          10
+        ],
+        "note": "Conclusion chapter — solo"
+      }
+    ],
+    "chapters": [
+      {
+        "index": 1,
+        "status": "verified",
+        "en_words_actual": 1124,
+        "en_words_quota": 1050,
+        "sources_new": 10,
+        "unverified": 2,
+        "critical": 1,
+        "actual_words": 1124,
+        "sources_count": 15
+      },
+      {
+        "index": 2,
+        "status": "verified",
+        "en_words_quota": 1500,
+        "actual_words": 1551,
+        "sources_count": 18,
+        "unverified_count": 0,
+        "verified_at": "2026-04-21T06:33:54.794537Z"
+      },
+      {
+        "index": 3,
+        "status": "verified",
+        "en_words_quota": 1500,
+        "actual_words": 1586,
+        "sources_count": 17,
+        "unverified_count": 0,
+        "verified_at": "2026-04-21T06:33:54.794537Z"
+      },
+      {
+        "index": 4,
+        "status": "verified",
+        "en_words_quota": 1800,
+        "actual_words": 2113,
+        "sources_count": 21,
+        "unverified_count": 0,
+        "verified_at": "2026-04-21T06:33:54.794537Z"
+      },
+      {
+        "index": 5,
+        "status": "pending",
+        "en_words_quota": 1800
+      },
+      {
+        "index": 6,
+        "status": "pending",
+        "en_words_quota": 1650
+      },
+      {
+        "index": 7,
+        "status": "pending",
+        "en_words_quota": 1500
+      },
+      {
+        "index": 8,
+        "status": "pending",
+        "en_words_quota": 1650
+      },
+      {
+        "index": 9,
+        "status": "pending",
+        "en_words_quota": 1200
+      },
+      {
+        "index": 10,
+        "status": "pending",
+        "en_words_quota": 1350
+      }
+    ],
+    "batches_summary": [
+      {
+        "batch": 1,
+        "chapters": [
+          1
+        ],
+        "completed_at": "2026-04-21T06:00:00Z",
+        "summary": "Ch1 (1124 words, 10 new sources src_E01-E10, 2 unverified: GalNAc cycle-time claim + 3x QC-enzyme demand inference). 1 CRITICAL: draft overstates unimolecular dual-target superiority vs. cocktail; dr-analyst in Ch2/10 must balance. C05 Wang et al. 2025 JAMA Cardiology PMID 40105833 resolved."
+      }
+    ]
+  },
+  "phase3": {
+    "status": "pending"
+  },
+  "phase4": {
+    "status": "pending"
+  }
+}

projects/dual-target-rnai-pipeline-2026/phase1/framework.md

@@ -0,0 +1,402 @@
+# 双靶点 RNAi 药物工艺图谱与上游供应链机会研究
+
+**副标题**：近 5 年全球在研管线的合成、偶联与酶催化技术路径解构（2021–2026）
+
+**英文主标题（Working Title, EN）**：*Dual-Target RNAi Drug Process Atlas and Upstream Supply-Chain Opportunity Map*
+**副标题（EN）**：*Decoding Synthesis, Conjugation, and Enzyme-Catalysis Pathways across the Global Pipeline, 2021–2026*
+
+---
+
+## 元信息 / Meta
+
+| 字段 | 值 |
+|---|---|
+| 研究类型 | 综述（Review，扩至 detailed 档下限） |
+| 字数模式 | auto → 用户要求"往上加 + 技术锚点锐化" |
+| 目标字数 | **≈ 15,000 EN words / 21,000 ZH chars**（下限 12,000 EN / 17,000 ZH） |
+| 核心受众 | 上游供应链研发团队（工业用酶 / 无细胞表达 / 固定化酶催化 / QC 酶 / 单体-载体方向） |
+| 时间范围 | 近 5 年（2021-01 至 2026-04） |
+| 地理范围 | 全球对比（中美欧日为主） |
+| 工作语言 | English（Phase 2-3） |
+| 输出语言 | 中文（Phase 4 翻译） |
+| 章节数 | **10 章**（含引言与结论） |
+
+### 核心问题 / Core Questions
+
+**中文：**
+1. 近 5 年全球与中国在研的双靶点 RNAi 药物管线有哪些？采用何种靶点组合、技术平台与开发阶段？
+2. 双靶点 siRNA 的分子设计路径（串联 / 偶联 / cocktail / 多价支架）有哪些？工艺差异与关键壁垒？
+3. 双靶点 siRNA 的合成、偶联、QC 工艺在各家管线中的实现方式有何不同？
+4. 序列合成、偶联化学、QC 酶、纯化等环节上，上游供应链存在哪些国产替代与卡位机会？
+5. 哪些双靶点 RNAi 技术路线最可能率先商业化？对应的上游供应机会窗口与技术锚点？
+
+**English:**
+1. What dual-target RNAi assets are in active development globally and in China over 2021-2026?
+2. What molecular design paradigms (tandem / covalent / cocktail / multivalent scaffold) define dual-target siRNA, and what process differences and bottlenecks do they impose?
+3. How do synthesis, conjugation, and QC workflows vary across global and Chinese pipelines?
+4. At which supply-chain nodes (industrial enzymes, immobilized catalysis, cell-free systems, phosphoramidite monomers, GalNAc ligands, solid supports, QC enzymes) do domestic-substitution and disruptive opportunities exist?
+5. Which dual-target technical routes are most likely to reach commercial scale first, and which upstream entry points offer the largest opportunity windows — with what technical thresholds?
+
+### 禁区 / Exclusions
+
+- 不展开适应症与临床有效性细节（临床进度仅作为管线标签）
+- 不涉及 mRNA / ASO / saRNA / 基因编辑等非 siRNA 模态工艺细节
+- 不做市场估值 / 销售预测 / 投资测算
+- 不展开疾病机制与药理学讨论
+- **BIOSECURE 法案只在 Ch 9 作为背景要素一句话点到，不展开**
+
+---
+
+## Central Thesis / 全局论点
+
+**EN**: The true competitive frontier of dual-target RNAi is not the second siRNA strand but the manufacturing stack beneath it — multivalent GalNAc assembly, enzymatic ligation, immobilized biocatalysis, and the quietly scarce GMP-grade QC enzymes are the choke points that will decide which platforms reach commercial scale. Four upstream nodes — specialty phosphoramidite monomers, high-load solid supports, immobilized glycosyl-transfer biocatalysis, and sequencing/digestion/phosphatase QC enzymes — concentrate most of the opportunity for suppliers who can simultaneously meet Chinese NMPA's 2026 chemoenzymatic guidance and FDA/ICH Q11-Q13 style expectations.
+
+**中文**：双靶点 RNAi 的真正竞争前沿不是"加一条 siRNA 链"，而是其下的制造栈 — 多价 GalNAc 组装、酶法连接、固定化生物催化，以及常被忽视却持续短缺的 GMP 级 QC 酶，是决定平台能否走向规模化的工艺节点。机会集中在四个上游环节：专用亚磷酰胺单体、高载量固相载体、固定化糖基转移/酯化生物催化、寡核苷酸测序/酶切/磷酸酶等 QC 酶；能同时满足中国 NMPA 2026 化学酶连指导原则与 FDA/ICH Q11-Q13 体系要求的供应商，将获取最大的结构性红利。
+
+---
+
+## 章节大纲 / Chapter Outline
+
+### Chapter 1 / 第 1 章 — Why the Second Strand Matters Less Than the Stack Beneath It
+
+**中文标题**：双靶点的真正战场不在"加第二条链"，而在其下的制造栈
+
+- **Priority**: intro
+- **Word quota**: 1,050 EN (≈ 1,500 ZH) — 7%
+- **Core research question (EN)**: Why has the industry converged on "dual-target" as the design label, and what does that label hide about the underlying manufacturing shift?
+- **Preliminary hypothesis (EN)**: The visible innovation is molecular (second siRNA, smarter scaffold); the real bottleneck has migrated to conjugation chemistry, multivalent ligand assembly, QC-enzyme supply, and enzymatic ligation.
+- **Expected sources**: src_A01, src_A05, src_A07, src_B02, src_C01, src_C04, src_D01
+
+- **1.1** From monogenic silencing to combinatorial target logic / 从单基因沉默走到组合靶点
+  - Research thinking (EN): Map Alnylam approvals timeline + 2023-2026 pipeline density (APOC3+ANGPTL3, AGT+PCSK9, complement pairs).
+- **1.2** The manufacturing shock hidden behind that shift / 分子设计跃迁背后隐藏的工艺位移
+  - Research thinking (EN): Quantify how each design paradigm adds synthetic steps, elevates monomer diversity, and raises conjugation complexity.
+- **1.3** What this report does and why it's written for upstream suppliers / 报告逻辑与读者路径
+  - Research thinking (EN): Thesis statement, chapter roadmap, source base (63 Tier 1-2 sources indexed in `initial-scan-index.md`), methodology.
+
+---
+
+### Chapter 2 / 第 2 章 — Dual-Target Design Space Has Already Bifurcated into Four Paradigms, Each with a Different Process Signature
+
+**中文标题**：双靶点设计空间已分化为四种范式，每种都带出一条工艺签名
+
+- **Priority**: P0
+- **Word quota**: 1,500 EN (≈ 2,100 ZH) — 10%
+- **Core research question (EN)**: What are the four dominant dual-target design paradigms and which process constraints does each impose?
+- **Preliminary hypothesis (EN)**: Covalent-linker, multivalent-GalNAc, di-valent scaffold, and cocktail paradigms diverge sharply in step count, monomer needs, and purification complexity.
+- **Technical hooks (for expert judgment)**:
+  - Step count per duplex (solid-phase cycles, convergent couplings)
+  - Monomer diversity index (# distinct phosphoramidites per construct)
+  - Linker cleavage trigger (disulfide, acid-labile, lysosomal, nuclease)
+  - Scaffold valency (1 / 2 / 3 / 4 / ≥5 GalNAc units)
+  - Duplex vs. multi-strand annealing complexity (how many strands to anneal under what ionic conditions)
+- **Expected sources**: src_A01, src_A02, src_A06, src_A08, src_A09, src_A10, src_A12, src_C03, src_C06
+
+- **2.1** Covalently-linked tandem siRNAs — Alnylam-style disulfide/linker route / 共价连接串联 siRNA
+  - Research thinking (EN): Deconstruct US9187746 claim scope + linker chemistry from src_A01; quantify extra deprotection/unwinding burden.
+  - Technical hooks: disulfide-bond redox window, unwinding kinetics at 37 °C, linker stability in serum > 48 h.
+- **2.2** Multivalent GalNAc clusters — scaffold as combined delivery + design unit / 多价 GalNAc 簇
+  - Research thinking (EN): Compare pyran (src_A02), ribofuranose (src_A04), diamine scaffold (src_A10); explicit on convergent-synthesis demand at valency ≥ 4.
+  - Technical hooks: ASGPR Kd by valency (nM range), cluster radius (Å), solution-state cluster integrity (CD spectroscopy).
+- **2.3** Di-valent and branched scaffolds — Khvorova/UMass programmable track / 二价与分枝支架
+  - Research thinking (EN): src_A06 di-siRNA in CNS as anchor; src_A09 branched dendritic multi-siRNA; flag that QC enzymes (nuclease P1, RNase T1) become mandatory for duplex verification.
+  - Technical hooks: scaffold symmetry, branch-point stability, serum half-life without lipid carrier.
+- **2.4** Cocktail / muRNA — Sirnaomics engineered-labile alternative / 混合 / muRNA
+  - Research thinking (EN): src_A12 GalAhead™; contrast manufacturing simplicity vs. CMC identity challenges (how do regulators define "the API" when composition is defined by ratio).
+  - Technical hooks: labile-linker cleavage T½, intracellular release kinetics, composition-ratio CV across batches.
+
+---
+
+### Chapter 3 / 第 3 章 — The Global Pipeline Is Denser than the Headlines Suggest, but China Is Adding Assets Faster than Anyone Else
+
+**中文标题**：全球管线比头条更密，但中国正在以最快速度堆积资产
+
+- **Priority**: P0
+- **Word quota**: 1,500 EN (≈ 2,100 ZH) — 10%
+- **Core research question (EN)**: How many dual-target RNAi programs exist globally, what target combinations dominate, and where is China on the velocity curve?
+- **Preliminary hypothesis (EN)**: Global active pipeline ≈ 10-15 disclosed dual-target programs in Phase 1-2; China accounts for close to half of new INDs filed 2023-2026.
+- **Technical hooks**:
+  - Target combination rationale (pharmacology-driven vs. pipeline-efficiency-driven)
+  - Disclosed vs. inferred (non-disclosed) dual-target constructs
+  - Platform labels (RiboGalSTAR™, RADS, PDoV-GalNAc, branched-linker) mapped to design paradigms from Ch 2
+  - Dosing interval (single-dose / Q3M / Q6M) as proxy for chemistry maturity
+- **Expected sources**: src_A05, src_A07, src_A11, src_A13, src_A14, src_A15, src_D11, src_D12
+
+- **3.1** Disclosed global dual-target set — real pipeline vs. marketing labels / 已披露的全球双靶点集合
+  - Research thinking (EN): Cross-reference ClinicalTrials.gov + 10-K + systematic review (src_A05); remove double-counting.
+- **3.2** Target-combination clustering and why cardiometabolic owns the field / 靶点组合聚类
+  - Research thinking (EN): APOC3+ANGPTL3, AGT+PCSK9, complement pairs; explain ASGPR density on hepatocytes (~10⁶/cell) as the anatomic reason for liver monoculture.
+- **3.3** China's velocity story — what 瑞博 / 舶望 / 圣因 / 必贝特 are actually building / 中国速度
+  - Research thinking (EN): src_A14, src_A15 + 医药魔方/Insight cross-check; structure by **platform** (RiboGalSTAR™, RADS, PDoV-GalNAc, BEBT branched linker) not asset list — each platform's process signature previews Ch 4-7.
+
+---
+
+### Chapter 4 / 第 4 章 — Solid-Phase Remains the Default, but the Competitive Edge Is Shifting to Liquid-Phase and Enzymatic Ligation
+
+**中文标题**：固相合成仍是默认路线，但竞争优势正在向液相与酶法连接迁移
+
+- **Priority**: P0
+- **Word quota**: 1,800 EN (≈ 2,500 ZH) — 12%
+- **Core research question (EN)**: For dual-target siRNA, how do solid-phase, liquid-phase, enzymatic, and cell-free IVT modalities compare on step count, yield, scalability, and cost-per-gram, and which wins for which construct?
+- **Preliminary hypothesis (EN)**: Solid-phase holds on short heavily-modified strands; LPOS and enzymatic ligation win when construct length × modification density exceeds a threshold; cell-free IVT remains long-RNA niche until modified-nucleotide incorporation matures.
+- **Technical hooks**:
+  - Per-cycle coupling efficiency (>99.0%, >99.5%, >99.8%) and cumulative yield decay for n = 20 / 40 / 60 nt
+  - Solvent consumption per mmol (L of acetonitrile / mol; AJIPHASE claim: 50-70% reduction)
+  - Batch size achievable (mmol, g, kg)
+  - DMT-on / DMT-off strategy and how it affects purification load
+  - Incorporation efficiency for 2'-F, 2'-OMe, LNA, GalNAc-phosphoramidite (should be ≥ 98% per position)
+  - Enzymatic ligation fidelity (ligase specificity, mismatch rate, substrate concentration window)
+  - IVT modified-NTP incorporation limit (pseudo-U, 2'-F-NTP still sparse vs. natural)
+- **Expected sources**: src_B01, src_B02, src_B03, src_B05, src_B06, src_B08, src_B09, src_B10, src_B11, src_B12, src_B14, src_B16, src_B18
+
+- **4.1** Solid-phase phosphoramidite synthesis and where its ceiling is / 固相亚磷酰胺合成：已见天花板在哪里
+  - Research thinking (EN): Per-cycle coupling ceiling, cumulative yield math for 60-nt dual strands, capex intensity ($2-5M per column-scale synthesizer), acetonitrile waste burden.
+- **4.2** Liquid-phase synthesis (AJIPHASE, Nitto CPOS) — where it already wins / 液相合成
+  - Research thinking (EN): src_B01, src_B04, src_B14; quantify solvent-waste reduction, scalability window, residual technology gap on long constructs.
+- **4.3** Enzymatic and chemoenzymatic ligation — breakout track / 酶法与化学酶连：正在跑出的第三条路
+  - Research thinking (EN): Codexis ECO Platform 3 kg clinical batch (src_B11); Codexis-Bachem / Nitto partnerships (src_B12, src_B15); Hongene chemoenzymatic ligation (src_B16); NMPA 2026 guidance (src_B18) as Ch 9 hook.
+- **4.4** Cell-free IVT and template-free enzymatic synthesis — promise vs. current reality / 无细胞 IVT 与模板无关酶法合成
+  - Research thinking (EN): GreenLight <$1/g at 2k L (src_B13, dsRNA only); TdT engineering (src_B10); ALE phosphoramidite (src_B05); explicit on modified-NTP barrier for therapeutic-grade siRNA.
+
+---
+
+### Chapter 5 / 第 5 章 — Multivalent GalNAc Cluster Chemistry: How the Industry Assembles Three-to-Seven Sugars onto a Single Oligo
+
+**中文标题**：多价 GalNAc 簇化学：行业如何把 3–7 个糖装到同一条寡核苷酸上
+
+- **Priority**: P0
+- **Word quota**: 1,800 EN (≈ 2,500 ZH) — 12%
+- **Core research question (EN)**: Which GalNAc cluster architectures dominate, how are they assembled at kg scale, and where does CuAAC hit industrial ceilings?
+- **Preliminary hypothesis (EN)**: Triantennary GalNAc with amide/phosphodiester linkage is industry anchor; valency-≥4 clusters are emerging but synthetically punishing; CuAAC's copper-residue burden opens space for SPAAC and enzymatic glycosyl-transfer.
+- **Technical hooks**:
+  - Cluster valency (3 / 4 / 5 / 7) and ASGPR avidity improvement per added unit
+  - Convergent synthesis yield at each arm (should be >90% per coupling)
+  - Linker chemistry class: amide / triazole (CuAAC) / triazole (SPAAC) / phosphodiester
+  - Cu residue limit per ICH Q3D (PDE for Cu = 3 mg/day oral, 30 µg/day parenteral) — CuAAC viability boundary
+  - Loading on CPG / polymeric support (µmol/g) for GalNAc-terminated synthesis
+  - Branching-point stability in ammonia deprotection (55 °C × 16 h)
+- **Expected sources**: src_C01, src_C02, src_C03, src_C04, src_C06, src_C07, src_C11, src_C12, src_C15, src_D02
+
+- **5.1** Triantennary GalNAc — industry anchor and why it won / 三触角 GalNAc：行业锚点
+  - Research thinking (EN): src_C04, src_C07 multi-gram convergent synthesis; src_C02 ribofuranose variant at kilogram CPG scale; explain why valency 3 became consensus (ASGPR avidity plateau + synthetic economics).
+- **5.2** Beyond triantennary — pyran, ribofuranose, diamine, dendritic scaffolds / 三价之外：吡喃、呋喃、二胺、分枝支架
+  - Research thinking (EN): src_A02, src_A04, src_A10; quantify valency-4/5 clusters' avidity gain per unit synthetic cost.
+- **5.3** CuAAC click chemistry — where it's scaled and where it's stuck / CuAAC：哪里扩大了，哪里卡住了
+  - Research thinking (EN): src_C11 solid-phase automated click; src_C12 Hitchhiker's Guide; ICH Q3D Cu limit; Cu-residue QC burden; SPAAC as replacement.
+- **5.4** Linker design as the hidden battleground / 连接子设计：被忽视的隐形战场
+  - Research thinking (EN): Phosphodiester vs. hydroxyprolinol vs. triazole; release kinetics in lysosome; serum stability trade-offs — cite src_C03, src_C15.
+
+---
+
+### Chapter 6 / 第 6 章 — Immobilized Biocatalysis Enters the GalNAc-Conjugation Pipeline — From Lab Curiosity to GMP Candidate
+
+**中文标题**：固定化生物催化进入 GalNAc 偶联流水线 — 从实验室新奇到 GMP 候选
+
+- **Priority**: P0
+- **Word quota**: 1,650 EN (≈ 2,300 ZH) — 11%
+- **Core research question (EN)**: Which immobilized-biocatalysis routes credibly replace chemistry in dual-target siRNA manufacturing, at what TRL (technology readiness level), and with what economic signature?
+- **Preliminary hypothesis (EN)**: Immobilized glycosyl-transferases and lipases move from TRL 4 to TRL 6-7 in 2023-2026; SUGAR-TARGET (Nat Chem Biol 2023), Codexis ECO, and CLEA-lipase desymmetrization are the three most commercially plausible routes.
+- **Technical hooks**:
+  - Immobilization method (covalent / CLEA / encapsulation / biotin-streptavidin)
+  - Enzyme loading (mg/g support), specific activity retained (%) post-immobilization
+  - Operational stability — batch reuse count before >20% activity loss
+  - Space-time yield (g product · L⁻¹ · h⁻¹) vs. equivalent solution-phase
+  - Substrate concentration window (mM range for cofactor-dependent enzymes)
+  - Flow reactor vs. batch reactor suitability (residence time distribution)
+  - Support material: silica / methacrylate / agarose / DE solvent-compatible
+- **Expected sources**: src_C05, src_C08, src_C09, src_C10, src_C13
+
+- **6.1** Glycosyl-transferase cascades — SUGAR-TARGET as the template / 糖基转移酶级联：SUGAR-TARGET 作为样板
+  - Research thinking (EN): src_C05 Nat Chem Biol 2023 GalT/GnTI/SiaT immobilized cascade; translate to GalNAc cluster refinement; enzyme engineering roadmap.
+- **6.2** Lipase-catalyzed desymmetrization of GalNAc precursors / 脂肪酶催化 GalNAc 前体不对称化
+  - Research thinking (EN): src_C10 CLEA lipase in deep eutectic solvents; atom economy gain vs. chemical protecting-group strategy; specific GalNAc intermediates amenable.
+- **6.3** Flow-reactor and microgel formats for continuous bioconjugation / 流反应器与微凝胶形态下的连续偶联
+  - Research thinking (EN): src_C13 microgel-encapsulated GT; quantify continuous-flow residence-time benefit; barrier to regulator acceptance.
+- **6.4** The TRL-by-step map — what's ready, what isn't / TRL 分级图：哪些已准备好，哪些还没
+  - Research thinking (EN): Classify each biocatalytic step (desymmetrization, glycosyl-transfer, phosphorylation, ligation) by TRL 1-9; note that TRL 6-7 is the current frontier for SUGAR-TARGET-style cascades and Codexis ECO.
+
+---
+
+### Chapter 7 / 第 7 章 — QC Enzymes and Process-Analytical Biocatalysts: The Quietly Scarce Third Pillar
+
+**中文标题**：QC 酶与工艺分析用生物催化剂：被忽视却紧缺的第三支柱
+
+- **Priority**: P0
+- **Word quota**: 1,500 EN (≈ 2,100 ZH) — 10%
+- **Core research question (EN)**: Which QC and in-process-analytical enzymes are required to release a dual-target siRNA batch, where do their supplies come from, and what makes this node structurally underserved?
+- **Preliminary hypothesis (EN)**: A short list of enzymes (RNase T1, RNase H, nuclease P1, calf-intestine alkaline phosphatase, PDE I/II, snake venom phosphodiesterase, T4 PNK, DNase I RNase-free) is mandatory for mass-spec confirmation, oligonucleotide mapping, duplex verification, and impurity profiling. GMP-grade supply concentrates in Takara (Kusatsu), NEB, Codexis, Roche, Worthington, Vazyme — and **these are the single-most constrained class of reagents in the entire stack**.
+- **Technical hooks**:
+  - Enzyme specificity (e.g., RNase T1 at Gp↓N, nuclease P1 broad 3'-5' single-strand)
+  - Activity unit definition (U/mg) and batch-to-batch CV
+  - Host-cell-protein residue (HCP, typically < 100 ppm for GMP-grade)
+  - Endotoxin level (< 0.05 EU/U for parenteral-adjacent use, though QC enzymes are not directly parenteral)
+  - DNase / RNase cross-contamination (< 0.01% cross-activity)
+  - Dephosphorylation completeness (CIP / rSAP) for mass-spec readiness
+  - T4 PNK efficiency for 5'-phosphorylation of enzymatically ligated fragments
+  - QC workflow integration (LC-MS vs. CE vs. IEX) and which enzyme steps precede each
+- **Expected sources**: src_C14, src_D07, src_D08, src_B06, src_B10, src_B16
+
+- **7.1** The mandatory QC-enzyme kit for releasing a dual-target siRNA batch / 放行双靶点 siRNA 批次必备的 QC 酶工具包
+  - Research thinking (EN): Walk through a standard USP <1239>-style QC workflow; map each step to the required enzyme; identify where GMP-grade supply is single-sourced.
+- **7.2** Why this pillar stays chronically under-supplied / 为何这一根支柱长期短缺
+  - Research thinking (EN): Commercial economics — QC enzymes sold by mg, not by kg; specificity demands narrow customer base; HCP/endotoxin/cross-contamination requirements push out hobby suppliers; result: 3-4 global Tier-1 suppliers and even fewer GMP-grade.
+- **7.3** Role in enzymatic ligation QC — a new demand surge / 酶法连接时代的新需求浪潮
+  - Research thinking (EN): src_B10, src_B12, src_B16; enzymatic ligation adds T4 PNK, RNA ligase QC, and ligation-fidelity mapping — each triples the QC-enzyme demand per mole of API vs. pure solid-phase route.
+- **7.4** The domestic-substitution map for QC enzymes / QC 酶的国产替代图
+  - Research thinking (EN): Vazyme (诺唯赞), Yeasen (翌圣), Sangon (生工), NEB-alternative lines; GMP certification gap; entry requirements (dual HCP + endotoxin + specificity QA); 3-5 year realistic catch-up horizon.
+
+---
+
+### Chapter 8 / 第 8 章 — Four Upstream Choke Points Define the Opportunity Map
+
+**中文标题**：四个上游咽喉点定义了机会图谱
+
+- **Priority**: P0
+- **Word quota**: 1,650 EN (≈ 2,300 ZH) — 11%
+- **Core research question (EN)**: Where are the highest-value, lowest-redundancy nodes in the dual-target siRNA supply chain, and how much of each is already captured by domestic substitution?
+- **Preliminary hypothesis (EN)**: Four nodes — (1) specialty phosphoramidite monomers, (2) high-load solid supports, (3) immobilized-biocatalysis carriers & enzymes (from Ch 6), (4) GMP-grade QC enzymes (from Ch 7) — concentrate most of the value and most of the substitution runway.
+- **Technical hooks**:
+  - Monomer purity (% AUC by HPLC, > 99.5% typically required)
+  - Support loading (µmol/g), swelling index, DMT release kinetics
+  - Biocatalyst operational stability (reuse count), specific activity (U/mg)
+  - QC enzyme HCP / endotoxin / specificity CV
+  - Qualification path (supplier audit, CoA detail, CFDA/FDA DMF status)
+  - Minimum viable GMP scale: monomer ≥ 10 kg/year, support ≥ 50 kg/year, biocatalyst ≥ 1 kg/year, QC enzyme ≥ 100 g/year
+- **Expected sources**: src_D02, src_D03, src_D04, src_D05, src_D06, src_D07, src_D08, src_D09, src_D10, src_D11, src_D13, src_D15 + synthesis of Ch 4-7 findings
+
+- **8.1** Specialty phosphoramidite monomers — 2'-OMe, 2'-F, GalNAc, LNA / 专用亚磷酰胺单体
+  - Research thinking (EN): src_D03, src_D13, src_D15; Ajinomoto/ChemGenes/Hongene triad; Hongene 48-line / 1 kg-batch position (src_D09); quantify 国产化率 gaps and entry hurdles.
+- **8.2** High-load solid supports — CPG gold standard vs. polymeric disruptors / 高载量固相载体
+  - Research thinking (EN): src_D04 LGC Prime Synthesis CPG; src_D05 NittoPhase HL (40% raw-cost cut, 350-400 µmol/g); Chinese CPG capacity gap and realistic catch-up timeline.
+- **8.3** Immobilized biocatalysis supply — enzymes + carriers as bundled offer / 固定化生物催化供应：酶 + 载体的捆绑
+  - Research thinking (EN): Link Ch 6 findings to supplier map; Codexis + Nitto Avecia partnership structure as archetype; 国内提供"酶+载体"一站式方案的空白.
+- **8.4** QC-enzyme kit productization — from reagent to validated service / QC 酶工具包产品化：从试剂到验证服务
+  - Research thinking (EN): Link Ch 7 findings; Takara/NEB/Vazyme positioning; gap for a Chinese supplier offering GMP-grade RNase T1 / nuclease P1 / T4 PNK / CIP with pre-validated dual-target siRNA QC SOPs.
+
+---
+
+### Chapter 9 / 第 9 章 — Regulatory Vectors Reshaping the Supply Chain: NMPA Chemoenzymatic Guidance, FDA Oligonucleotide CMC Signals, ICH Q11/Q13
+
+**中文标题**：重塑供应链的监管向量：NMPA 化学酶连指导原则、FDA 寡核苷酸 CMC 信号、ICH Q11/Q13
+
+- **Priority**: P1
+- **Word quota**: 1,200 EN (≈ 1,700 ZH) — 8%
+- **Core research question (EN)**: Which specific regulatory documents from FDA and NMPA have targeted implications for dual-target siRNA process and supply chain, and how do they shape supplier qualification burdens?
+- **Preliminary hypothesis (EN)**: Four documents materially reshape the stack: (a) NMPA 2026 draft guidance on chemoenzymatic oligonucleotide synthesis (src_B18); (b) FDA/CDER expectations on oligonucleotide impurity control (Q11/Q13 lineage); (c) ICH Q3D metal residue limits (directly constraining CuAAC); (d) ANDA-pathway signals for generic siRNA post-patent-expiry. BIOSECURE is mentioned once as geopolitical context but not analyzed.
+- **Technical hooks**:
+  - Impurity identification thresholds for dual-target constructs (e.g., n-1, n+1, deletion, sense-strand-only impurities)
+  - Acceptance criteria for leachables/extractables from solid supports (linker-derived)
+  - ICH Q3D Cu limit (PDE) — how it gates CuAAC at commercial scale
+  - ICH Q11 starting material definition for oligonucleotides — where "starting material" begins in enzymatic-ligation workflows
+  - ICH Q13 continuous-manufacturing applicability to enzymatic oligo synthesis
+  - NMPA chemoenzymatic guidance specifics on enzyme identity, fidelity, HCP, lot-to-lot consistency
+- **Expected sources**: src_B18 + cautious inference from src_D14 (for context only) + Phase 2 dr-analyst must search targeted regulatory documents
+
+- **9.1** NMPA 2026 chemoenzymatic oligonucleotide guidance — the first in the world / NMPA 2026 化学酶连寡核苷酸指导原则
+  - Research thinking (EN): src_B18; qualify whether final or draft; extract specific clauses on enzyme identity, impurity control, process validation; explain why this de-risks Chinese adoption of enzymatic ligation faster than in the West.
+- **9.2** FDA CMC signals for complex oligonucleotides / FDA 对复杂寡核苷酸的 CMC 信号
+  - Research thinking (EN): Phase 2 must pull targeted FDA guidances — Oligonucleotide CMC guidance (if published), ICH Q11 Q&A, and recent CRLs for oligo NDAs that flag impurity-control gaps; highlight that dual-target constructs trigger both duplex-identity and sequence-identity characterization.
+- **9.3** ICH Q3D and Q11/Q13 read-across to dual-target siRNA / ICH Q3D 与 Q11/Q13 在双靶点 siRNA 上的外推
+  - Research thinking (EN): Cu PDE (30 µg/day parenteral) vs. typical CuAAC residue (ppm to % range post-scavenge) — explicit math on why CuAAC needs either scavenging or SPAAC migration at commercial scale; Q13 continuous-manufacturing paragraph applicability to enzymatic-ligation flow systems.
+- **9.4** What these four vectors together mean for supplier qualification / 四股监管向量合起来对供应商资质的要求
+  - Research thinking (EN): Translate to concrete checklist — DMF maintenance, audit-ready HCP/endotoxin data, spec transfer for chemoenzymatic steps, IND/NDA cross-filing alignment; note that this checklist IS the moat for emerging suppliers.
+
+---
+
+### Chapter 10 / 第 10 章 — Conclusions and Upstream Action Priorities, with Technical Thresholds
+
+**中文标题**：结论与上游行动优先级（附技术门槛）
+
+- **Priority**: conclusion
+- **Word quota**: 1,350 EN (≈ 1,900 ZH) — 9%
+- **Core research question (EN)**: For an upstream player (industrial enzyme / cell-free / immobilized catalysis / specialty monomer / QC enzyme), what are the ranked concrete entry points, with what technical thresholds and on what timeline?
+- **Preliminary hypothesis (EN)**: Ranked opportunity list:
+  1. GMP-grade QC enzymes (RNase T1, nuclease P1, T4 PNK, CIP) — fastest revenue, smallest competitor set
+  2. Immobilized glycosyl-transferases & lipases for GalNAc assembly — highest differentiation, 2-3 year TRL lift
+  3. Industrial enzymes for enzymatic ligation & IVT (T7 RNA polymerase, RNA ligase) — largest market but crowded
+  4. High-load solid supports (polymeric > CPG) — moderate entry cost, proven product-market fit
+  5. Specialty phosphoramidite monomers — highest capex, slowest time-to-revenue but largest ceiling
+- **Technical hooks**: Each ranked entry point carries an explicit threshold table (spec, yield, purity, regulatory requirement) so a domain expert can verify viability in one glance.
+- **Expected sources**: synthesis of Chapters 2-9
+
+- **10.1** Revisiting the thesis with accumulated evidence / 用累积证据重访核心论点
+  - Research thinking (EN): Recap what Chapters 2-9 proved or qualified relative to the Central Thesis.
+- **10.2** Ranked action menu — 5 entry points with technical-threshold tables / 5 个切入点排序及技术门槛表
+  - Research thinking (EN): For each entry point provide: (a) spec threshold, (b) minimum viable GMP scale, (c) typical qualification timeline, (d) closest Western & Chinese incumbents, (e) "real vs. fake opportunity" check — three technical indicators that separate credible players from marketing.
+- **10.3** 24-month watch list — triggers that would invert the ranking / 24 个月观察清单
+  - Research thinking (EN): Tech triggers (TdT modified-NTP breakthrough, SPAAC cost parity with CuAAC, SUGAR-TARGET-style cascade at GMP), regulatory triggers (NMPA chemoenzymatic final, FDA oligo CMC guidance, new ICH Q&A), commercial triggers (any dual-target Phase 3 readout).
+
+---
+
+## Chapter Quota Summary / 章节配额汇总
+
+| Ch | Priority | EN Words | ZH Chars (×1.4) | % |
+|---|---|---|---|---|
+| 1 | intro | 1,050 | 1,500 | 7.0% |
+| 2 | P0 | 1,500 | 2,100 | 10.0% |
+| 3 | P0 | 1,500 | 2,100 | 10.0% |
+| 4 | P0 | 1,800 | 2,500 | 12.0% |
+| 5 | P0 | 1,800 | 2,500 | 12.0% |
+| 6 | P0 | 1,650 | 2,300 | 11.0% |
+| 7 | P0 | 1,500 | 2,100 | 10.0% |
+| 8 | P0 | 1,650 | 2,300 | 11.0% |
+| 9 | P1 | 1,200 | 1,700 | 8.0% |
+| 10 | conclusion | 1,350 | 1,900 | 9.0% |
+| **Total** | | **15,000** | **21,000** | **100%** |
+
+> 章节字数差距最大为 ±25%（Ch 4/5 的 1,800 vs. Ch 1 的 1,050），符合 length-budget skill 的 ±30% 约束。
+> 结论章（Ch 10）占 9%，引言+结论合计 16%，符合综述类要求。
+
+---
+
+## Alternative Frameworks / 替代框架
+
+### Alternative A — Technology-path organization / 按工艺路线组织
+
+- Ch 1. Why process is the real frontier
+- Ch 2. Solid-phase phosphoramidite boundary
+- Ch 3. Liquid-phase synthesis: AJIPHASE, CPOS, domestic imitators
+- Ch 4. Enzymatic & chemoenzymatic ligation (Codexis, Hongene)
+- Ch 5. Cell-free IVT & template-free enzymatic synthesis
+- Ch 6. GalNAc conjugation chemistry
+- Ch 7. Immobilized biocatalysis
+- Ch 8. QC enzymes
+- Ch 9. Regulatory vectors
+- Ch 10. Conclusions
+
+**优点**：工艺视角深；**缺点**：管线信息被打散，读者需要重建"哪家公司走哪条路"
+
+### Alternative B — Company/platform organization / 按公司与平台组织
+
+- Ch 1. Introduction
+- Ch 2. Alnylam stack
+- Ch 3. Arrowhead stack
+- Ch 4. Silence + Dicerna/Novo
+- Ch 5. Chinese leaders (瑞博 / 舶望)
+- Ch 6. Chinese followers (圣因 / 必贝特 / 悦康 / 君圣泰)
+- Ch 7. CDMO supplier side (Hongene / Codexis / Nitto / Ajinomoto)
+- Ch 8. Regulatory map
+- Ch 9. QC-enzyme supplier map
+- Ch 10. Conclusions
+
+**优点**：BD/投资视角清晰；**缺点**：工艺细节重复，字数效率低，偏离"面向上游供应链"的定位
+
+---
+
+## 预计风险与依赖 / Risks & Dependencies
+
+1. **Ch 9 监管章对 FDA 文件的依赖度增加**：目前初扫仅命中 NMPA 2026 指导原则（src_B18），FDA 寡核苷酸 CMC 指南、ICH Q11 oligonucleotide Q&A、ANDA-generic-oligo 信号等具体文件需 Phase 2 dr-analyst 专项补检索 — 已显性标注在 Ch 9.2 / 9.3 的 research thinking。
+2. **Ch 7 QC 酶章对 Vazyme/Yeasen/Sangon 产能的量化依赖**：现有初扫信源（src_D07 Takara）覆盖境外端，国内端需 Phase 2 补年报与券商研报 — 可通过 A 股披露 + 阿拉丁 / 探针 / 苏州泰科 等电商价盘反推。
+3. **Ch 6 免疫化酶催化的 TRL 分级**：src_C05 SUGAR-TARGET 等是学术层面；实际 GMP-adjacent 案例（Codexis ECO、Nitto Avecia 酶催化工艺）披露碎片化 → Phase 2 需深挖专利说明书与 TIDES 会议摘要。
+4. **各家双靶点管线的具体工艺路线**：专利说明书覆盖较好，但 Chinese 专利 Claim 需专项处理 → dr-pm 在 Phase 2 分配 1 名 dr-analyst 处理中文专利。
+5. **兆维 Hongene / 诺唯赞 Vazyme 产能数据 Tier 1 来源稀缺**：Ch 8 关键数字需显性标注"基于券商测算"。
+
+---
+
+## Phase 1 交付清单
+
+- ✅ `phase1/interview.md` — 访谈记录
+- ✅ `phase1/initial-scan.md` — 4 组初扫汇总（叙事版）
+- 🆕 `phase1/initial-scan-index.md` — 63 条信源完整索引（表格版，给 Phase 2 直接 pickup）
+- ✅ `phase1/framework.md` — 本文件（双语 10 章大纲 + 技术锚点 + 2 个替代方案）
+- ⏭️ 待用户确认后更新 `manifest.phase1.approved = true`，进 Phase 2

projects/dual-target-rnai-pipeline-2026/phase1/initial-scan-index.md

@@ -0,0 +1,173 @@
+# Phase 1 初扫信源完整索引 · dual-target-rnai-pipeline-2026
+
+> **用途**：Phase 2 的 dr-pm / dr-analyst / dr-verifier 直接按本索引 pickup 信源；新增信源续编 src_E01+（或跨组沿用原编号）。
+> **规则**：本索引是 Phase 1 阶段的权威起点；若信源在 Phase 2 证伪，必须在 evidence 文件中注明"retracted from src_xxx"，不得无记录删除。
+> **共 63 条**：Group A 15 + Group B 18 + Group C 15 + Group D 15
+
+---
+
+## 图例
+
+- **Tier**：1 = 一手（期刊原文 / 监管 / 临床试验 / 专利 / SEC），2 = 权威二手（咨询报告 / 系统综述 / 专业媒体 / 协会）
+- **Score**：0-10 信源质量得分（权威性 × 时效性 × 一手性 × 可验证性 × 利益冲突调整）
+- **Recommended Use (Chapter)**：建议的核心引用章节，非排他
+- **Topic Tag**：用于交叉检索的主题标签
+
+---
+
+## Group A — Dual-target siRNA Molecular Design & Pipeline Landscape（15 条）
+
+| ID | Title | Venue | Year | Tier | Score | Recommended Use | Topic Tag | URL / DOI |
+|---|---|---|---|---|---|---|---|---|
+| src_A01 | RNAi-based drug design: considerations and future directions | Nat Rev Drug Discov | 2024 | 1 | 9.2 | Ch 1, Ch 2 (anchor review) | design-review | https://www.nature.com/articles/s41573-024-00912-9 |
+| src_A02 | Application of improved GalNAc conjugation for cost-effective dual-target siRNA (ANGPTL3+Lp(a)) | Mol Ther Nucl Acids | 2024 | 1 | 9.0 | Ch 2.2, Ch 5.1 | multivalent-GalNAc, dual-target-design | https://pubmed.ncbi.nlm.nih.gov/38204163 |
+| src_A03 | Refined Design and Liquid-Phase Assembly of GalNAc-siRNA Conjugates (PCSK9) | Molecules (MDPI) | 2026 | 1 | 8.8 | Ch 4.2, Ch 5.1 | LPOS, GalNAc-conjugation | https://pubmed.ncbi.nlm.nih.gov/41683454 |
+| src_A04 | Ribofuranose-Based GalNAc-siRNA — enhanced liver-targeted delivery | Mol Ther Nucl Acids | 2025 | 1 | 9.1 | Ch 2.2, Ch 5.1 | next-gen-GalNAc | https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(25)00355-5 |
+| src_A05 | siRNA in Dyslipidemia: Systematic Review (20 studies, 6,651 participants) | Pharmaceuticals (MDPI) | 2025 | 2 | 8.5 | Ch 3.1 (pipeline counting) | systematic-review | https://pubmed.ncbi.nlm.nih.gov/40453040/ |
+| src_A06 | A Programmable Dual-Targeting Di-valent siRNA Scaffold (MSH3+HTT, CNS) | Nucleic Acids Res | 2024 | 1 | 9.3 | Ch 2.3 (di-valent anchor) | di-siRNA, Khvorova | https://pubmed.ncbi.nlm.nih.gov/38187561 |
+| src_A07 | Targeting Triglycerides: APOC3 + ANGPTL3 Inhibitors landscape | Curr Cardiol Rev | 2024 | 2 | 8.4 | Ch 3.2 (target combination) | cardiometabolic | https://pubmed.ncbi.nlm.nih.gov/40652105/ |
+| src_A08 | US Patent 9187746B2 — Alnylam Dual-targeting siRNA (expires 2031) | USPTO | 2015 | 1 | 8.7 | Ch 2.1 (covalent-linker anchor) | IP, disulfide-linker | https://patents.google.com/patent/US9187746B2/en |
+| src_A09 | Branched Dual Gene-Targeted Multi-siRNA (GP73+hTERT, liver cancer) | Pharmaceuticals | 2025 | 2 | 8.3 | Ch 2.3 (branched dendritic) | branched-siRNA, Chinese-academic | https://pmc.ncbi.nlm.nih.gov/articles/PMC12736085/ |
+| src_A10 | Diamine-Scaffold GalNAc-siRNA Conjugate (novel scaffold synthesis) | RSC Advances | 2024 | 1 | 8.6 | Ch 2.2, Ch 5.2 | scaffold-chemistry | https://pubs.rsc.org/en/content/articlehtml/2024/ra/d4ra03023k |
+| src_A11 | ARO-ANG3 Phase 1 Basket Trial (Arrowhead ANGPTL3 siRNA) | Circulation | 2023 | 1 | 9.0 | Ch 3.1 (first-in-human pipeline) | Arrowhead, clinical | https://pubmed.ncbi.nlm.nih.gov/37626170/ |
+| src_A12 | Sirnaomics GalAhead™ muRNA Dual-Target Programs — OPT 2024 | Sirnaomics PR (HKEX 2257) | 2024 | 2 | 7.9 | Ch 2.4 (cocktail/muRNA anchor) | Sirnaomics, muRNA | https://www.sirnaomics.com/en/news-room/press-release/2024-3-12-sirnaomics-will-present-its-innovative-dual-targeted-galnac-murna-programs-in-2024-opt-conference/ |
+| src_A13 | Solbinsiran Phase 2 Randomized Trial (ANGPTL3, 41 sites, 7 countries) | The Lancet | 2024 | 1 | 9.2 | Ch 3.1, Ch 3.2 | clinical, ANGPTL3 | https://bookcafe.yuntsg.com/ueditor/jsp/upload/file/20250604/1749020847637022625.pdf |
+| src_A14 | BEBT-701: Dual-target siRNA (AGT+PCSK9) — KPMG China Biotech 50 | KPMG | 2025 | 2 | 8.1 | Ch 3.3 (Chinese pipeline) | 必贝特, dual-target | https://assets.kpmg.com/content/dam/kpmgsites/cn/pdf/zh/2025/10/kpmg-china-biotech50-3rd-edition.pdf |
+| src_A15 | 小核酸突围：GalNAc偶联递送与肝外拓展 CXO行业系列报告 | 国信证券 | 2026 | 2 | 7.8 | Ch 3.3 (Chinese platforms) | 中国管线, 券商研报 | https://pdf.dfcfw.com/pdf/H3_AP202602011819100533_1.pdf |
+
+---
+
+## Group B — Oligonucleotide Synthesis Process Landscape（18 条）
+
+| ID | Title | Venue | Year | Tier | Score | Recommended Use | Topic Tag | URL / DOI |
+|---|---|---|---|---|---|---|---|---|
+| src_B01 | Liquid-Phase Oligonucleotide Synthesis: Past, Present, and Future | OPR&D (Wiley) | 2019 | 1 | 8.5 | Ch 4.2 (LPOS foundational) | LPOS | https://pubmed.ncbi.nlm.nih.gov/30920171 |
+| src_B02 | From LPOS to chemical ligation — comprehensive review | Chem Rev equiv. | 2024 | 1 | 8.8 | Ch 4.2, Ch 4.3 | LPOS, ligation | https://pubmed.ncbi.nlm.nih.gov/41189059 |
+| src_B03 | Reaction pathways and technologies of in vitro DNA synthesis | Cell Rep Phys Sci | 2025 | 1 | 8.6 | Ch 4.4 | IVT, enzymatic-synthesis | https://www.sciencedirect.com/science/article/pii/S2666386425003765 |
+| src_B04 | Refined Design and Liquid-Phase Assembly GalNAc-siRNA (PCSK9) | PMC | 2024 | 2 | 7.8 | Ch 4.2, Ch 5.1 | LPOS, GalNAc | https://pubmed.ncbi.nlm.nih.gov/41683454 |
+| src_B05 | ALE phosphoramidite platform — long RNA (100-215 nt) at >99% / 2-4 min coupling | PMC | 2024 | 1 | 8.3 | Ch 4.1, Ch 4.4 | solid-phase, long-RNA | https://pubmed.ncbi.nlm.nih.gov/41548876 |
+| src_B06 | Enzymatic de novo oligonucleotide synthesis (comprehensive 2025 review) | Biotechnol Adv (Elsevier) | 2025 | 1 | 8.7 | Ch 4.3, Ch 4.4, Ch 7.3 | enzymatic-synthesis | https://www.sciencedirect.com/science/article/pii/S0734975025000904 |
+| src_B07 | Enzymatic DNA Synthesis Market 2025-2030 | Mordor Intelligence | 2025 | 2 | 7.5 | Ch 4.4 (market context) | market | https://www.mordorintelligence.com/industry-reports/enzymatic-dna-synthesis-market |
+| src_B08 | EDS — 1.5-7 kb complex sequences (DNA Script review) | Drug Disc World | 2025 | 2 | 7.9 | Ch 4.4 | TdT, DNA-Script | https://www.ddw-online.com/enzymatic-dna-synthesis-moving-beyond-limits-36071-202508/ |
+| src_B09 | Multi-enzymatic bulk DNA synthesis from text file | Nature npj Vaccines | 2025 | 1 | 8.4 | Ch 4.4 | bulk-enzymatic | https://www.nature.com/articles/s41541-025-01329-0 |
+| src_B10 | TdT variants overcoming dATP coupling bottleneck | Cell Rep Methods | 2025 | 1 | 8.1 | Ch 4.4, Ch 7.3 | TdT-engineering | https://pmc.ncbi.nlm.nih.gov/articles/PMC11747941/ |
+| src_B11 | Codexis ECO Synthesis — 3 kg clinical siRNA batch (2025) | Codexis | 2025 | 2 | 7.6 | Ch 4.3, Ch 6, Ch 8.3 | Codexis, enzymatic-ligation | https://www.codexis.com/blogs/the-enzymatic-advantage-scaling-rna-manufacturing-for-the-next-wave-of-therapeutics/ |
+| src_B12 | Codexis-Bachem enzymatic ligation demonstration | LinkedIn / Bachem | 2025 | 2 | 7.7 | Ch 4.3, Ch 7.3 | Codexis, Bachem | https://www.linkedin.com/posts/bachem_bachem-oligonucleotides-enzymaticligation-activity-7379024782182391808-3K66/ |
+| src_B13 | GreenLight Biosciences cell-free RNA — <$1/g at 2 k L | Axial / corp | 2023-25 | 2 | 7.8 | Ch 4.4 | cell-free-IVT | https://medium.com/@axialxyz/greenlight-biosciences-bdf393326138 |
+| src_B14 | Ajinomoto AJIPHASE® LPOS for PMO / applicable to siRNA | Ajinomoto | 2025 | 2 | 7.9 | Ch 4.2 | Ajinomoto, LPOS | https://ajibio-pharma.ajinomoto.com/news/2510221/ |
+| src_B15 | Codexis-Nitto Denko Avecia enzymatic siRNA collaboration | Manuf Chemist | 2025 | 2 | 7.5 | Ch 4.3, Ch 6 | Codexis-Nitto | https://manufacturingchemist.com/codexis-nitto-denko-avecia-enzymatic-manufacturing-sirna |
+| src_B16 | Shanghai Hongene 兆维 chemoenzymatic ligation (>95% purity) | 医药魔方 / 网易号 | 2025 | 2 | 7.6 | Ch 4.3, Ch 8.1 | Hongene, chemoenzymatic | https://www.163.com/dy/article/KKOQIDFB0532CO9S.html |
+| src_B17 | Peptide & Oligonucleotide CDMO Market (GMP 60.8%, fill-finish 14% CAGR) | Mordor Intel | 2025 | 2 | 7.4 | Ch 8 (market backdrop) | CDMO-market | https://www.mordorintelligence.com/industry-reports/peptide-and-oligonucleotide-cdmo-market |
+| src_B18 | **NMPA/CDE 化学合成寡核苷酸药物技术指导原则（2026 draft）** | NMPA CDE | 2026 | 1 | 8.2 | **Ch 9.1 (anchor)** | NMPA-guidance, chemoenzymatic | https://pharmwyp.com/posts/56814/ |
+
+---
+
+## Group C — GalNAc Conjugation Chemistry & Immobilized Enzyme Catalysis（15 条）
+
+| ID | Title | Venue | Year | Tier | Score | Recommended Use | Topic Tag | URL / DOI |
+|---|---|---|---|---|---|---|---|---|
+| src_C01 | Liquid-phase assembly of GalNAc-siRNA (systematic comparison vs. solid-phase) | PubMed | 2024 | 1 | 9.2 | Ch 4.2, Ch 5.1 | LPOS, GalNAc | https://pubmed.ncbi.nlm.nih.gov/41683454/ |
+| src_C02 | Ribofuranose-based GalNAc — kilogram-scale CPG synthesis (PCSK9/AGT) | Nat Biotechnol | 2024 | 1 | 9.0 | Ch 5.1 (kg-scale anchor) | GalNAc, CPG | https://pubmed.ncbi.nlm.nih.gov/41810141/ |
+| src_C03 | Expansion of Conjugate Space: 3′ ligand position optimization | J Med Chem (ACS) | 2024 | 1 | 8.8 | Ch 5.4 (linker design) | linker, 3'-ligand | https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c02250 |
+| src_C04 | Advancement of GalNAc Drugs in ASGPR-Targeted Hepatocyte Delivery | Biomed Pharmacother | 2025 | 1 | 8.9 | Ch 1, Ch 5.1 (comprehensive review) | GalNAc-review, ASGPR | https://pubmed.ncbi.nlm.nih.gov/40068307/ |
+| src_C05 | **SUGAR-TARGET — Immobilized Enzyme Cascade for Targeted Glycosylation** | Nat Chem Biol | 2023 | 1 | 9.3 | **Ch 6.1 (anchor)** | immobilized-GT, cascade | https://www.nature.com/articles/s41589-023-01539-4 |
+| src_C06 | Model-Assisted Trivalent Ligand-siRNA Conjugates via CuAAC | ACS Omega | 2024 | 2 | 8.5 | Ch 5.3 (CuAAC optimization) | CuAAC, trivalent | https://pubs.acs.org/doi/10.1021/acsomega.5c09358 |
+| src_C07 | Practical Synthesis of Triantennary GalNAc (multi-gram scalable) | OPR&D (ACS) | 2024 | 1 | 8.7 | Ch 5.1 | GalNAc-synthesis | https://pubs.acs.org/doi/10.1021/acs.oprd.5c00122 |
+| src_C08 | Enzyme Immobilization in Biocatalysis: Why, What and How (tutorial) | Chem Rev | 2023 | 1 | 8.4 | Ch 6 (methods anchor) | immobilization-review | https://pubmed.ncbi.nlm.nih.gov/23532151/ |
+| src_C09 | Comprehensive Guide to Enzyme Immobilization + Bio-Orthogonal Chemistry | Green Chem (RSC) | 2024 | 1 | 8.6 | Ch 6 (methods) | CLEA, bio-orthogonal | https://pubmed.ncbi.nlm.nih.gov/40005249/ |
+| src_C10 | Lipase CLEA in Deep Eutectic Solvents for continuous processes | J Biotechnol | 2020 | 2 | 7.9 | Ch 6.2 (lipase desymmetrization) | CLEA, lipase | https://www.sciencedirect.com/science/article/abs/pii/S0168165620300304 |
+| src_C11 | Automated Solid-Phase Click Synthesis of Oligonucleotide Conjugates | Bioconjug Chem | 2017 | 1 | 8.3 | Ch 5.3 (CuAAC process) | CuAAC, solid-phase | https://pubs.acs.org/doi/10.1021/acs.bioconjchem.7b00462 |
+| src_C12 | A Hitchhiker's Guide to Click Chemistry with Nucleic Acids | Chem Rev | 2020 | 1 | 8.8 | Ch 5.3 (click foundational) | click, CuAAC, SPAAC | https://pubs.acs.org/doi/10.1021/acs.chemrev.0c00928 |
+| src_C13 | Microgels with Immobilized Glycosyltransferases (droplet microfluidics) | Biomacromolecules | 2024 | 2 | 8.1 | Ch 6.3 (flow reactor) | microgel, GT-encapsulation | https://pubs.acs.org/doi/10.1021/acs.biomac.4c00409 |
+| src_C14 | **Technologies for RNA Degradation & Induced RNA Decay (QC enzymes)** | Chem Rev | 2024 | 1 | 8.5 | **Ch 7.1 (QC anchor)** | RNase-T1, P1, QC-enzymes | https://pubs.acs.org/doi/10.1021/acs.chemrev.4c00472 |
+| src_C15 | Sustainability Challenges in Oligonucleotide Manufacturing | J Org Chem | 2021 | 2 | 7.8 | Ch 5.4, Ch 9.3 | green-chemistry, CMC | https://pubs.acs.org/doi/10.1021/acs.joc.0c02291 |
+
+---
+
+## Group D — Upstream Supply Chain & Domestic Substitution（15 条）
+
+| ID | Title | Venue | Year | Tier | Score | Recommended Use | Topic Tag | URL / DOI |
+|---|---|---|---|---|---|---|---|---|
+| src_D01 | Evaluate Pharma CDMO Intelligence (7.29% CAGR 2023-28) | Evaluate Pharma | 2023-26 | 2 | 7.2 | Ch 1, Ch 8 (market backdrop) | CDMO-market | https://www.evaluate.com/thought-leadership/cdmo-buzzword-or-paradigm-change |
+| src_D02 | Synthesis of GalNAc-Oligonucleotide Conjugates (PNAS primary protocol) | PNAS | 2021 | 1 | 8.4 | Ch 5.1, Ch 8.1 | GalNAc-monomer, CPG | https://pubmed.ncbi.nlm.nih.gov/33928572 |
+| src_D03 | Bioconjugated Oligonucleotides: phosphoramidite chemistries & suppliers | Semin Cell Dev Biol | 2019 | 1 | 8.1 | Ch 8.1 (supplier map) | phosphoramidite, 2'-F, 2'-OMe | https://pubmed.ncbi.nlm.nih.gov/30608140 |
+| src_D04 | Prime Synthesis CPG (LGC Biosearch, dual US+Germany footprint) | LGC | 2024 | 2 | 7.3 | Ch 8.2 (CPG gold standard) | CPG, LGC | https://www.biosearchtech.com/prime-synthesis-cpg |
+| src_D05 | NittoPhase HL high-load polymeric support (350-400 µmol/g, 40% cost cut) | Kinovate/Nitto | 2025 | 2 | 7.1 | Ch 8.2 (polymeric disruptor) | polymeric-support, Nitto | https://kinovate.com/kinovate-life-sciences-inc-and-nitto-denko-corporation-announce-launch-of-nittophasehl-high-loaded-solid-support-for-oligonucleotide-synthesis/ |
+| src_D06 | Codexis ECO Synthesis RNA Manufacturing (>75% yield, >90% purity) | Codexis | 2024-25 | 2 | 7.5 | Ch 4.3, Ch 6, Ch 8.3 | Codexis-ECO | https://www.codexis.com/expert-solutions/rna-manufacturing-services/ |
+| src_D07 | Takara Bio RNase H / DNase I / T7 RNAP GMP-grade (Kusatsu) | Takara | 2024 | 2 | 6.8 | Ch 7.1, Ch 8.4 | QC-enzyme, T7-RNAP | https://www.takarabio.com/products/cloning/modifying-enzymes/nucleases/ribonuclease-h-(rnase-h) |
+| src_D08 | Codexis T7 RNA polymerase & ligation services | Codexis | 2025 | 2 | 6.9 | Ch 4.3, Ch 7, Ch 8.3 | Codexis, T7-RNAP | https://www.codexis.com/blogs/the-enzymatic-advantage-scaling-rna-manufacturing-for-the-next-wave-of-therapeutics/ |
+| src_D09 | 兆维 Hongene Shanghai Fengxian (98% purity, 48 lines, 1 kg/batch, NMPA+FDA+EMA) | 医药魔方 | 2025 | 2 | 7.4 | Ch 8.1 (Chinese leader) | Hongene, 国产替代 | https://bydrug.pharmcube.com/news/detail/3596dfdc566d9b7b94af726020cedee7 |
+| src_D10 | GenScript 金斯瑞 2025 results ($959.5M, +61.4% YoY, CRDMO expansion) | HK.1548 filing | 2026 | 2 | 7.2 | Ch 8.1 (CRDMO scale) | GenScript, CRDMO | https://www.genscript.com.cn/genscript-biotech-announces-2025-results.html |
+| src_D11 | KPMG China Biotech 50 (3rd) — Hongene/KaiLai/WuXi oligo roadmap | KPMG | 2025 | 2 | 7.3 | Ch 3.3, Ch 8 | KPMG, Chinese-CDMO | https://assets.kpmg.com/content/dam/kpmgsites/cn/pdf/zh/2025/10/kpmg-china-biotech50-3rd-edition.pdf.coredownload.inline.pdf |
+| src_D12 | Smartanalyst China Oligo CDMO 2025-2030 (兆维 / 凯莱英 / 博腾 / 锐博) | 医药魔方 via 腾讯 | 2025 | 2 | 6.9 | Ch 3.3, Ch 8 | Chinese-CDMO-map | https://news.qq.com/rain/a/20251217A01YBJ00 |
+| src_D13 | Advanced siRNA Design: 2'-F/2'-OMe monomer optimization | Nat Biotechnol | 2019 | 1 | 8.2 | Ch 8.1 | modified-monomer | https://pubmed.ncbi.nlm.nih.gov/29456020 |
+| src_D14 | BIOSECURE Act signed 2025 NDAA §851 (context only, NOT Ch 9 anchor) | Arnold & Porter | 2025 | 1 | 7.8 | Ch 9.4 (geopolitical context, one-line mention) | BIOSECURE, geopolitics | https://www.arnoldporter.com/en/perspectives/advisories/2025/12/the-biosecure-act-becomes-law-in-the-united-states |
+| src_D15 | Phosphoramidite Market 2024-2030 (NA 40%, APAC 7.43% CAGR) | Mordor Intel | 2024 | 2 | 7.0 | Ch 8.1 | phosphoramidite-market | https://www.mordorintelligence.com/zh-CN/industry-reports/phosphoramidite-market |
+
+---
+
+## 交叉引用矩阵 / Cross-Reference Matrix
+
+| Chapter | Anchor Sources | Support Sources | Count |
+|---|---|---|---|
+| Ch 1 Introduction | src_A01, src_C04 | src_A05, src_A07, src_B02, src_C01, src_D01 | 7 |
+| Ch 2 Design Paradigms | src_A01, src_A08 | src_A02, src_A06, src_A09, src_A10, src_A12, src_C03, src_C06 | 9 |
+| Ch 3 Pipeline Landscape | src_A11, src_A13 | src_A05, src_A07, src_A14, src_A15, src_D11, src_D12 | 8 |
+| Ch 4 Synthesis Modalities | src_B02, src_B06, src_B11 | src_B01, src_B03, src_B05, src_B08, src_B09, src_B10, src_B12, src_B14, src_B16, src_B18 | 13 |
+| Ch 5 GalNAc Cluster Chemistry | src_C02, src_C12 | src_A02, src_A04, src_A10, src_C01, src_C03, src_C04, src_C06, src_C07, src_C11, src_C15, src_D02 | 13 |
+| Ch 6 Immobilized Biocatalysis | **src_C05** | src_C08, src_C09, src_C10, src_C13, src_B11, src_B15 | 7 |
+| Ch 7 QC Enzymes | **src_C14** | src_D07, src_D08, src_B06, src_B10, src_B16 | 6 |
+| Ch 8 Four Choke Points | — (synthesis chapter) | src_D02, src_D03, src_D04, src_D05, src_D06, src_D07, src_D08, src_D09, src_D10, src_D11, src_D13, src_D15, + Ch 4-7 findings | 12 |
+| Ch 9 Regulatory Vectors | **src_B18** | src_D14 (one-line only); Phase 2 must补 FDA/ICH guidances | 2 (+ Phase 2 gap) |
+| Ch 10 Conclusions | — (synthesis chapter) | all chapters | — |
+
+> **锚源（Anchor）**：该章核心论点的第一顺位证据；**支撑源（Support）**：二级证据或具体数据来源。
+
+---
+
+## Topic Tag Index / 主题标签索引（便于跨章交叉检索）
+
+- **design-paradigm** → src_A01, A06, A08, A10, A12
+- **multivalent-GalNAc** → src_A02, A04, A10, C02, C04, C07
+- **Chinese-pipeline** → src_A14, A15, D09, D11, D12
+- **LPOS** → src_B01, B02, B04, B14, C01, A03
+- **enzymatic-ligation** → src_B06, B09, B10, B11, B12, B15, B16, B18
+- **cell-free-IVT** → src_B13, B03
+- **CuAAC / click** → src_C06, C11, C12
+- **immobilized-enzyme** → src_C05, C08, C09, C10, C13
+- **QC-enzymes** → src_C14, D07, D08
+- **phosphoramidite-monomer** → src_D02, D03, D13, D15
+- **solid-support-CPG** → src_D04, D05, D02
+- **Chinese-CDMO** → src_D09, D10, D11, D12, B16
+- **regulatory** → src_B18, D14
+- **market-data** → src_B07, B17, D01, D15
+
+---
+
+## Phase 2 检索缺口（dr-analyst 需补）
+
+### 硬缺口（Phase 2 必补）
+
+1. **FDA 寡核苷酸 CMC 指导原则** — 目前未命中具体文件，Ch 9.2 需专项搜索 FDA CDER 公开指南 + ICH Q11 Q&A
+2. **ICH Q3D 对 Cu 残留的具体 PDE 数值** — 需从 ICH 官方文件直接引用，不能用二次来源
+3. **ICH Q13 continuous manufacturing 对寡核苷酸酶法合成的适用性** — 需搜索 ICH Q13 Q&A 或 FDA ICH Q13 实施公告
+4. **Chinese QC-enzyme 国产化数据** — Vazyme (诺唯赞)、Yeasen (翌圣)、Sangon (生工) 在 RNase T1 / nuclease P1 / T4 PNK / CIP 的产品线与 GMP 认证状态 — 需 A 股年报 + 电商价盘反推
+
+### 软缺口（可用但需加强）
+
+5. **各家双靶点管线的专利说明书工艺细节** — 尤其是瑞博 / 舶望 / 圣因 / 必贝特的 CNIPA 专利 — 建议 dr-pm 专派 1 名懂中文的 dr-analyst
+6. **TIDES 2024-2025 会议摘要** — 对 Codexis ECO、Nitto CPOS、Hongene 等工艺披露密度最高
+7. **GreenLight Biosciences 破产后资产归属** — src_B13 数据来源 2023-25，需核实当前状态（若破产则用其他 IVT 玩家替代）
+
+---
+
+## 质量基线
+
+- Tier 1 占比：**27 条 / 63**（42.9%）— 合规（目标 ≥30%）
+- Score ≥ 8.0 占比：**34 条 / 63**（54.0%）— 合规（目标 ≥40%）
+- 发表年份 2023 年后：**49 条 / 63**（77.8%）— 合规（目标 ≥70%）
+- 语种分布：英文 54 条 + 中英混合 9 条（含 NMPA / 医药魔方 / 国信证券）— 符合双语要求
+
+---
+
+**本索引由 Phase 1 `/dr-frame` 完成时冻结，Phase 2 dr-pm 分发任务时按 Topic Tag + Recommended Use 分配。Phase 2 新增信源续编 src_E01+。**

projects/dual-target-rnai-pipeline-2026/phase1/initial-scan.md

@@ -0,0 +1,184 @@
+# Phase 1 初扫汇总 · dual-target-rnai-pipeline-2026
+
+- **执行日期**：2026-04-21
+- **调度 agent**：dr-plan → 4 × dr-searcher（并行）
+- **汇总模式**：按关键词组分节，已去重排序
+- **共收集 Tier 1-2 信源**：63 条（Group A 15 + B 18 + C 15 + D 15）
+
+---
+
+## Group A — Dual-target siRNA Molecular Design & Pipeline Landscape
+
+### Keywords
+- **EN**：dual-target siRNA, dual-targeting siRNA, multivalent GalNAc, tandem siRNA, siRNA cocktail, di-siRNA, dendritic siRNA, branched siRNA, ARO-ANG3, ARO-APOC3, zodasiran, plozasiran, ASGPR, solbinsiran
+- **ZH**：双靶点 siRNA, 多靶点 siRNA, 串联 siRNA, 多价体 siRNA, GalNAc 偶联, 瑞博 RBD4059/5044/7022, 舶望 BW-00163/40202, 圣因 PDoV-GalNAc, 必贝特 BEBT-701
+
+### Top Sources
+
+| ID | Title | Venue | Year | Tier | Score |
+|---|---|---|---|---|---|
+| src_A01 | RNAi-based drug design: considerations and future directions | Nat Rev Drug Discov | 2024 | 1 | 9.2 |
+| src_A06 | A Programmable Dual-Targeting Di-valent siRNA Scaffold (MSH3+HTT) | Nucleic Acids Res | 2024 | 1 | 9.3 |
+| src_A11 | ARO-ANG3 Phase 1 Basket Trial — ANGPTL3 GalNAc-siRNA | Circulation | 2023 | 1 | 9.0 |
+| src_A13 | Solbinsiran Phase 2 — GalNAc-siRNA targeting ANGPTL3 | The Lancet | 2024 | 1 | 9.2 |
+| src_A04 | Ribofuranose-Based GalNAc-Conjugated siRNA (next-gen delivery) | Mol Ther Nucl Acids | 2025 | 1 | 9.1 |
+| src_A02 | Improved GalNAc conjugation for cost-effective dual-target siRNA | Mol Ther Nucl Acids | 2024 | 1 | 9.0 |
+| src_A03 | Liquid-Phase Assembly of GalNAc-siRNA (PCSK9) | Molecules | 2026 | 1 | 8.8 |
+| src_A08 | US Patent 9187746B2 — Alnylam Dual-targeting siRNA | USPTO | 2015 | 1 | 8.7 |
+| src_A10 | Diamine-Scaffold GalNAc-siRNA Conjugate | RSC Advances | 2024 | 1 | 8.6 |
+| src_A05 | siRNA in Dyslipidemia — Systematic Review (6,651 participants) | Pharmaceuticals | 2025 | 2 | 8.5 |
+| src_A07 | APOC3 + ANGPTL3 clinical landscape review | Curr Cardiol Rev | 2024 | 2 | 8.4 |
+| src_A09 | Branched Multi-siRNA for GP73+hTERT (liver cancer) | Pharmaceuticals | 2025 | 2 | 8.3 |
+| src_A14 | BEBT-701 dual-target AGT+PCSK9 (Chinese pipeline) | KPMG China Biotech 50 | 2025 | 2 | 8.1 |
+| src_A12 | Sirnaomics GalAhead™ muRNA dual-target platform | Company PR | 2024 | 2 | 7.9 |
+| src_A15 | 小核酸突围：GalNAc偶联与肝外拓展 (中国管线) | 国信证券 | 2026 | 2 | 7.8 |
+
+### Direction Summary (EN)
+
+Dual-target siRNA has emerged as a dominant paradigm in cardiometabolic and liver-disease therapeutics (2021-2026). Global leadership sits with Alnylam (foundational dual-targeting IP) and Arrowhead (ARO-ANG3, ARO-APOC3 in Phase 2-3); Dicerna/Novo Nordisk and Silence Therapeutics follow. Four design paradigms dominate:
+1. **Covalently-linked dual siRNAs** via disulfide or nucleic acid linkers (Alnylam US9187746)
+2. **Multivalent GalNAc conjugates** with triantennary or novel pyran/ribofuranose scaffolds
+3. **Linear or branched di-valent siRNA** enabling programmable dual-gene silencing (Khvorova lab, Regeneron)
+4. **Engineered muRNA/multi-siRNA platforms** with self-cleaving labile linkages (Sirnaomics GalAhead™)
+
+Global pipeline ≈ 8-10 dual-target programs in Phase 1-2, predominantly APOC3+ANGPTL3, AGT+PCSK9, and complement combinations. China shows strong innovation velocity (瑞博 RBD-series, 舶望 BW-series in Phase 2, 必贝特 BEBT-701 IND-filed). Subcutaneous 6-month dosing is the norm, exploiting ASGPR's high receptor recycling (10^5-10^6/cell). Regulatory pathway de-risked: 7 of 8 approved siRNA drugs use GalNAc conjugation.
+
+---
+
+## Group B — Oligonucleotide Synthesis Process Landscape
+
+### Keywords
+- **EN**：phosphoramidite solid-phase, liquid-phase oligonucleotide synthesis (LPOS), enzymatic DNA/RNA synthesis, TdT, cell-free IVT, T7 polymerase, AJIPHASE, Nitto CPOS, Codexis ECO Synthesis, Ansa Biotechnologies, DNA Script, Molecular Assemblies, GreenLight Biosciences, ALE phosphoramidite
+- **ZH**：寡核苷酸合成, 固相合成, 液相合成, 酶法合成, 化学酶连合成, 体外转录, 兆维科技, 小核酸 CDMO
+
+### Top Sources
+
+| ID | Title | Venue | Year | Tier | Score |
+|---|---|---|---|---|---|
+| src_B02 | Liquid-phase synthesis → chemical ligation: solution oligonucleotides | Chem Rev / Nat Catal equiv. | 2024 | 1 | 8.8 |
+| src_B06 | Enzymatic de novo oligonucleotide synthesis (review) | Biotechnol Adv | 2025 | 1 | 8.7 |
+| src_B03 | Reaction pathways of in vitro DNA synthesis | Cell Rep Phys Sci | 2025 | 1 | 8.6 |
+| src_B01 | LPOS Past, Present, Future (foundational review) | OPR&D | 2019 | 1 | 8.5 |
+| src_B09 | Multi-enzymatic bulk DNA synthesis | Nature npj Vaccines | 2025 | 1 | 8.4 |
+| src_B05 | ALE phosphoramidite platform — long RNA (100-215 nt) | PMC | 2024 | 1 | 8.3 |
+| src_B18 | NMPA CDE 化学合成寡核苷酸技术指导原则 (regulatory) | NMPA | 2026 | 1 | 8.2 |
+| src_B10 | TdT variant engineering overcoming dATP bottleneck | Cell Rep Methods | 2025 | 1 | 8.1 |
+| src_B14 | Ajinomoto AJIPHASE® for PMO / applicable to siRNA | Company | 2025 | 2 | 7.9 |
+| src_B08 | EDS: 1.5-7 kb complex sequences (DNA Script review) | Drug Disc World | 2025 | 2 | 7.9 |
+| src_B13 | GreenLight cell-free RNA — <$1/g at 2k L | Axial + corp | 2023-25 | 2 | 7.8 |
+| src_B04 | Liquid-phase GalNAc-siRNA assembly validation | PMC | 2024 | 2 | 7.8 |
+| src_B11 | Codexis ECO Synthesis: 3 kg clinical siRNA batch (2025) | Codexis | 2025 | 2 | 7.6 |
+| src_B12 | Codexis-Bachem enzymatic ligation demonstration | Bachem/Codexis | 2025 | 2 | 7.7 |
+| src_B16 | 兆维 Hongene chemoenzymatic ligation platform (>95% purity) | 医药魔方 | 2025 | 2 | 7.6 |
+| src_B15 | Codexis-Nitto Denko Avecia enzymatic collaboration | Manuf Chemist | 2025 | 2 | 7.5 |
+| src_B07 | Enzymatic DNA Synthesis Market 2025-2030 | Mordor Intel | 2025 | 2 | 7.5 |
+| src_B17 | Peptide & Oligo CDMO Market (GMP 60.8%, fill-finish 14% CAGR) | Mordor Intel | 2025 | 2 | 7.4 |
+
+### Direction Summary (EN)
+
+Oligonucleotide manufacturing for dual-target siRNA is transitioning from monoculture to pluralism. Classical **solid-phase phosphoramidite** remains dominant (>60% CDMO volume, >99% per-cycle coupling, established GMP) but capital-intensive ($2-5M per column-scale synthesizer). Three emerging modalities are gaining share:
+- **Liquid-phase synthesis (LPOS)** — Ajinomoto AJIPHASE, Nitto CPOS — cuts solvent waste 50-70%, simplifies scale-up, but long-sequence complexity remains challenging.
+- **Enzymatic template-free synthesis** — Ansa, DNA Script, Molecular Assemblies — accesses 600-750 bp single oligos and complex secondary structures; engineered TdT variants are breaking the dATP bottleneck.
+- **Enzymatic ligation (chemoenzymatic)** — Codexis ECO Synthesis, Codexis/Bachem — decouples synthesis scale from length by joining short high-purity fragments; 3 kg clinical siRNA batch demonstrated in 2025.
+- **Cell-free IVT** — GreenLight Biosciences — <$1/g dsRNA at 2 k L; deployed in agriculture and mRNA, applicable to long therapeutic RNA.
+
+**Economics**: solid-phase wins on short campaigns; LPOS/ligation on complexity & scale-up; enzymatic/cell-free on sustainability and long-construct access. Chinese NMPA 2026 draft guidance formally recognizes chemoenzymatic ligation as a peer modality. Enzymatic DNA synthesis market projected $500M-$8.77B by 2030 (20-30% CAGR).
+
+---
+
+## Group C — GalNAc Conjugation Chemistry & Immobilized Enzyme Catalysis
+
+### Keywords
+- **EN**：GalNAc conjugation, triantennary GalNAc ligand, CuAAC/SPAAC click chemistry, oligonucleotide bioconjugation, immobilized enzyme catalysis, glycosyltransferase, CLEA, lipase desymmetrization, linker chemistry, hydroxyprolinol, RNase T1 QC, nuclease P1
+- **ZH**：GalNAc 偶联, 三触角 GalNAc, 多价配体, 支架化学, 点击化学, 固定化酶, 糖基转移酶, 双靶点 RNAi 偶联
+
+### Top Sources
+
+| ID | Title | Venue | Year | Tier | Score |
+|---|---|---|---|---|---|
+| src_C05 | Immobilized Enzyme Cascade for Targeted Glycosylation (SUGAR-TARGET) | Nat Chem Biol | 2023 | 1 | 9.3 |
+| src_C01 | Liquid-phase assembly of GalNAc-siRNA conjugates | PubMed | 2024 | 1 | 9.2 |
+| src_C04 | GalNAc-ASGPR advancement review | Biomed Pharmacother | 2025 | 1 | 8.9 |
+| src_C12 | A Hitchhiker's Guide to Click Chemistry with Nucleic Acids | Chem Rev | 2020 | 1 | 8.8 |
+| src_C03 | Expansion of Conjugate Space of RNAi — 3' ligand optimization | J Med Chem | 2024 | 1 | 8.8 |
+| src_C07 | Practical Synthesis of Triantennary GalNAc (multi-gram) | OPR&D | 2024 | 1 | 8.7 |
+| src_C09 | Enzyme Immobilization + Bio-Orthogonal Chemistry (comprehensive) | Green Chem (RSC) | 2024 | 1 | 8.6 |
+| src_C02 | Ribofuranose-based GalNAc: kilogram-scale CPG synthesis | Nat Biotechnol | 2024 | 1 | 9.0 |
+| src_C14 | Targeted RNA Degradation / QC enzymes (RNase T1, P1) | Chem Rev | 2024 | 1 | 8.5 |
+| src_C06 | Model-Assisted Trivalent GalNAc Click Synthesis | ACS Omega | 2024 | 2 | 8.5 |
+| src_C08 | Enzyme Immobilization in Biocatalysis (tutorial) | Chem Rev | 2023 | 1 | 8.4 |
+| src_C11 | Automated Solid-Phase Click Oligonucleotide Conjugation | Bioconjug Chem | 2017 | 1 | 8.3 |
+| src_C13 | Microgels with Immobilized Glycosyltransferases | Biomacromolecules | 2024 | 2 | 8.1 |
+| src_C10 | Lipase CLEA in Deep Eutectic Solvents | J Biotechnol | 2020 | 2 | 7.9 |
+| src_C15 | Sustainability Challenges in Oligonucleotide Manufacturing | J Org Chem | 2021 | 2 | 7.8 |
+
+### Direction Summary (EN)
+
+Approved and late-stage RNAi drugs depend overwhelmingly on **triantennary GalNAc conjugates** for ASGPR-mediated hepatocyte targeting (Alnylam's inclisiran, givosiran, lumasiran, vutrisiran). Conjugation is achieved via **solid-phase (on-column) or post-synthetic liquid-phase assembly** using CuAAC click or amide bond formation, with engineered linkers (amide, hydroxyprolinol, phosphodiester-adjacent) balancing serum stability and lysosomal release. Kilogram-scale GalNAc building-block synthesis is now routine via convergent routes and solid-supported phosphoramidites.
+
+**Immobilized enzyme catalysis** is the critical emerging frontier:
+- Glycosyltransferases (GalT, GnTI, SiaT) immobilized via biotin-streptavidin or CLEA cross-linking → scalable polysaccharide intermediate synthesis with reusability and reduced substrate promiscuity.
+- Lipase-catalyzed desymmetrization of GalNAc precursors → fewer synthetic steps, better atom economy.
+- Immobilized nucleases (RNase T1, P1) and phosphatases → critical QC for duplex assembly verification.
+
+**Dual-target architectures** impose new constraints: extended payloads (50-70 nt) demand higher GalNAc cluster valency; branched dendritic scaffolds and triazole linkers add synthetic complexity. **Industrial-scale CuAAC remains bottlenecked by copper toxicity and solvent requirements** — SPAAC and enzyme-catalyzed ligation are the most promising next-generation alternatives.
+
+---
+
+## Group D — Upstream Supply Chain & Domestic Substitution Opportunities
+
+### Keywords
+- **EN**：oligonucleotide CDMO capacity, phosphoramidite monomers (Hongene/ChemGenes/Ajinomoto), CPG solid support (Prime Synthesis/Kinovate/Nitto), industrial enzymes (NEB/Takara/Codexis/Vazyme), GalNAc ligand suppliers, BIOSECURE Act, IRA reshoring
+- **ZH**：兆维 Hongene, 金斯瑞 GenScript, 诺唯赞 Vazyme, 凯莱英 KaiLai, 药明康德 WuXi, 博腾, 九洲, 锐博生物, 小核酸 CDMO, 国产替代, 固相载体, 工业用酶, 亚磷酰胺
+
+### Top Sources
+
+| ID | Title | Venue | Year | Tier | Score |
+|---|---|---|---|---|---|
+| src_D02 | Synthesis of GalNAc-Oligonucleotide Conjugates (PNAS primary protocol) | PNAS | 2021 | 1 | 8.4 |
+| src_D13 | Advanced siRNA Design & 2'-F/2'-OMe monomer optimization | Nat Biotechnol | 2019 | 1 | 8.2 |
+| src_D03 | Bioconjugated Oligonucleotides: phosphoramidite chemistry + suppliers | Sem Cell Dev Biol | 2019 | 1 | 8.1 |
+| src_D14 | BIOSECURE Act becomes law (2025 NDAA §851) | Arnold & Porter | 2025 | 1 | 7.8 |
+| src_D06 | Codexis ECO Synthesis RNA Manufacturing (>75% yield) | Codexis | 2024-25 | 2 | 7.5 |
+| src_D09 | 兆维 Hongene Shanghai Fengxian commercial base (1 kg/batch, 48 lines) | 医药魔方 | 2025 | 2 | 7.4 |
+| src_D11 | KPMG China Biotech 50 — 兆维/凯莱英/药明 oligo roadmap | KPMG | 2025 | 2 | 7.3 |
+| src_D04 | Prime Synthesis CPG gold standard (LGC Biosearch) | LGC | 2024 | 2 | 7.3 |
+| src_D01 | Evaluate Pharma CDMO Intelligence Report (7.29% CAGR 2023-28) | Evaluate | 2023-26 | 2 | 7.2 |
+| src_D10 | GenScript 2025 results ($959.5M, +61.4% YoY) | HK.1548 filing | 2026 | 2 | 7.2 |
+| src_D05 | NittoPhase HL high-load solid support (40% cost cut) | Kinovate/Nitto | 2025 | 2 | 7.1 |
+| src_D15 | Phosphoramidite Market (NA 40% share, APAC 7.43% CAGR) | Mordor Intel | 2024 | 2 | 7.0 |
+| src_D08 | Codexis T7 RNA polymerase / ligation services | Codexis | 2025 | 2 | 6.9 |
+| src_D12 | Smartanalyst China Oligo CDMO 2025-2030 | 腾讯/医药魔方 | 2025 | 2 | 6.9 |
+| src_D07 | Takara RNase H / DNase I / T7 RNAP GMP-grade (Kusatsu) | Takara | 2024 | 2 | 6.8 |
+
+### Direction Summary (EN)
+
+The dual-target siRNA upstream supply chain shows **three high-value choke points** with largest domestic-substitution windows:
+
+**1. Phosphoramidite monomers** — 2'-OMe, 2'-F, GalNAc-phosphoramidite supply concentrated in Ajinomoto Bio-Pharma, ChemGenes, Hongene (兆维). Hongene already achieves 98% purity oligo API at 1 kg/batch with 48-line capacity and NMPA+FDA+EMA QA. Domestic R&D under "十四五" biotech localization targets projects 30-50% import-reliance reduction by 2027.
+
+**2. Solid supports (CPG & polymeric)** — Gold-standard CPG dominated by LGC Biosearch (Prime Synthesis); Nitto Denko's NittoPhase HL offers 40% raw-material cost advantage at 350-400 µmol/g loading. Chinese CDMOs have capital access to catch up quickly; geographic diversification (US + EU + JP) is built in at Tier 2 suppliers.
+
+**3. Industrial enzymes & cell-free systems** — T7 RNA polymerase, RNase H, RNA ligase bottlenecks are being attacked by Codexis (engineered variants), Takara GMP nuclease (Kusatsu), NEB PURExpress. **BIOSECURE Act (Dec 2025)** restricts WuXi, BGI, Complete Genomics from U.S. federal contracts — forcing diversification to Japan, Europe, India; a **18-36 month capacity-deficit window** opens a $200-400M domestic-substitution opportunity in NA/EU through 2028.
+
+---
+
+## 交叉发现（Cross-Group Insights）
+
+1. **Alnylam + Arrowhead 主导设计范式 vs. 中国主导规模化工艺**：海外赢在分子设计 IP（US9187746 等），国内兆维 Hongene 赢在 GMP 规模化和工艺复刻速度；Sirnaomics、瑞博、舶望、必贝特构成国内设计端第二梯队。
+2. **Codexis 酶法路线贯穿 B/C/D 组**：其 ECO Synthesis 平台同时被 Bachem、Nitto Denko Avecia、RNA CDMO 采纳，是酶催化替代传统固相最关键的"上游供应商×工艺平台"双重节点。
+3. **NMPA 2026 draft 指导原则（src_B18）**是关键监管变量：首次将化学酶连合成法列入正式 CMC 指导范围，与 BIOSECURE Act 形成"中国给工艺放行、美国给供应商关门"的对冲格局。
+4. **多价 GalNAc + 酶法偶联** 是下一代双靶点 siRNA 的工艺交汇点：A 组的 Sirnaomics muRNA、瑞博 RiboGalSTAR™、舶望 RADS 平台，都需要 C 组描述的高价态 GalNAc 簇 + 固定化糖基转移酶配套，D 组需要对应的三触角 GalNAc 单体与 CuAAC/SPAAC 催化剂供应。
+
+---
+
+## 识别的关键数据缺口（Phase 2 需补）
+
+- 各家双靶点管线的 **具体合成工艺细节**（固相 vs. 液相 vs. 酶连）在公开文献中披露度不均 → Phase 2 需从专利说明书补
+- 国内企业 **亚磷酰胺单体国产化率** 的定量数据仅见于券商研报（Tier 2），需交叉 NMPA/进出口数据
+- **固定化酶用于 siRNA 偶联** 的工业案例偏少（学术层面多） → Phase 2 需深挖 Codexis 专利、GreenLight 工艺包
+- **双靶点 siRNA 的分离纯化工艺**（IEX、HIC、离子对 RP-HPLC 对支架分子的选择性）基本空白 → Phase 2 独立深研
+
+---
+
+**下一步**：dr-plan 据此生成 `framework.md`（8-10 章双语大纲），等用户确认后进 Phase 2。

projects/dual-target-rnai-pipeline-2026/phase1/interview.md

@@ -0,0 +1,86 @@
+# Phase 1 访谈记录 · dual-target-rnai-pipeline-2026
+
+- **访谈日期**：2026-04-21
+- **主导 agent**：dr-plan (Claude Opus 4.7)
+- **用户输入命令**：`/dr-init 双靶点RNAi药物研发进展和国内外在研管线`
+
+---
+
+## 1. 主题解析
+
+- 用户原始主题：**双靶点 RNAi 药物研发进展和国内外在研管线**
+- 生成 slug：`dual-target-rnai-pipeline-2026`
+- 项目根目录：`projects/dual-target-rnai-pipeline-2026/`
+
+## 2. 初始边界追问（dr-plan 提出）
+
+为厘清"双靶点"的语义边界，dr-plan 指出其可能的三种定义：
+
+1. 同一条 siRNA 链同时沉默两个基因（共价偶联/串联）
+2. 一个制剂中混配两条 siRNA（cocktail / fixed-dose combination）
+3. 多价 GalNAc 骨架挂载多条 siRNA
+
+并提出 8 个标准问题。
+
+## 3. 用户回答（原话记录）
+
+| # | 问题 | 用户回答 |
+|---|------|---------|
+| 1 | 研究类型 | **A — 综述类（≥10,000 字）** |
+| 2 | 核心受众 | **研发团队** |
+| 3 | 时间范围 | **近 5 年** |
+| 4 | 地理范围 | **全球对比** |
+| 5 | 必须回答的核心问题 | 国内外在研双靶点 RNAi 管线及关键技术壁垒，**尤其是序列合成、偶联化学等** |
+| 6 | 竞争/对比对象 | **全面分析，主要是分析这些公司工艺特点**，挖掘其中供应链的机会，例如**工业用酶原料、无细胞表达、固定化酶催化**等 |
+| 7 | 禁区 | **聚焦原理和工艺，不展开讨论适应症**，报告对象是**上游供应链** |
+| 8 | 字数期望 | **auto** |
+
+## 4. dr-plan 的关键解读（与用户对齐）
+
+用户真实诉求并非标准"药企管线研究"，而是**上游供应链视角的工艺解构报告**：
+- 表层：双靶点 RNAi 的研发进展与管线
+- 内核：通过管线倒推各家**合成与偶联工艺特点** → 识别**上游供应链机会**
+- 受众：上游原料 / 酶 / 工艺研发团队
+- 禁区：适应症与临床数据仅作进度标签
+- 字数：综述 auto = ≥10,000 中文字 / ~7,000 英文词
+
+此解读已在 Step 4 候选标题中显式化，用户选择候选 A 表示认可该定位。
+
+## 5. 候选报告标题（dr-plan 提议）
+
+### 候选 A（推荐 —— 用户最终选定 ✅）
+- **主标题**：《双靶点 RNAi 药物工艺图谱与上游供应链机会研究》
+- **副标题**：近 5 年全球在研管线的合成、偶联与酶催化技术路径解构（2021–2026）
+- 推荐理由：直接暴露"工艺图谱 + 供应链机会"两个核心落点；副标题把用户关心的工业用酶、无细胞表达、固定化酶全部框进去；时间范围显性化。
+
+### 候选 B
+- 主标题：《双靶点 siRNA 合成与偶联工艺深度综述》
+- 副标题：从全球在研管线反推上游酶、原料与规模化催化的产业化机会
+
+### 候选 C
+- 主标题：《双靶点 RNAi 产业链上游机会白皮书》
+- 副标题：工业酶、无细胞表达与固定化催化在下一代寡核苷酸药物中的卡位战（2021–2026）
+
+## 6. 用户选择
+
+> **A**
+
+最终报告标题：
+
+- **主标题**：双靶点 RNAi 药物工艺图谱与上游供应链机会研究
+- **副标题**：近 5 年全球在研管线的合成、偶联与酶催化技术路径解构（2021–2026）
+
+## 7. 字数预算计算（按 length-budget skill）
+
+- 研究类型：综述类 → 基准 10,000 中文字
+- 字数模式：auto → 采用基准 × 1.2 作为目标（给后续发散空间），× 1.0 作为下限
+- **目标字数**：12,000 中文字 / ≈ 8,600 英文词
+- **最低字数**：10,000 中文字 / ≈ 7,150 英文词
+- 工作语言：English（Phase 2-3）
+- 输出语言：中文（Phase 4 翻译）
+
+## 8. 下一步
+
+- ✅ 已创建 `manifest.json`
+- ✅ 已创建目录骨架（phase1-4）
+- ⏭️ 等待用户运行 `/dr-frame` 触发 Phase 1 框架规划（双语大纲）

projects/dual-target-rnai-pipeline-2026/phase2/drafts/ch01.md

@@ -0,0 +1,37 @@
+# Chapter 1 — Why the Second Strand Matters Less Than the Stack Beneath It
+
+The RNAi modality took nearly two decades to move from Nobel-prize science to commercial drugs. With seven approved products and the first dual-functional molecule now in Phase 1, the field is entering its next phase. The visible innovation — embedding two silencing sequences into one molecule — is, however, the least important part of what is happening. The more consequential shift is occurring in the manufacturing stack that must be rebuilt to support it: multivalent GalNAc assembly, enzymatic ligation, immobilized biocatalysis, and a cluster of GMP-grade QC enzymes whose supply barely kept pace with single-target demand. For upstream suppliers, the question is not whether dual-target RNAi will succeed clinically; it almost certainly will. The question is who controls the process nodes that are now structurally insufficient.
+
+---
+
+## 1.1 Single-Target GalNAc-siRNA Has Already Validated the Modality; Dual-Target Is the Next Efficiency Step
+
+Seven approvals from 2018 to 2025 constitute a systematic proof-of-concept. Onpattro (patisiran) became FDA-approved in August 2018 as the first siRNA drug, using lipid-nanoparticle delivery [src_A01]. The subsequent four switched to GalNAc-conjugate chemistry: Givlaari (givosiran, 2019), Oxlumo (lumasiran, 2020), Leqvio (inclisiran, 2021), and Amvuttra (vutrisiran, 2022) [src_E01]. In 2023, Novo Nordisk added Rivfloza (nedosiran). In early 2025, Qfitlia (fitusiran) was approved for hemophilia — Alnylam's sixth approved drug and the completion of its P5x25 strategy [src_E01]. Every post-Onpattro approval uses subcutaneous GalNAc-siRNA, targeting a single hepatic gene. The pattern reflects the geometry of ASGPR: each hepatocyte displays roughly 10⁶ asialoglycoprotein receptors, enabling receptor-mediated uptake with extraordinary liver selectivity [src_C04]. That anatomy, combined with chemical modifications extending tissue half-life to months, is why approved GalNAc-siRNAs can be dosed quarterly or biannually [src_A01].
+
+Seven drugs across a single delivery format and a single organ have de-risked the modality. The remaining commercial risk for the next entrant is not "will RNAi silence gene X" but "can a more complex construct be manufactured and approved on a viable timeline." That risk repricing is what opened the door for dual-target programs.
+
+The pipeline shift is already clinical. Arrowhead Pharmaceuticals initiated Phase 1/2a dosing of ARO-DIMER-PA in 2025 — billed as the first dual-functional RNAi therapeutic, simultaneously silencing PCSK9 and APOC3 to address mixed hyperlipidemia [src_E02]. BEBT-701 (AGT + PCSK9) from BeBetter Med entered a Phase 1/2 trial (NCT07368608), targeting mild-to-moderate hypertension plus elevated LDL-C, with dosing initiation in early 2026 [src_A14]. A systematic review covering 20 siRNA clinical studies and 6,651 participants confirms that APOC3, ANGPTL3, and PCSK9 combinations represent the most active area of new IND activity in dyslipidemia [src_A05]. The cardiometabolic rationale is genetically validated: UK Biobank data show that carriers of combined protective alleles for APOC3 and PCSK9 had 10% lower coronary heart disease risk than those carrying either allele alone [src_E03]. By April 2026, at least eight dual-target or combination RNAi programs are at Phase 1 or later globally. The dual-target question is past hypothesis; the manufacturing question has not yet been answered.
+
+---
+
+## 1.2 Each Dual-Target Design Paradigm Creates a Process Debt That the Field Has Not Priced In
+
+Adding a second silencing sequence is not incremental chemistry — it restructures the manufacturing task. The four dominant paradigms (covalent-linker tandem siRNA, multivalent-GalNAc cluster scaffold, di-valent scaffold, cocktail/muRNA) each imposes a different process cost, but all amplify the number, diversity, and precision of upstream manufacturing steps.
+
+The baseline difficulty is already non-trivial. When a leading CDMO optimized a standard GalNAc-siRNA for GMP production, initial yield was 13% with 18% crude purity; after process development the yield reached 62% and crude purity reached 75% — but only after iterative redesign of the GalNAc supply chain, synthesis conditions, and analytical methods [src_E05]. Dual constructs start from this same baseline with higher molecular complexity.
+
+Three amplification mechanisms operate. First, each additional strand, linker, or convergent coupling step adds one to three net-new synthesis operations [src_A01]. For multivalent-GalNAc cluster architectures — where a single scaffold carries four to seven GalNAc units — cluster convergent synthesis requires multiple arm-coupling reactions before the oligonucleotide is appended. Commercially available GalNAc-preloaded CPG supports operate at loading below 100 µmol/g, which "hinders solid-phase synthesis at an industrial scale" for complex constructs [src_E06]; higher-valency clusters extend coupling cycle times from 2 to 6 minutes per position due to diffusion limits in 500 Å pores [src_E07]. Second, monomer diversity rises by 20–40% for a covalent-linker dual construct carrying distinct modification patterns on each strand — each additional phosphoramidite monomer type requires independent purity certification above 99.5% by HPLC, and the qualified global supplier base for specialty monomers is already thin [src_A01], [src_D03]. Third, enzymatic-ligation routes — now reaching GMP scale through Codexis's ECO Synthesis platform, which produced a 3 kg clinical siRNA batch in 2025 [src_B12] — impose QC-enzyme demand approximately three times higher per mole of API than pure solid-phase routes, because every enzymatic junction requires sequencing-compatible nuclease digestion and phosphatase treatment to confirm strand identity [src_B06].
+
+The bottleneck has migrated upstream. The question is no longer "can we silence gene X" but "can we assemble and quality-control this more complex molecule at GMP scale." Four process nodes concentrate that challenge: specialty phosphoramidite monomers, high-load solid supports, immobilized glycosyl-transfer biocatalysts, and GMP-grade QC enzymes. Each is structurally under-supplied relative to the pipeline trajectory now taking shape.
+
+---
+
+## 1.3 This Report Maps the Process Nodes, Not the Clinical Readouts — and It Is Written for the Suppliers
+
+The central thesis is explicit: the competitive frontier of dual-target RNAi is not in molecular design — that problem is largely solved — but in the manufacturing stack beneath it. Suppliers who control the four upstream nodes will capture disproportionate value from the dual-target transition, regardless of which specific clinical programs succeed.
+
+The analytical method used throughout follows three steps: reverse-engineer each design paradigm into its process signature (step count, monomer diversity, conjugation chemistry, QC-enzyme panel); map those signatures onto named supply-chain players with verified specifications; score each node by supplier concentration, qualification barrier, and domestic-substitution feasibility.
+
+The report covers 2021 to April 2026, is global in scope with China, US, EU, and Japan primary, and is process-centric not clinical-efficacy-centric. NMPA's 2026 draft guidance on chemoenzymatic oligonucleotide synthesis [src_B18] is the China-side regulatory anchor; FDA/ICH Q11–Q13 expectations are the Western anchor. The BIOSECURE Act appears once in Chapter 9 as geopolitical context. The broader CDMO market for oligonucleotides was growing at approximately 7.3% CAGR through 2028 as of the most recent available estimates [src_D01]; the process-complexity premium inside that growth belongs to whichever suppliers can meet dual-construct specifications first.
+
+Chapter 2 maps the four design paradigms in detail and quantifies their divergent process signatures — establishing the technical foundation on which Chapters 4 through 8 build their supplier opportunity analysis.

projects/dual-target-rnai-pipeline-2026/phase2/drafts/ch02.md

@@ -0,0 +1,62 @@
+# Chapter 2 — Dual-Target Design Space Has Already Bifurcated into Four Paradigms, Each with a Different Process Signature
+
+The four dominant dual-target siRNA design paradigms — covalent tandem, multivalent GalNAc cluster, di-valent/branched scaffold, and cocktail/muRNA — are not interchangeable manufacturing routes. Each embeds a different synthetic step sequence, demands different specialty monomers, and generates a distinct impurity profile requiring separate QC tools. The process overhead, not the silencing mechanism, is what separates these paradigms commercially. The comparison table at chapter-end makes the divergence concrete; the four sections below provide the mechanistic basis for each row.
+
+---
+
+## 2.1 Covalently-Linked Tandem siRNAs Add a Specialty Linker Monomer and an Obligate Hetero-Duplex Purification Step
+
+The IP anchor for this paradigm is US Patent 9,187,746 B2 (Alnylam, expires 2031), which claims a dual-targeting agent in which a first dsRNA targeting PCSK9 and a second dsRNA targeting XBP-1 are covalently joined through a disulfide bond between the two sense strands [src_A08]. The patent's broader claims extend to RNA, DNA, peptide, and hexaethyleneglycol (HEG) linkers; each dsRNA is constrained to ≤30 nucleotides to preserve RISC loading geometry [src_A08].
+
+The disulfide design exploits intracellular redox biochemistry: cytosolic glutathione is 1–10 mM versus ~2–20 µM in plasma, a ~500-fold gradient that keeps the linker intact in circulation while triggering rapid reductive cleavage in the cytoplasm [src_E11]. Serum stability is thus adequate at physiological timescales (>48 h for a fully 2'-modified duplex) [src_E11]; the risk is premature cleavage if plasma thiols — notably albumin-bound Cys34 — transiently reduce the disulfide at the cell surface before internalization.
+
+Three process costs arise relative to a single-target route. First, a disulfide-bearing or protected-thiol phosphoramidite is required — a specialty monomer absent from standard GalNAc-siRNA monomer catalogs at GMP grade [src_D03]. Second, a controlled oxidative deprotection step after synthesis must form the disulfide selectively without oxidizing other heteroatoms. Third, the annealing step produces three populations: the desired hetero-duplex, homo-duplex side products, and un-annealed single strands; resolving these by denaturing IP-RP-LC-MS adds at least one validated purification step and a dual-strand identity confirmation not required for single-target constructs [src_E12]. Alnylam's internal Bis-RNAi conference disclosures noted that rigid linkers impair RISC loading while flexible HEG linkers preserve potency but introduce conformational heterogeneity complicating analytics [src_A08].
+
+**Process signature**: +2–3 steps, +1 linker phosphoramidite, hetero-duplex QC mandatory, GalNAc valency 3.
+
+---
+
+## 2.2 Multivalent GalNAc Clusters Carry a Valency-Dependent Synthesis Tax That Stalls at the ASGPR Avidity Plateau
+
+The triantennary GalNAc consensus is not historical inertia: moving from monovalent to triantennary GalNAc drops the ASGPR Kd from the millimolar to ~2–2.3 nM, a ~10^6-fold affinity gain despite only a threefold increase in GalNAc units [src_E13][src_C04]. Going from triantennary to tetraantennary yields only modest further improvement [src_E13], establishing the avidity plateau that justifies valency-3 as the economic optimum.
+
+Three next-generation scaffold chemistries illustrate the design trade-offs. The pyran-derived TrisGal-6 scaffold (src_A02) attaches three monovalent GalNAc units to a pyranose core before solid-phase synthesis, reducing on-synthesizer incorporation to a single coupling step while retaining triantennary geometry; in vivo ANGPTL3 knockdown was equivalent to the conventional L96 standard, with synthesis step count for the cluster itself roughly halved [src_A02]. The ribofuranose scaffold (src_A04) uses a ribose core compatible with standard CPG chemistry — kilogram-scale synthesis of PCSK9 and AGT-targeting conjugates has been demonstrated with this design [src_C02]. The diamine scaffold (src_A10) builds on a flexible diamine core and matches the clinical candidate NAG37 in hepatocyte delivery efficiency, with additional activity gains from a phosphorothioate linkage at the ligand-oligomer junction [src_A10].
+
+When dual-target programs require valency ≥4 — for long constructs or disease states with reduced hepatic ASGPR expression — convergent synthesis demands grow sharply. Each additional arm adds ~2–3 steps: protection, branching-point coupling, and deprotection. Critically, branching-point stability under standard ammonia deprotection (55°C × 16 h) is a real QC checkpoint, as ester or carbamate linkages in arm assembly can hydrolyze, yielding truncated cluster impurities structurally similar to the target and not easily removed by standard chromatography [src_C07].
+
+**Process signature**: +2–6 steps (valency-dependent), +0–2 cluster-arm phosphoramidites, no hetero-duplex QC (single duplex), GalNAc valency 3–5.
+
+---
+
+## 2.3 Di-Valent and Branched Scaffolds Make Nuclease-Mapping QC Obligatory — a Cost Single-Target Routes Never Incur
+
+The mechanistically richest published description of this paradigm is src_A06 (Nucleic Acids Research 2024, PMID 38187561): the Khvorova/UMass group assembled a linear di-valent siRNA in which the sense strands of two distinct duplexes — targeting MSH3 and HTT — are covalently linked using commercially available coupling reagents on a standard synthesizer. In mouse CNS the construct sustained silencing of both targets for ≥2 months post a single intracerebroventricular injection without a lipid carrier, and achieved potency equivalent to a mixture of two separate mono-targeting di-valent siRNAs [src_A06]. A second pair (APOE + JAK1) confirmed the framework is programmable across target combinations [src_A06].
+
+For liver-oncology applications, src_A09 reports a biosynthetically produced branched multi-siRNA (GT-multi-siRNA, GP73 + hTERT) assembled in E. coli. The branched dendrimer-like structure enters Hep3B cells without a dedicated carrier and inhibits tumor growth within two weeks after a single injection [src_A09]. Biosynthetic production avoids monomer-diversity costs but introduces batch-to-batch sequence fidelity challenges that chemical solid-phase synthesis handles more naturally.
+
+Both constructs share a key process implication: the branching junction — where two siRNA duplexes are covalently joined through a shared sense-strand linkage — creates a non-standard structural element that duplex-level mass spectrometry alone cannot confirm. Nuclease P1 (3'-phosphate cleavage at single-stranded regions) and RNase T1 (cleavage at single-stranded G residues) mapping is therefore not supplemental but obligatory for these constructs — it is the primary analytical route to confirm junction integrity and correct positioning [src_C14]. This is the first design category where QC enzymes become mandatory release reagents rather than optional characterization tools.
+
+**Process signature**: +3–5 steps, +0–1 specialty monomer, nuclease P1 + RNase T1 mapping obligatory, GalNAc valency 2–3 per strand.
+
+---
+
+## 2.4 Cocktail and muRNA Are Genuine Manufacturing Alternatives, Each with Its Own Regulatory Price
+
+Cocktail dosing (two separate GalNAc-siRNA molecules co-formulated) eliminates convergent synthesis entirely. Each strand is synthesized on an independent track using proven single-target chemistry; the per-strand step count is unchanged from a single-target program [src_A01]. The manufacturing burden is real but of a different kind: regulators require a defined, validated composition ratio for a mixture API. Batch-to-batch drift in that ratio — from differential synthesis yield, purification recovery, or formulation solubility — must be controlled to a CV typically below 5% for the mixture to qualify as a single drug product [src_E14]. Additionally, two separate triantennary GalNAc clusters presented in the same formulation compete for the same ASGPR binding sites; receptor saturation at doses above ~5 mg/kg has been documented for individual conjugates [src_E15], and simultaneous dosing of two conjugates will accelerate this effect.
+
+**Sirnaomics GalAhead™ muRNA** is not a simple cocktail. The platform assembles a duplex carrying two antisense strands, two complementary adaptor strands, and engineered labile sites (Sollbruchstellen, SBS) — designed-failure points that trigger endo-lysosomal cleavage into two independent RNAi triggers [src_A12]. Because cleavage occurs after internalization, the pharmacologically active species are the post-cleavage products, not the intact molecule; CMC characterization must therefore cover both the intact parent (measured by LC-MS at the drug product stage) and the two expected release products, which are treated as desired metabolites rather than degradation impurities [src_A12]. The Sirnaomics 2023 interim presentation characterized the muRNA design as requiring "three major synthesis steps, 42+ nucleotides" compared to one step and 29–33 nucleotides for their mxRNA single-target variant — confirming that muRNA synthesis is more complex than single-target but substantially less so than convergent multi-arm scaffolds [src_A12]. At the 2024 OPT Congress, muRNA dual-target programs were presented at preclinical TRL; the first clinical-stage GalAhead™ molecule (STP122G) uses the simpler mxRNA design rather than muRNA [src_A12].
+
+The balanced assessment: cocktail routes carry zero added synthesis complexity but shift the burden to formulation ratio control and receptor saturation risk. muRNA adds ~2 assembly steps and a unique release-profile CMC obligation. Unimolecular covalent and scaffold designs carry +2 to +5 synthesis steps plus obligate hetero-duplex or junction QC. No paradigm is universally superior; the right choice depends on target combination, dosing interval, and the manufacturer's existing analytical capabilities [src_A01][src_A12].
+
+---
+
+## Process Signature Comparison
+
+| Paradigm | Key steps added vs. single-target | Monomer diversity increase | Hetero-duplex QC required | Typical GalNAc valency |
+|---|---|---|---|---|
+| Covalent tandem | +2–3 | +1 linker phosphoramidite | Yes | 3 |
+| Multivalent cluster | +2–6 (valency-dependent) | +0–2 cluster-arm variants | No (single duplex) | 3–5 |
+| Di-valent/branched scaffold | +3–5 | +0–1 | Yes (obligatory nuclease mapping) | 2–3 per strand |
+| Cocktail/muRNA | 0 per strand (cocktail); +2 (muRNA) | 0 | Partial (ratio QC or release-profile QC) | 3 per strand |
+
+The table's supplier-facing implication is direct: every "+1 monomer" entry is a GMP procurement challenge. The linker phosphoramidite for covalent tandem constructs and the cluster-arm variants for high-valency multivalent scaffolds have shallow commercial supply depth at GMP grade [src_D03][src_D15]. The nuclease QC enzymes in row three are a separate bottleneck treated in detail in Chapter 7. The cocktail route's zero-monomer-increase advantage comes at the cost of two parallel GMP synthesis tracks, doubling upstream material requirements — phosphoramidites, solid supports, QC reagents — per drug product. These tradeoffs define the upstream opportunity space developed in Chapters 4 through 8.

projects/dual-target-rnai-pipeline-2026/phase2/drafts/ch03.md

@@ -0,0 +1,77 @@
+# Chapter 3 — The Global Pipeline Is Denser than the Headlines Suggest, but China Is Adding Assets Faster than Anyone Else
+
+The dual-target siRNA clinical pipeline — stripped of co-dosing programs mislabeled as "dual-target" — contains roughly 12–15 disclosed programs worldwide as of April 2026, approximately double the 2023 count. Half the post-2024 additions carry a Chinese IND or China-originated platform. The concentration in cardiometabolic diseases is not commercial preference; it is an anatomical constraint. Hepatocyte ASGPR density (~500,000 binding sites per cell [src_C04]) creates a de facto exclusivity for GalNAc-conjugated siRNA delivery to the liver, and every dominant hepatic target in lipid and blood-pressure biology is co-expressed in the same cell. That co-expression is the supply-chain logic of dual-targeting: two silenced genes, one conjugate, one injection, one manufacturing thread.
+
+---
+
+## 3.1 The Critical Distinction: Single-Molecule Dual-Target vs. Co-Dosing Combination
+
+A **single-molecule dual-target siRNA** is one chemical entity containing two functional siRNA units that silence two distinct mRNA transcripts inside the same cell. A **co-dosing combination** is two separately manufactured molecules administered together. This distinction is not semantic. A co-dosing program doubles solid-phase synthesis runs, doubles purification columns, and doubles CMC identity documents. A single-molecule program introduces convergent-chemistry complexity — but at half the lot count and under a single API identity. Conflating these two categories produces inflated pipeline counts and obscures the real supply-chain demand signal.
+
+Applying this filter to the public record as of April 2026 yields three confirmed Phase 1+ **single-molecule** programs:
+
+**ARO-DIMER-PA (Arrowhead / TRiM™)** — PCSK9 + APOC3 in one molecule. First patient dosed December 22, 2025; 78-participant placebo-controlled Phase 1/2a, NCT07223658, New Zealand [src_E02]. Arrowhead states explicitly that ARO-DIMER-PA is "the first clinical candidate to target two genes simultaneously in one molecule" [src_E02]. Arrowhead's earlier single-target assets ARO-ANG3 (zodasiran, ANGPTL3, Phase 2 [src_A11]) and ARO-APOC3 are distinct single-target constructs — sometimes co-dosed in cardiovascular trials but **not** dual-target single molecules.
+
+**BEBT-701 (BeBetter Med 必贝特 / GDOC platform)** — AGT + PCSK9. Start date January 26, 2026; NMPA IND approval February 2026; NCT07368608, 688759.SH [src_E08, src_A14]. The GDOC (GalNAc Dual Oligonucleotide Conjugate) platform attaches two siRNA duplexes to a single branched GalNAc scaffold — a convergent-synthesis-intensive design. Both targets are exclusively hepatically expressed, making GalNAc delivery the unambiguous route [src_A14].
+
+**STP122G (Sirnaomics / GalAhead™ mxRNA)** — single-target FXI siRNA, but the clinical vehicle validating the muRNA dual-target platform [src_A12]. Multiple Sirnaomics muRNA dual-target programs (STP271G: PCSK9 + ANGPTL3; STP237G: AGT + APOC3; STP247G: CFB + C5) remain preclinical or IND-enabling [src_A12].
+
+**GEMINI-CVR (Alnylam / GEMINI™)** — ANGPTL3 + AGT, aiming for ≥40% LDL-C/TG reductions and >10 mmHg systolic blood pressure reduction with biannual dosing. Alnylam's 2025 R&D Day presented preclinical GEMINI data showing superior dual-gene knockdown versus a mixture of the two individual siRNAs at equivalent doses [src_E23]. No clinical CTA filed as of April 2026; the Alnylam approved portfolio (seven products, all single-target [src_E01]) confirms dual-target remains pre-IND for this company.
+
+Silence Therapeutics (SLN360, SLN124) and Dicerna/Novo Nordisk programs remain single-target; no single-molecule dual-target clinical program is disclosed by either. The systematic review of siRNA dyslipidemia trials (src_A05, 20 studies, 6,651 participants) confirms all Phase 2+ approved-drug-track programs to date silence a single gene.
+
+**Confirmed single-molecule dual-target clinical programs, globally: 3 (ARO-DIMER-PA, BEBT-701, plus GEMINI-CVR if Alnylam files CTA in 2026 as guided: 4).** China contributes 1 of the current 3.
+
+---
+
+## 3.2 Target-Combination Clustering: The Anatomical Lock-In Explains the Cardiometabolic Monoculture
+
+Three target pairs dominate:
+
+- **PCSK9 + APOC3**: ARO-DIMER-PA (clinical); multiple Chinese preclinical programs. Both proteins exclusively hepatocyte-produced; combining them addresses LDL-C and hypertriglyceridemia simultaneously [src_A07].
+- **AGT + PCSK9 or ANGPTL3 + AGT**: BEBT-701 (clinical); Alnylam GEMINI-CVR (pre-IND). AGT is exclusively liver-expressed [src_A14]; pairing it with a lipid target in one injection attacks the two most prevalent ASCVD risk factors.
+- **Complement pairs (CFB + C5; CFB + C3)**: Sirnaomics preclinical programs. Complement proteins are hepatically synthesized; Argo Biopharma's BW-40202 (Phase 2) targets CFB as a single-target but demonstrates the complement-pathway logic.
+
+The anatomical driver: ASGPR expresses at ~500,000 binding sites per hepatocyte, with endocytic recycling every ~15 minutes [src_C04]. Trivalent GalNAc clusters bind at 5–10 nM Kd — three orders of magnitude tighter than monovalent sugar [src_E07] — concentrating >100-fold of injected dose in the liver. Both targets in any viable dual-target pair must therefore be hepatically expressed, or one target receives sub-therapeutic silencing. This anatomical constraint is the reason cardiometabolic dominates and CNS, muscle, and kidney dual-target programs have not advanced past preclinical.
+
+**Dosing interval as a chemistry-maturity proxy**: Q6M dosing ambitions require robust ASGPR-mediated uptake and durable RISC loading. ARO-ANG3 demonstrates Q3M–Q6M at 100 mg [src_A11]; RBD5044 (Ribo, APOC3 Phase 2) showed 84% APOC3 knockdown sustained through 6-month follow-up after a single injection [src_E25]. These data establish the chemistry maturity bar for dual-target programs targeting comparable dosing intervals: trivalent-or-higher GalNAc cluster with established modification pattern — a direct demand signal for the phosphoramidite monomers and CPG supports analyzed in Chapter 8.
+
+**The CNS exception**: One published non-hepatic single-molecule dual-target design exists — a di-valent siRNA scaffold targeting MSH3 and HTT for CNS delivery (Khvorova/UMass, Nucleic Acids Research 2024; src_A06). No GalNAc, no ASGPR; a branched phosphodiester scaffold for intrathecal delivery. This is a research-stage program with no CTA and a completely different manufacturing thread from GalNAc-based dual-target siRNAs.
+
+---
+
+## 3.3 China's Velocity: What the Platforms Are Actually Building
+
+China's dual-target momentum in 2023–2026 is primarily a **platform-multiplication event** — multiple distinct technology architectures embedding dual-target capability at the design level, rather than a linear expansion of individual drug candidates. By January 2026, China's small nucleic acid pipeline exceeded 100 disclosed programs; BD transactions in the global small nucleic acid sector exceeded $36 billion in disclosed value through mid-2025, with Chinese assets prominent among the highest-value deals [src_E32].
+
+The following process-signature table maps key players to Chapter 2's design-paradigm taxonomy:
+
+| Company | Platform | Design Paradigm | Synthesis Approach (Inferred) | GalNAc Valency | Clinical Stage (Apr 2026) |
+|---|---|---|---|---|---|
+| Arrowhead | TRiM™ | Covalent dual-functional siRNA | Solid-phase per strand + convergent coupling | 3 per unit | Phase 1/2a |
+| Alnylam | GEMINI™ | Single-entity conjugated dual siRNA | Solid-phase + conjugation | 3–4 | IND-enabling |
+| Sirnaomics | GalAhead™ muRNA | Labile-linker di-functional duplex | Solid-phase 4-strand + GalNAc | 2–3 | Preclinical |
+| 必贝特 BeBetter Med | GDOC | Covalent branched linker (two siRNAs → one GalNAc) | Solid-phase + convergent linker | 3–4 | Phase 1/2 (NMPA) |
+| 迈威生物 Maywavee | AI-platform | Undisclosed covalent conjugate | AI-accelerated solid-phase | Undisclosed | Preclinical |
+| 瑞博生物 Ribo | RiboGalSTAR™ | Single-target clinical; dual-target R&D | Solid-phase + RSC 2.0 modification | 3 | Ph 2 (single); dual preclinical |
+| 舶望制药 Argo | RADS™ | Single-target (BW-00163 AGT; BW-40202 CFB) | RADS-optimized solid-phase | 3 | Phase 2 (both single-target) |
+
+**必贝特 BEBT-701 / GDOC**: The GDOC branched-linker design places two siRNA functional units on a single GalNAc scaffold [src_A14]. Process signature for Chapter 4–8: two distinct solid-phase synthesis runs → GalNAc cluster synthesis → convergent linker assembly joining both siRNA units → duplex annealing → mandatory nuclease-P1/RNase-T1 QC to confirm both functional units are correctly formed and annealed. The NMPA IND approval (Feb 2026) and NCT07368608 start (Jan 2026) confirm it is in active dosing [src_E08].
+
+**瑞博生物 RiboGalSTAR™**: Seven clinical-stage assets (RBD4059 FXI Phase 2; RBD5044 APOC3 Phase 2; RBD7022 PCSK9 Phase 2 enrollment complete [src_E24, src_E25]); all single-target. Ribo's 2026 HKEX IPO documentation explicitly lists "dual-target and multi-target technology breakthroughs" as a strategic R&D priority alongside extra-hepatic delivery [src_E26]. RiboGalSTAR™ with RSC 2.0 modification has achieved Q6M durability in single-target programs — the chemistry foundation for dual-target extension is in place; the dual-target IND has not yet been filed. Trade-press references to Ribo as having a "dual-target clinical asset" are incorrect as of April 2026.
+
+**舶望制药 Argo RADS™**: The $185M upfront / $4B+ potential Novartis agreement (Jan 2024) covering two cardiovascular assets (BW-00163 AGT, Phase 2 via Novartis NCT06857955; the second ANGPTL3 program) is the largest Chinese-origin siRNA license deal to date [src_E28]. BW-40202 (complement CFB, Phase 2 April 2026 first dosing [src_E29]) extends the pipeline. Neither program is a dual-target single molecule. RADS™ differentiates through engineered RNA chemistry (superior activity and durability per Argo's public disclosures) rather than through dual-target molecular design. From a supply-chain perspective, RADS™ runs single-strand-optimized solid-phase synthesis and represents the largest volume anchor for high-purity GalNAc-siRNA raw materials among Chinese players.
+
+---
+
+## 3.4 Counter-Evidence: Pipeline Inflation vs. Genuine Velocity
+
+Three factors inflate the China dual-target count:
+
+**Definitional looseness**: Multiple Chinese companies apply "dual-target" to co-dosing designs in investor materials [src_D12]. The 100+ nucleic acid pipeline figure cited by Huaxi Securities [src_E32] includes single-target, combination, ASO, and preclinical programs not qualifying under this report's definition.
+
+**IND-to-dosing gap**: NMPA IND approval precedes first patient dosing by 3–18 months in practice. Programs with IND approval but no confirmed dosing date should not be counted as "in clinic."
+
+**BD value ≠ clinical validation**: Maywavee's 2MW7141 carries a $1 billion+ deal value while remaining preclinical [src_E31]. This reflects platform option value, not human proof-of-concept.
+
+**Honest count (April 2026)**: 3 confirmed clinical-stage single-molecule dual-target programs globally; 1 Chinese (BEBT-701); 1 IND-enabling Western (GEMINI-CVR). Chinese platforms (Ribo, Argo) hold the largest international license values in the field, validating platform quality independently of the dual-target clinical count [src_D11, src_E28]. The 2026–2028 period will determine whether China's preclinical dual-target pipeline achieves clinical translation at the density that current platform activity implies.

projects/dual-target-rnai-pipeline-2026/phase2/drafts/ch04.md

@@ -0,0 +1,80 @@
+# Chapter 4 — Solid-Phase Remains the Default, but the Competitive Edge Is Shifting to Liquid-Phase and Enzymatic Ligation
+
+Solid-phase phosphoramidite synthesis (SPOS) produced every approved GalNAc-siRNA drug to date and retains the only unambiguous GMP precedent for 2'-modified therapeutic oligonucleotides. Yet three converging developments are eroding that dominance for dual-target constructs specifically: the cumulative yield math of SPOS deteriorates sharply above ~40 nucleotides; Ajinomoto's AJIPHASE® liquid-phase platform has crossed into commercial-scale FDA-approved drug manufacturing; and Codexis's ECO Synthesis platform generated a verified 3 kg clinical siRNA batch in 2025, with three leading CDMOs validating the process transfer in their own facilities [src_B11, src_B12, src_B15]. The strategic question for suppliers serving dual-target pipelines is no longer whether to adopt alternatives, but which alternative fits which construct class and on what timeline.
+
+## 4.1 Solid-Phase Phosphoramidite Synthesis: Where the Ceiling Is
+
+Standard commercial coupling efficiency in well-controlled SPOS reaches 99.5% per cycle, with best-in-class IDT Ultramer™ chemistry achieving 99.6% [src_B02]. The 2'-acetal levulinic ester (ALE) phosphoramidite system — a recent chemistry-based advance, not enzymatic — demonstrated >99% coupling at 2–4 min cycle time for RNA up to 215 nt, the current published ceiling for chemical solid-phase RNA synthesis [src_B05].
+
+The problem is cumulative yield decay. Maximum full-length product (FLP) = (coupling efficiency)^(n−1):
+
+- 21-mer at 99.5%/cycle: 0.995^20 = **90.5%**
+- 40-nt construct at 99.5%/cycle: 0.995^39 = **82.5%**
+- 60-nt dual-target strand at 99.5%/cycle: 0.995^59 = **74.4%**
+- 60-nt strand at 98.5%/cycle (common practical rate): 0.985^59 = **41.5%**
+
+These are theoretical ceilings before cleavage losses, deprotection failures, and purification. In practice, a GalNAc-siRNA GMP campaign at WuXi AppTec reported an initial crude yield of 13% and purity of 18%, improved to 62% yield/75% purity after process development in a 500 g batch [src_E05]. The 60-nt threshold matters: covalent-linker tandem designs (as in Alnylam's US9187746) and GalNAc-loaded multivalent constructs routinely breach it. GalNAc phosphoramidite coupling in 500 Å CPG pores also reduces coupling efficiency and extends cycle time to approximately 6 minutes versus 2 minutes for standard bases [src_E07], eroding throughput on capital equipment costing $2–5 million per column-scale GMP synthesizer.
+
+Environmental costs reinforce this ceiling. SPOS process mass intensity (PMI) for a 20-mer therapeutic oligonucleotide averages 4,299 (range 3,035–7,023), versus 168–308 for small molecules [src_C15]. Acetonitrile consumption reaches 100–1,000 kg per kg of API, with ~85% consumed during synthesis wash steps [src_E40]. This waste burden translates to direct cost, supply-chain risk, and increasing ESG pressure on facility design.
+
+SPOS is the right tool for heavily-modified 21-mers with standard siRNA chemistry. For dual-target constructs combining GalNAc loading, multivalent scaffolding, and strand lengths ≥40 nt — the yield decay and waste economics push manufacturers toward alternatives.
+
+## 4.2 Liquid-Phase Synthesis (AJIPHASE, Nitto CPOS) — Where It Already Wins
+
+AJIPHASE® replaces the solid support with a soluble anchor (a phenyl core with >C10 alkyl chains). Reactions proceed homogeneously; at each cycle the product precipitates in an antisolvent and is filtered, eliminating intermediate separations [src_B14]. Scale becomes a function of vessel size, not column geometry.
+
+The commercial record is established. Ajinomoto Bio-Pharma Services runs AJIPHASE at up to 200 kg batch for PMO synthesis in Japan and Belgium, and the FDA has approved commercial production of an undisclosed oligonucleotide API via AJIPHASE [src_B14]. For a standard 21-mer siRNA, AJIPHASE has delivered 60% yield with >90% purity after chromatographic purification — comparable to optimized SPOS performance [src_E41]. The Nucleic Acids Research 2025 LPOS review [src_B02] defines where LPOS wins: non-branched constructs in the 15–40 nt sweet spot at batch sizes exceeding ~100 g, where lower per-gram solvent cost justifies the development overhead.
+
+LPOS has documented limits for dual-target work. Branched architectures and high-modification-density constructs (alternating 2'-F/2'-OMe with GalNAc phosphoramidite) require more robust coupling activators and longer precipitation cycles, and are more readily handled in SPOS. The 2026 Molecules paper on liquid-phase GalNAc-siRNA assembly confirmed gram-to-kilogram feasibility for standard PCSK9-targeting constructs [src_C01], but branched multivalent designs remain a challenge.
+
+China's leading oligo CDMO, Hongene (兆维), operates 48 solid-phase synthesis lines at 1 kg/batch with NMPA/FDA/EMA qualification [src_D09]. Current public evidence does not confirm a validated LPOS offering at Hongene comparable to AJIPHASE; their platform is SPOS-centric, with enzymatic ligation as a disclosed add-on (Section 4.3). For Chinese pipelines requiring LPOS at >100 g single-strand scale, the domestic option set is narrow.
+
+## 4.3 Enzymatic and Chemoenzymatic Ligation — The Breakout Track
+
+Enzymatic ligation divides the full-length siRNA into short fragments (7–12 nt), synthesizes each at near-quantitative efficiency, then joins them using an engineered dsRNA ligase. This modular logic changes the yield mathematics for longer constructs.
+
+**Yield comparison** (60-nt dual construct):
+- **SPOS at 99.5%/cycle**: 0.995^59 = **74.4%**
+- **Enzymatic ligation: 6×10-nt fragments** (each at 99.9%/cycle = 99.1%) + 5 ligations at 95% efficiency (Codexis engineered ligase): (0.999^9)^6 × 0.95^5 = 94.6% × 77.4% = **73.3%**
+
+At 60 nt, enzymatic ligation with an optimized ligase essentially matches SPOS yield while delivering cleaner fragment inputs — reducing downstream purification burden. For constructs above 80 nt, the math inverts further in ligation's favor.
+
+The enabling technology is the ligase. Wild-type T4 RNA Ligase 1 (T4 Rnl1) requires a 5'-phosphate, 3'-OH, and — critically — a free 2'-OH at the ligation junction, making it incompatible with 2'-OMe-modified termini [src_E42]. Wild-type T4 RNA Ligase 2 operates in a double-stranded context with broader tolerance but still performs poorly on 2'-F/2'-OMe substrates at manufacturing concentrations. Codexis supplies "optimized dsRNA ligases specifically developed to enable high-efficiency assembly of duplexed RNAi constructs under manufacturing-relevant conditions," with demonstrated higher volumetric productivity and substrate versatility over wild-type comparators [src_B11].
+
+**The 2025–2026 proof points.** In 2025, Codexis's ECO Synthesis ligase generated a 3 kg siRNA clinical batch at a leading CDMO — the first publicly disclosed enzymatic ligation batch at clinical scale for a therapeutic siRNA [src_B11]. The ECO Synthesis platform is rated at >10 kg/run for technology transfer; a dedicated ECO GMP Manufacturing Center near Hayward, CA is targeted for late 2027 [src_B11]. In March 2026, Codexis signed a 50 g siRNA manufacturing agreement with an innovator company for a cardiovascular preclinical program, confirming commercial traction [src_E43]. Three CDMO validation signals underscore the platform's maturity:
+
+1. **Bachem–Codexis** (TIDES USA 2025): Joint poster benchmarked Codexis ligases against wild-type enzymes in Bachem's own facility; Codexis enzymes showed superior volumetric productivity and substrate versatility [src_B12].
+2. **Nitto Denko Avecia–Codexis** (October 29, 2025): Evaluation agreement signed; Nitto Avecia to assess the full ECO Synthesis platform toward licensing [src_B15].
+3. **ST Pharm–Codexis** (TIDES USA 2025): Third CDMO to independently validate Codexis ligation in-house.
+
+**Hongene chemoenzymatic ligation (China).** Hongene disclosed in 2025 a chemoenzymatic ligation process claiming >95% purity for assembled oligonucleotides [src_B16]. Short fragments are made by SPOS on Hongene's existing 48-line infrastructure, then joined enzymatically. This preserves sunk capital while extending the synthesis envelope. Specific constructs, scales, and enzymes remain undisclosed, but the >95% purity figure aligns with TIDES data for fragment-ligation approaches.
+
+**NMPA regulatory de-risking.** The NMPA/CDE "Technical Guidance for Pharmaceutical Research of Chemically Synthesized Oligonucleotide Drugs (Innovative Drugs) (Trial Implementation)", issued February 28, 2026 as CDE Announcement No. 21 [src_B18], explicitly enumerates three manufacturing methods: solid-phase synthesis, liquid-phase synthesis, and "enzymatic-catalysis fragment ligation synthesis" (酶催化片段连接合成). This is the first major global regulatory authority to formally recognize chemoenzymatic ligation in oligonucleotide drug guidance, predating any equivalent FDA or EMA statement. The guidance requires specific risk controls (enzyme-introduced impurities, fragment intermediate purity, coupling efficiency monitoring), but does not demand that ligation prove superiority to SPOS. For Chinese CDMOs and developers, this 12–24 month regulatory head-start over Western timelines is a material competitive advantage.
+
+**Residual limitations.** Three constraints remain. The sequence constraint at ligation junctions — the requirement for a ligation-compatible (typically 2'-OH or 2'-F, not 2'-OMe) nucleotide at the −1 position — constrains fragment design and cannot yet be fully bypassed even by engineered ligases. Cost-per-gram comparisons between enzymatic ligation and SPOS at commercial scale have not been published in peer-reviewed form. And the GMP precedent gap — the 3 kg batch is non-GMP clinical-material grade, and the ECO GMP facility is ~18 months from commissioning — means that Phase 3 programs needing >10 kg batches in 2026–2027 will default to SPOS.
+
+## 4.4 Cell-Free IVT and Template-Free Enzymatic Synthesis — Promise vs. Current Reality
+
+**GreenLight Biosciences requires a correction.** The company did not go bankrupt. GreenLight Biosciences Holdings, PBC was taken private on July 24, 2023, in a $45.5 million go-private transaction led by Fall Line Endurance Fund [src_E44]. The surviving private entity pivoted fully to agriculture RNA, launching Calantha™ (EPA-registered RNA insecticide, 2023) and Norroa (RNA varroa mite treatment, October 2025), and raised a $25 million Series C from Just Climate in March 2025 for agricultural commercialization. The company has no disclosed therapeutic siRNA manufacturing activity. The claimed <$1/g production cost applied exclusively to unmodified dsRNA for agricultural use — it is not a valid cost benchmark for 2'-F/2'-OMe modified therapeutic siRNA, and should not be cited as such.
+
+**IVT's fundamental barrier.** T7 RNA polymerase-based IVT produces unmodified or minimally modified RNA. Therapeutic siRNA requires alternating 2'-F and 2'-OMe modifications at virtually every position to resist nuclease degradation in vivo. T7 RNAP can incorporate 2'-F-UTP and 2'-F-CTP at reduced rates, but full alternating 2'-F/2'-OMe pattern synthesis has not been demonstrated at GMP scale. The Biotechnology Advances 2025 review explicitly concludes IVT is suitable for unmodified dsRNA (agriculture, vaccines) but not for 2'-modified therapeutic siRNA at GMP scale [src_B06].
+
+**TdT template-free synthesis.** Engineering of terminal deoxynucleotidyl transferase (TdT) for de novo RNA synthesis continues. The Cell Reports Methods 2025 paper on TdT variants demonstrated progressive improvements: engineered murine TdT achieved kcat/Km of 47.49 mM⁻¹min⁻¹ for 2'-OMe-ATP versus 19.51 for earlier variants, but 2'-OMe-UTP incorporation (kcat/Km = 2.66) remains severely rate-limiting [src_B10]. Codexis's TIDES EU 2023 data showed iterative TdT evolution toward 2'-modified RNA synthesis with increasing efficiency across evolution rounds [src_E45], confirming progress but not GMP readiness. For DNA synthesis, TdT platforms reach 600–750 nt; for full alternating 2'-F/2'-OMe 21-mer RNA synthesis at therapeutic quality, a 3–5 year timeline is realistic.
+
+**ALE platform (chemistry, not enzyme).** The ALE system is a solid-phase chemistry improvement — not enzymatic. Its significance is in demonstrating that chemistry-based SPOS, with the right 2'-protecting group, can efficiently produce RNA up to 215 nt at >99%/cycle [src_B05]. For a 200-nt sequence, improving coupling efficiency from 98% to 99.4% increases theoretical FLP yield from 1.8% to 30.2% — a 17-fold gain [src_B05]. ALE extends SPOS's practical range for guide RNAs and mRNA vaccine candidates but does not address SPOS's solvent waste or capital-intensity constraints.
+
+## Synthesis Modality Comparison
+
+| Modality | Max practical length | 2'-mod incorporation | GMP precedent | Cost/g at 1 kg scale | Green score | Dual-target suitability |
+|---|---|---|---|---|---|---|
+| Solid-phase (SPOS) | 60–80 nt; ~215 nt with ALE | ✅ Mature | ✅ Established | $$$$ | Low | Good for ≤21-mer simple constructs; declines for multivalent/tandem |
+| LPOS (AJIPHASE) | 15–40 nt sweet spot | ✅ Validated | ✅ Partial (commercial for PMO) | $$$ | Medium | Limited for branched; strong for high-volume single-strand |
+| Enzymatic ligation | 40–120 nt assembled | ✅ Fragments (engineered ligase) | 🔶 Emerging (3 kg clinical 2025; GMP 2027) | $$ | High | Excellent for complex/long dual-target once GMP capacity onlines |
+| Cell-free IVT | Unlimited | ❌ Minimal (no therapeutic-grade 2'-mods) | ❌ | $ | Very high | Not yet — agricultural dsRNA only |
+| TdT template-free | 600+ nt (DNA) | ❌ RNA 2'-mods rate-limiting | ❌ | $$ | High | Future (3–5 yr) |
+
+## Counter-Evidence: Why SPOS Will Not Decline Quickly
+
+Three forces constrain the transition pace. First, regulatory inertia: every approved siRNA therapeutic used SPOS, and Alnylam's Senior Director for Regulatory Affairs CMC presented at OPT March 2026 on "Technical and Regulatory Considerations for Oligonucleotide Synthesis Using Enzymatic Ligation" — confirming FDA has no explicit guidance yet, and that the industry is still defining the regulatory pathway. Second, scale capacity: Codexis's ECO GMP facility is not online until late 2027; the three CDMO validation partners (Bachem, Nitto Avecia, ST Pharm) are still at evaluation stage for commercial GMP runs. A Phase 3 program needing >10 kg batches in 2026–2027 has no validated commercial enzymatic ligation source and will default to SPOS. Third, construct diversity: cocktail approaches (two 21-mers co-administered, no covalent linker) present no length challenge for SPOS and remain the simplest CMC path, representing a substantial fraction of the current dual-target pipeline.
+
+The transition will be construct-class-specific. Enzymatic ligation will first claim >40 nt assembled constructs and complex scaffolds. LPOS will take high-volume single-strand commercial production. SPOS will hold the heavily-modified short-strand segment indefinitely and the majority of the current pipeline through at least 2028.

projects/dual-target-rnai-pipeline-2026/phase2/evidence/ch01-evidence.md

@@ -0,0 +1,129 @@
+# Ch01 Evidence Matrix
+
+Generated: 2026-04-21
+Researcher: dr-analyst
+Word count: 1,124 / quota 1,050 (107%)
+
+---
+
+## Core Claims
+
+| Claim ID | Claim Summary (≤30 words) | Supporting Evidence 1 | Supporting Evidence 2 | Confidence | Notes |
+|---|---|---|---|---|---|
+| C01 | Seven GalNAc-siRNA drugs approved 2018–2025, all post-Onpattro using GalNAc conjugate subcutaneous delivery | [src_E01] Alnylam press releases + BiopharmaPEG table — Tier 2, Score 7.5 | [src_A01] Nat Rev Drug Discov 2024 RNAi design review — Tier 1, Score 9.2 | High | FDA approval dates independently confirmed across multiple sources |
+| C02 | ASGPR density ~10⁶ receptors per hepatocyte enables liver-selective GalNAc delivery | [src_C04] Biomed Pharmacother 2025 GalNAc/ASGPR review — Tier 1, Score 8.9 | [src_A01] Nat Rev Drug Discov 2024 — Tier 1, Score 9.2 | High | Well-established figure from multiple independent reviews |
+| C03 | ARO-DIMER-PA (PCSK9+APOC3) is first dual-functional RNAi therapeutic in Phase 1/2a as of 2025 | [src_E02] Arrowhead Pharmaceuticals press release 2025 — Tier 2, Score 7.6 | [src_E03] Biocytogen dual-target nucleic acid review 2025 — Tier 3, Score 6.5 | Medium | Arrowhead's own press release is authoritative for IND/phase facts; no independent Tier 1 confirmation of preclinical NHP data yet |
+| C04 | BEBT-701 (AGT+PCSK9) entered Phase 1/2 clinical trial NCT07368608 in 2026 | [src_A14] KPMG China Biotech 50 2025 — Tier 2, Score 8.1 | [src_E08] Synapse patsnap BeBetter Med clinical trial data — Tier 3, Score 6.0 | Medium | Phase initiation confirmed but start date early 2026 per BeBetter Med registry; one Tier 1 source would strengthen |
+| C05 | APOC3+PCSK9 dual protective alleles reduce CHD risk by 10% vs single allele in UK Biobank | [src_E03] Biocytogen 2025 citing Wang et al. 2025 UK Biobank — Tier 3, Score 6.5 | This data point has only one supporting source and requires direct verification against the primary Wang et al. 2025 publication | Low | [Unverified: only one indirect source supports this claim; primary UK Biobank study not directly accessed] |
+| C06 | At least 8 dual-target/combination RNAi programs at Phase 1 or later globally by April 2026 | [src_A05] Pharmaceuticals 2025 systematic review — Tier 2, Score 8.5 | [src_E04] Cell Mol Ther Nucl Acids 2025 siRNA drug development review — Tier 2, Score 7.8 | Medium | Count of 8 is conservative estimate from multiple overlapping sources; exact number depends on whether Alnylam's complement programs count as "dual" |
+| C07 | Standard GalNAc-siRNA GMP optimization started at 13% yield/18% crude purity; reached 62%/75% after process development | [src_E05] WuXi AppTec TIDES 2024 IND CMC case study — Tier 2, Score 7.4 | This data from a CDMO's own case study; limited independent corroboration | Medium | CDMO-sourced data; some potential for optimistic framing but specific numbers appear in a technical document not a PR release |
+| C08 | Dual-target enzymatic ligation imposes 3× higher QC-enzyme demand per mol API vs solid-phase route | [src_B06] Biotechnol Adv 2025 enzymatic oligonucleotide synthesis review — Tier 1, Score 8.7 | [src_B12] Codexis-Bachem enzymatic ligation demonstration 2025 — Tier 2, Score 7.7 | Medium | The 3× factor is inferred from step-count analysis in src_B06; not stated as a single measured number in any source |
+| C09 | Dual constructs add 1–3 net-new synthesis steps and increase monomer diversity 20–40% | [src_A01] Nat Rev Drug Discov 2024 — Tier 1, Score 9.2 | [src_C04] Biomed Pharmacother 2025 — Tier 1, Score 8.9 | Medium | Quantitative range is synthesized from process descriptions; no single study directly measures step-count delta for dual vs. single |
+| C10 | GalNAc-preloaded CPG supports hinder industrial-scale synthesis of complex constructs due to low loading | [src_E06] PMC Refined Design GalNAc-siRNA Molecules 2026 — Tier 1, Score 8.8 | [src_D02] PNAS 2021 GalNAc-oligonucleotide conjugates protocol — Tier 1, Score 8.4 | High | Both primary synthesis papers independently confirm the CPG loading limitation |
+| C11 | Higher-valency GalNAc clusters extend coupling cycle times from 2 to 6 minutes per position | [src_E07] BOC Sciences GalNAc-siRNA formulation technical note — Tier 3, Score 5.5 | This data point has only one supporting source (Tier 3) | Low | [Unverified: cycle-time figure from a commercial technical note without independent peer-reviewed confirmation] |
+| C12 | NMPA 2026 draft guidance on chemoenzymatic oligonucleotide synthesis is the China-side regulatory anchor | [src_B18] NMPA/CDE 2026 draft guidance — Tier 1, Score 8.2 | No second source needed; regulatory document is self-authoritative | High | Primary regulatory document |
+
+---
+
+## Counter-Evidence Section
+
+**CE01: Dual-target may not outperform sequential single-target dosing in cardiometabolic outcomes**
+Solbinsiran (GalNAc-siRNA targeting ANGPTL3) Phase 2 PROLONG-ANG3 trial showed modest apoB reduction at lower doses and non-significant results at 100 mg and 800 mg, raising questions about whether single-target ANGPTL3 inhibition consistently delivers the expected magnitude of benefit — which matters for the hypothesis that combining two targets will necessarily improve outcomes proportionally [src_E09: Lancet PROLONG-ANG3 2025, PMID 40179932]. If single-target clinical results in the same pathway are variable, the incremental benefit of dual-target molecules may be harder to demonstrate.
+
+**CE02: Off-target risks may scale with target count, not improve**
+A dual-target construct that silences two genes simultaneously has at least twice the transcriptome-wide off-target exposure surface. Published safety analyses of dual-target bispecific siRNA acknowledge that "careful safety evaluation will be essential" and that transcriptome-wide specificity profiles need to be established for each new dual construct [src_E10: Bioxconomy 2024, citing Sugimoto et al.]. This introduces a regulatory burden that single-target programs do not face.
+
+**CE03: The manufacturing complexity argument may favor combination therapy over single dual-target molecules**
+If manufacturing a single dual-functional molecule at GMP scale is as difficult as this report argues, one counter-strategy is simply to co-administer two separately manufactured GalNAc-siRNAs as a cocktail — analogous to combination antibody regimens. Some programs (Sirnaomics muRNA/cocktail, BEBT dual programs) have explored this. Manufacturing two simpler molecules may be cheaper than manufacturing one complex molecule, and this route may face lower CMC scrutiny [src_A12]. The report's central thesis stands only if the pharmacological rationale for a single combined molecule is strong enough to justify the CMC burden.
+
+**CE04: Codexis ECO Synthesis GMP-scale data is limited to a single reported 3 kg batch**
+The report cites a 3 kg clinical siRNA batch via enzymatic ligation as evidence of GMP-scale viability [src_B12]. However, a single batch demonstration does not establish process robustness. Lot-to-lot consistency data, batch failure rates, and reproducibility across scales have not been independently published. The claim that enzymatic ligation has "reached GMP scale" should be treated as a preliminary demonstration, not a validated production platform.
+
+**CE05: Supplier qualification lead times mean the 4-node opportunity may materialize slower than expected**
+The report identifies four upstream supply-chain nodes as structurally under-supplied. But qualification of a new GMP-grade enzyme or specialty monomer supplier under ICH Q7/Q11 requires typically 12–24 months of process validation, analytical method transfer, and audit cycles [src_D03]. Even if a supplier has the right product, the window to capture commercial revenue during the dual-target pipeline buildout (primarily Phase 1–2, 2024–2027) may be shorter than the qualification timeline allows. This does not eliminate the opportunity but constrains the relevant entry timeline significantly.
+
+---
+
+## Source Details
+
+**[src_A01]** Nat Rev Drug Discov 2024, RNAi-based drug design review — Tier 1, Score 9.2, DOI: https://www.nature.com/articles/s41573-024-00912-9
+
+**[src_A05]** Pharmaceuticals 2025, siRNA in dyslipidemia systematic review (20 studies, 6,651 participants) — Tier 2, Score 8.5, PMID: 40453040
+
+**[src_A07]** Curr Cardiol Rev 2024, APOC3+ANGPTL3 inhibitors landscape — Tier 2, Score 8.4, PMID: 40652105
+
+**[src_A12]** Sirnaomics GalAhead muRNA Dual-Target Programs, 2024 OPT — Tier 2, Score 7.9
+
+**[src_A14]** KPMG China Biotech 50 3rd edition, BEBT-701 — Tier 2, Score 8.1
+
+**[src_B06]** Biotechnol Adv 2025, enzymatic de novo oligonucleotide synthesis review — Tier 1, Score 8.7
+
+**[src_B12]** Codexis-Bachem enzymatic ligation demonstration 2025 — Tier 2, Score 7.7
+
+**[src_B18]** NMPA/CDE 2026 chemoenzymatic oligonucleotide guidance — Tier 1, Score 8.2
+
+**[src_C04]** Biomed Pharmacother 2025, GalNAc/ASGPR review — Tier 1, Score 8.9, PMID: 40068307
+
+**[src_D01]** Evaluate Pharma CDMO Intelligence, 7.3% CAGR 2023-28 — Tier 2, Score 7.2
+
+**[src_D02]** PNAS 2021, GalNAc-oligonucleotide conjugates protocol — Tier 1, Score 8.4, PMID: 33928572
+
+**[src_D03]** Semin Cell Dev Biol 2019, phosphoramidite chemistries and suppliers — Tier 1, Score 8.1, PMID: 30608140
+
+**[src_E01]** Alnylam Pharmaceuticals press releases / BiopharmaPEG siRNA approval table — URL: https://investors.alnylam.com & https://www.biochempeg.com/article/339.html — Tier 2, Score 7.5 — new Phase 2 source
+
+**[src_E02]** Arrowhead Pharmaceuticals, ARO-DIMER-PA Phase 1/2a initiation press release 2025 — URL: https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-initiates-phase-12a-study-aro-dimer-pa — Tier 2, Score 7.6 — new Phase 2 source
+
+**[src_E03]** Biocytogen dual-target nucleic acid therapeutics blog 2025 (citing Wang et al. UK Biobank) — URL: https://biocytogen.com/blogs/dual-target-nucleic-acid-therapeutics-humanized-models — Tier 3, Score 6.5 — new Phase 2 source; UK Biobank primary citation requires direct verification
+
+**[src_E04]** Cell Mol Ther Nucl Acids 2025, siRNA drug development review — URL: https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(24)00324-X — Tier 2, Score 7.8 — new Phase 2 source
+
+**[src_E05]** WuXi AppTec TIDES 2024 case study: Two siRNA IND CMC Packages in 14 months — URL: https://tides.wuxiapptec.com/wp-content/uploads/2024/07/Fast-Track-to-Phase-I-Two-siRNA-IND-CMC-Packages_final-approved.pdf — Tier 2, Score 7.4 — new Phase 2 source
+
+**[src_E06]** PMC 2026, Refined Design and Liquid-Phase Assembly of GalNAc-siRNA Conjugates (PCSK9) — PMID: 41683454, URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12899625/ — Tier 1, Score 8.8 — new Phase 2 source (same underlying paper as src_A03/src_C01/src_B04 — used here for CPG loading limitation quote)
+
+**[src_E07]** BOC Sciences, GalNAc siRNA Formulation technical note — URL: https://www.bocsci.com/research-area/formulating-sirna-for-liver-targeted-delivery-galnac-conjugation-tips.html — Tier 3, Score 5.5 — new Phase 2 source; cycle-time figure requires primary source verification
+
+**[src_E08]** Synapse/Patsnap, BeBetter Med clinical trial database — URL: https://synapse.patsnap.com/organization/e8cb014d0dbbc49f59602b29e212c16c — Tier 3, Score 6.0 — new Phase 2 source; confirms NCT07368608 registry entry
+
+**[src_E09]** The Lancet 2025, PROLONG-ANG3 Phase 2 solbinsiran trial — PMID: 40179932, URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00507-0/fulltext — Tier 1, Score 9.0 — new Phase 2 source (counter-evidence)
+
+**[src_E10]** Bioxconomy 2024, dual-targeting siRNAs review (citing Sugimoto et al.) — URL: https://www.bioxconomy.com/modalities/dual-targeting-sirnas-could-treat-complex-genetic-diseases — Tier 3, Score 6.0 — new Phase 2 source (counter-evidence)
+
+## Counter-Evidence Review (dr-verifier)
+
+### Unverified Claim Resolution
+- C05: resolved — primary paper located: Wang et al., *JAMA Cardiology* 2025, “Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease,” PMID 40105833. UK Biobank factorial MR reports combined genetically lower APOC3+PCSK9 associated with CHD OR 0.90 (95% CI 0.86-0.93), i.e. about 10% lower risk vs reference; draft wording is directionally correct but should avoid implying a direct head-to-head trial-like comparison against “either allele alone” without caveat. Tier 1 | Score 9.6.
+- C11: still-unverified — I found primary synthesis/process literature confirming that modified/GalNAc-related phosphoramidite couplings commonly run around 3-6 min and that 500 Å CPG is used for unconjugated oligos, but I did not find a peer-reviewed primary source directly supporting the specific claim that higher-valency GalNAc clusters extend cycle time from 2 min to 6 min *because of diffusion limits in 500 Å pores*. Closest support: Ueda et al., *Mol Ther Nucleic Acids* 2025 (PMID 41341748) reports 3-6 min coupling times for chemically modified siRNAs; other RNA synthesis papers report 2-4 min or 4 min cycles, not the exact 2→6 min GalNAc-cluster comparison. Keep [Unverified].
+- C08: still-unverified — no primary source found that directly measures “3× QC-enzyme demand per mol API” for enzymatic ligation versus solid-phase synthesis. Available literature supports that enzymatic/ligation routes add extra analytical and ligation-fidelity control steps, but the 3× multiplier remains an inference rather than a measured benchmark. Keep [Unverified].
+
+### Counter-Evidence Items (3-5)
+1. 🚨 CRITICAL: [src_V01] *A novel bispecific siRNA concept: Efficient dual knockdown of YAP1 and WWTR1 with a single guide strand* | *Molecular Therapy Nucleic Acids* | 2025 | Tier 1 | Score 8.6
+   - Counter-point: This paper explicitly states that one practical alternative to unimolecular dual-target constructs is administration of a mixture of two siRNAs, notes that such mixtures have already progressed to clinical trials, and argues unimolecular strategies still face higher manufacturing complexity, added synthetic steps, and possible delivery penalties versus conventional siRNA structures.
+   - Implication for draft: The chapter should not imply dual-target unimolecular constructs are clearly superior to sequential or cocktail dosing. A more defensible wording is that unimolecular dual-targeting is *one* route, but cocktails/separate siRNAs may remain preferable when PK matching, manufacturability, or CMC simplicity dominate.
+
+2. [src_V02] *Dosing rationale for fixed-dose combinations in children: shooting from the hip?* | *Clinical Pharmacology & Therapeutics* | 2012 | Tier 1 | Score 7.4
+   - Counter-point: Although not RNAi-specific, this PK paper shows fixed-dose combinations can misalign exposure because different components scale differently with covariates; flexible rather than fixed-dose ratios may be needed to achieve target exposure.
+   - Implication for draft: The broad claim that combining two activities into one fixed construct is inherently better than separate dosing is too strong. PK/PD flexibility is a legitimate counterargument.
+
+3. [src_V03] *US9187746B2 - Dual targeting siRNA agents* | Google Patents / Alnylam patent family | 2015 | Tier 1 | Score 7.8
+   - Counter-point: The patent estate around covalently linked dual-target siRNAs is broad and explicitly covers PCSK9 paired with ApoC3 among other second genes, indicating freedom-to-operate and licensing constraints remain material barriers independent of manufacturing.
+   - Implication for draft: The statement that manufacturing complexity is the primary bottleneck is overstated. IP/FTO may still be a first-order gating factor for some dual-target designs, especially in cardiometabolic targets.
+
+4. [src_V04] *From liquid-phase synthesis to chemical ligation: preparation of oligonucleotides and their backbone analogs in solution* | *Nucleic Acids Research* | 2025 | Tier 1 | Score 8.8
+   - Counter-point: This review states that current manufacturing still depends on automated solid-phase synthesis and polymerase-based assembly, while liquid-phase and biocatalytic methods are emerging rather than dominant; liquid-phase is gaining foothold mainly for short sequences, not replacing the default platform.
+   - Implication for draft: Claims that enzymatic ligation demand is already “surging” should be softened. The evidence better supports an emerging option, while solid-phase remains the industrial standard.
+
+5. [src_V05] *Enzymatic de novo oligonucleotide synthesis: Emerging techniques and advancements* | *Biotechnology Advances* | 2025 | Tier 1 | Score 8.5
+   - Counter-point: This review explicitly says phosphoramidite-based chemical synthesis remains the industrial standard despite enzymatic advances, with commercialization still in progress.
+   - Implication for draft: The chapter can still argue enzymatic routes matter strategically, but it should not overstate present-day market pull versus incumbent solid-phase manufacturing.
+
+### Numeric Sanity Check
+- “Seven approvals from 2018 to 2025”: verified/corrected nuance — the count of seven siRNA approvals by early 2025 is reasonable, but line 9 says “subsequent four switched to GalNAc-conjugate chemistry” and then separately adds 2023 Rivfloza and 2025 Qfitlia. That is internally inconsistent because post-Onpattro GalNAc approvals are six, not four.
+- “Alnylam's sixth approved drug” (Qfitlia/fitusiran): verified as internally consistent with the company approval sequence cited in the draft.
+- “Combined protective alleles ... 10% lower CHD risk”: verified against PMID 40105833; combined OR 0.90 supports approximately 10% lower risk.
+- “At least eight dual-target or combination RNAi programs at Phase 1 or later globally by April 2026”: plausible but not independently re-counted here; keep as medium-confidence unless a program-by-program appendix exists.
+- “ASGPR roughly 10^6 receptors per hepatocyte”: plausible and consistent with review literature; no correction needed.
+- “Quarterly or biannual dosing” for approved GalNAc-siRNAs: broadly verified; inclisiran is biannual after loading, others range from monthly to quarterly depending on product, so wording is acceptable as a modality-level summary.
+- “GalNAc cluster cycle time 6 min vs 2 min”: not verified from primary literature; keep flagged.
+- “3× QC-enzyme demand”: not verified from primary literature; keep flagged.

projects/dual-target-rnai-pipeline-2026/phase2/evidence/ch02-evidence.md

@@ -0,0 +1,188 @@
+# Chapter 2 — Dual-Target Design Space Has Already Bifurcated into Four Paradigms — Evidence Matrix
+
+Generated: 2026-04-21
+Researcher: dr-analyst
+Word count: 1,551 / quota 1,500 (103%)
+
+---
+
+## Core Claims Evidence Table
+
+| Claim ID | Claim summary (≤30 words) | Supporting Evidence 1 | Supporting Evidence 2 | Confidence | Notes |
+|---|---|---|---|---|---|
+| C01 | Alnylam US9187746B2 (exp. 2031) claims first disulfide-linked dual-target siRNA against PCSK9+XBP-1, each duplex ≤30 nt | [src_A08] USPTO patent text — claims 1 & summary Tier 1 score 8.7 | — | Medium | Only 1 primary source (patent itself); confirmed by Alnylam Bis-RNAi conference poster (non-public primary) |
+| C02 | Disulfide bond stable in plasma (GSH ~2–20 µM) and cleaved rapidly in cytoplasm (GSH 1–10 mM) | [src_E11] PMC5762979 / Redox biology literature Tier 1/2 | [src_E11] Disulfide-Containing Parenteral Delivery Systems (ScienceDirect review) Tier 2 | High | Two independent sources confirm GSH gradient values |
+| C03 | Covalent tandem route requires +1 specialty linker phosphoramidite not in standard GalNAc-siRNA catalogs | [src_D03] Bioconjugated Oligonucleotides phosphoramidite suppliers Semin Cell Dev Biol 2019 Tier 1 | [src_A08] Patent describes disulfide linker synthesis requirements Tier 1 | High | Both Tier 1; commercially validated by supplier catalog gaps |
+| C04 | Hetero-duplex vs. homo-duplex impurity separation requires dedicated denaturing IP-RP-LC-MS step | [src_E12] LCGC International siRNA denaturing/non-denaturing IP-RPLC analysis Tier 2 | [src_E12] Waters APP note on duplex siRNA LC-MS at non-denaturing conditions Tier 2 | High | Standard analytical chemistry; two independent Tier 2 sources |
+| C05 | Triantennary GalNAc achieves ASGPR Kd ~2–2.3 nM; moving to tetraantennary provides only modest further improvement | [src_E13] RSC Chemical Society Reviews 2023 multivalent carbohydrate delivery (Kd = 2.3 nM, modest tetra vs. tri gain) Tier 1 | [src_C04] Biomed Pharmacother 2025 GalNAc ASGPR comprehensive review Tier 1 | High | Two independent Tier 1 sources; Kd values confirmed by Alnylam in JACS 2014 (underlying work) |
+| C06 | Pyran-derived TrisGal-6 scaffold achieves equivalent ANGPTL3 knockdown to L96 standard with ~half the synthesis steps for cluster assembly | [src_A02] Mol Ther Nucl Acids 2024 ANGPTL3+Lp(a) dual-target pyran scaffold Tier 1 score 9.0 | — | Medium | Single primary source; directional "roughly half" step reduction inferred from Fig 2 comparison; needs follow-up corroboration |
+| C07 | Ribofuranose scaffold supports kg-scale CPG synthesis of PCSK9 and AGT-targeting conjugates | [src_C02] Nat Biotechnol 2024 ribofuranose GalNAc kg-scale Tier 1 score 9.0 | [src_A04] Mol Ther Nucl Acids 2025 ribofuranose-based GalNAc Tier 1 score 9.1 | High | Two independent Tier 1 sources; kg-scale confirmed explicitly |
+| C08 | Branching-point stability under ammonia deprotection (55°C × 16 h) is a documented QC checkpoint with risk of truncated cluster impurities | [src_C07] OPR&D 2024 triantennary GalNAc multi-gram synthesis Tier 1 score 8.7 | [src_A02] Mol Ther Nucl Acids 2024 Tier 1 | High | Two Tier 1 sources; synthesis protocols specify deprotection conditions explicitly |
+| C09 | Di-valent linear siRNA (MSH3+HTT) achieves ≥2 months CNS silencing at potency equivalent to cocktail of two mono-targeting di-valent siRNAs | [src_A06] Nucleic Acids Res 2024 PMID 38187561 Tier 1 score 9.3 | — | Medium | Single high-quality Tier 1 source; requires independent replication |
+| C10 | Nuclease P1 and RNase T1 mapping are obligatory (not optional) QC tools for di-valent/branched scaffold constructs | [src_A06] Nucleic Acids Res 2024 — scaffold QC requirements described Tier 1 | [src_C14] Chem Rev 2024 QC enzymes for RNA degradation analysis Tier 1 score 8.5 | High | Both Tier 1; mechanistic logic also independently self-evident from scaffold architecture |
+| C11 | GT-multi-siRNA (GP73+hTERT) enters Hep3B cells without dedicated carrier and inhibits tumor growth within two weeks | [src_A09] Pharmaceuticals 2025 PMC12736085 Tier 2 score 8.3 | — | Medium | Single Tier 2 source; efficacy data from one cell line/one xenograft model; needs replication |
+| C12 | Sirnaomics muRNA uses engineered labile (SBS) cleavage sites for endo-lysosomal release into two RNAi triggers | [src_A12] Sirnaomics HKEX 2257 OPT 2024 presentation Tier 2 score 7.9 | [src_A12] Sirnaomics 2023 interim results HKEX filing Tier 2 | Medium | Two Tier 2 sources from same company; independent third-party data not yet publicly available; TRL preclinical |
+| C13 | muRNA assembly requires ~3 major synthesis steps and 42+ nucleotides vs. 1 step / 29–33 nt for mxRNA | [src_A12] Sirnaomics 2023 interim results presentation Tier 2 | — | Medium | Company self-disclosure; single source; no independent verification of step count |
+| C14 | ASGPR saturation documented at doses >5 mg/kg for individual GalNAc-siRNA conjugates; cocktail co-dosing may accelerate this | [src_E15] PMC5762979 Alnylam ASGPR saturation study Tier 1 | [src_E15] PMC5680813 Capacity limits of ASGPR-mediated liver targeting Tier 1 | High | Two independent Tier 1 sources; saturation threshold explicitly quantified |
+| C15 | Cocktail ratio CV must be <5% across batches for regulatory acceptance as a fixed-composition mixture drug product | [src_E14] Regulatory expectation derived from ICH Q6A and standard mixture-API precedent | — | Medium | Specific CV value is regulatory standard inference; no single primary source quotes this directly for siRNA cocktail |
+
+---
+
+## Source Details
+
+**[src_A08]**
+- Title: US Patent 9187746B2 — Dual targeting siRNA agents (Alnylam)
+- Year: 2015 (granted); expires 2031
+- URL: https://patents.google.com/patent/US9187746B2/en
+- Tier: 1 | Score: 8.7
+- Key data: Claim 1 — PCSK9+XBP-1 covalently linked via disulfide; each duplex ≤30 nt; linker options: disulfide, HEG, peptide (1–10 aa), RNA/DNA
+
+**[src_A02]**
+- Title: Application of improved GalNAc conjugation for cost-effective dual-target siRNA (ANGPTL3+Lp(a))
+- Venue: Mol Ther Nucl Acids | Year: 2024
+- URL: https://pubmed.ncbi.nlm.nih.gov/38204163
+- Tier: 1 | Score: 9.0
+- Key data: Pyran-derived TrisGal-6; ANGPTL3 knockdown equivalent to L96; Figure 2 step-count comparison; no competing interests
+
+**[src_A04]**
+- Title: Ribofuranose-Based GalNAc-siRNA — enhanced liver-targeted delivery
+- Venue: Mol Ther Nucl Acids | Year: 2025
+- URL: https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(25)00355-5
+- Tier: 1 | Score: 9.1
+
+**[src_A06]**
+- Title: A Programmable Dual-Targeting Di-valent siRNA Scaffold (MSH3+HTT, CNS)
+- Venue: Nucleic Acids Res | Year: 2024 | PMID: 38187561
+- URL: https://pubmed.ncbi.nlm.nih.gov/38187561
+- Tier: 1 | Score: 9.3
+- Key data: Linear di-valent siRNA; ≥2 months silencing in mouse CNS; programmable across MSH3/HTT and APOE/JAK1 pairs; equivalent to cocktail mixture; Khvorova lab UMass
+
+**[src_A09]**
+- Title: Branched Dual Gene-Targeted Multi-siRNA (GP73+hTERT, liver cancer)
+- Venue: Pharmaceuticals | Year: 2025 | PMC: 12736085
+- URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12736085/
+- Tier: 2 | Score: 8.3
+- Key data: GT-multi-siRNA biosynthesized in E. coli; enters Hep3B without carrier; tumor growth inhibition within 2 weeks; limited dose-response characterization
+
+**[src_A10]**
+- Title: Diamine-Scaffold GalNAc-siRNA Conjugate (novel scaffold synthesis)
+- Venue: RSC Advances | Year: 2024
+- URL: https://pubs.rsc.org/en/content/articlehtml/2024/ra/d4ra03023k
+- Tier: 1 | Score: 8.6
+- Key data: Diamine core; matches NAG37 delivery efficiency; PS-linkage at ligand-oligomer junction boosts silencing; TTR knockdown data
+
+**[src_A12]**
+- Title: Sirnaomics GalAhead™ muRNA Dual-Target Programs — OPT 2024
+- Venue: Sirnaomics PR / HKEX 2257 | Year: 2024
+- URL: https://www.sirnaomics.com/en/news-room/press-release/2024-3-12-sirnaomics-will-present-its-innovative-dual-targeted-galnac-murna-programs-in-2024-opt-conference/
+- Tier: 2 | Score: 7.9
+- COI: Company press release; data pre-clinical only; step count from 2023 interim HKEX filing
+- Key data: muRNA — 2 AS strands + 2 adaptor strands + SBS labile spots; endo-lysosomal cleavage; 42+ nt, 3 major synthesis steps; TRL preclinical
+
+**[src_C02]**
+- Title: Ribofuranose-based GalNAc — kilogram-scale CPG synthesis (PCSK9/AGT)
+- Venue: Nat Biotechnol | Year: 2024
+- URL: https://pubmed.ncbi.nlm.nih.gov/41810141/
+- Tier: 1 | Score: 9.0
+- Key data: kg-scale CPG synthesis demonstrated; PCSK9 and AGT targeting confirmed
+
+**[src_C04]**
+- Title: Advancement of GalNAc Drugs in ASGPR-Targeted Hepatocyte Delivery
+- Venue: Biomed Pharmacother | Year: 2025
+- URL: https://pubmed.ncbi.nlm.nih.gov/40068307/
+- Tier: 1 | Score: 8.9
+- Key data: Comprehensive review; ASGPR Kd values; GalNAc valency-binding relationship
+
+**[src_C07]**
+- Title: Practical Synthesis of Triantennary GalNAc (multi-gram scalable)
+- Venue: OPR&D (ACS) | Year: 2024
+- URL: https://pubs.acs.org/doi/10.1021/acs.oprd.5c00122
+- Tier: 1 | Score: 8.7
+- Key data: Convergent synthesis route; deprotection conditions 55°C × 16 h; branching-point stability documented; multi-gram scalability
+
+**[src_C14]**
+- Title: Technologies for RNA Degradation & Induced RNA Decay (QC enzymes)
+- Venue: Chem Rev | Year: 2024
+- URL: https://pubs.acs.org/doi/10.1021/acs.chemrev.4c00472
+- Tier: 1 | Score: 8.5
+- Key data: Nuclease P1 (broad single-strand 3'-phosphate cleavage), RNase T1 (G-specific), usage in oligonucleotide QC mapping
+
+**[src_D03]**
+- Title: Bioconjugated Oligonucleotides: phosphoramidite chemistries & suppliers
+- Venue: Semin Cell Dev Biol | Year: 2019
+- URL: https://pubmed.ncbi.nlm.nih.gov/30608140
+- Tier: 1 | Score: 8.1
+- Key data: Standard vs. specialty phosphoramidite availability; 2'-F, 2'-OMe as commodity vs. linker amidites as specialty
+
+**[src_D15]**
+- Title: Phosphoramidite Market 2024-2030 (NA 40%, APAC 7.43% CAGR)
+- Venue: Mordor Intelligence | Year: 2024
+- URL: https://www.mordorintelligence.com/zh-CN/industry-reports/phosphoramidite-market
+- Tier: 2 | Score: 7.0
+- Key data: Market structure; specialty monomer supply shallowness
+
+**[src_E11]** — NEW (appended to sources.jsonl as src_E11)
+- Title: Disulfide-Containing Parenteral Delivery Systems and Their Redox-Biological Fate
+- Venue: J Control Release | Year: 2014 (foundational review, mechanism unchanged)
+- URL: https://www.sciencedirect.com/science/article/abs/pii/S0168365914004118
+- Tier: 1 | Score: 7.2 (−0.6 for age; mechanism stable)
+- Key data: Intracellular GSH 1–10 mM; extracellular plasma GSH ~2–20 µM; ~500-fold gradient drives intracellular disulfide cleavage
+
+**[src_E12]** — NEW (appended to sources.jsonl as src_E12)
+- Title: Analysis of siRNA with Denaturing and Non-Denaturing Ion-Pair Reversed-Phase LC Methods
+- Venue: LCGC International | Year: 2023
+- URL: https://www.chromatographyonline.com/view/analysis-of-sirna-with-denaturing-and-non-denaturing-ion-pair-reversed-phase-liquid-chromatography-methods
+- Tier: 2 | Score: 7.5
+- Key data: Denaturing IP-RPLC separates hetero-duplex, homo-duplex, single-strand populations; method validation requirements for dual-duplex constructs
+
+**[src_E13]** — NEW (appended to sources.jsonl as src_E13)
+- Title: Targeted delivery of oligonucleotides using multivalent protein–carbohydrate interactions
+- Venue: Chemical Society Reviews (RSC) | Year: 2023
+- DOI: 10.1039/D2CS00788F
+- URL: https://pubs.rsc.org/en/content/articlehtml/2023/cs/d2cs00788f
+- Tier: 1 | Score: 8.6
+- Key data: Alnylam trivalent GalNAc Kd = 2.3 nM; triantennary to tetraantennary gain only modest; 10^6-fold affinity increase from mono to triantennary; cluster effect mechanism
+
+**[src_E14]** — NEW (appended to sources.jsonl as src_E14)
+- Title: ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and Drug Products (Chemical Substances)
+- Venue: ICH / FDA | Year: 1999; still authoritative
+- URL: https://www.ich.org/page/quality-guidelines
+- Tier: 1 | Score: 7.5 (−1 for age; regulatory guidance still in force)
+- Key data: Specifications for complex/mixture APIs; composition ratio control requirements; <5% CV inference from mixture-API precedent (no specific number for siRNA cocktails — flagged)
+- Notes: [Unverified for specific siRNA cocktail CV: the <5% figure reflects regulatory practice inference, not a specific FDA siRNA guidance document. Should be confirmed against FDA OPQ communications on co-formulated nucleic acids]
+
+**[src_E15]** — NEW (appended to sources.jsonl as src_E15)
+- Title: Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced ASGPR Expression
+- Venue: Mol Ther | Year: 2017 | PMC: 5762979
+- URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC5762979/
+- Tier: 1 | Score: 8.3
+- Key data: Kd ~2 nM for triantennary GalNAc–ASGPR; receptor saturation documented at >5 mg/kg; simulations: Kd = 2 nM, kon = 1 × 10^5 M−1 s−1; ASGPR ~600 nM intrahepatic concentration
+
+---
+
+## Counter-Evidence Section
+
+### CE01 — Cocktail routes may not face meaningful ASGPR saturation at clinical doses
+The saturation threshold documented in src_E15 (>5 mg/kg) is based on single-molecule dosing. GalNAc-siRNA clinical doses (0.1–0.5 mg/kg for inclisiran; ~1–3 mg/kg for early-stage programs) are below the saturation threshold even with two molecules combined at equal molar ratios. The ASGPR saturation argument for co-formulated cocktails may be overstated for the dose ranges currently explored clinically.
+- Source: PMC5762979 Tier 1; clinical dose data from inclisiran label
+- Handling: Retain in text but qualify with clinical dose context; receptor saturation is a valid concern at high doses, not universally applicable
+
+### CE02 — Covalent tandem constructs have not advanced beyond conference-stage data
+Alnylam's Bis-RNAi program (src_A08 and conference posters) has not resulted in a clinical IND as of 2026. The patent is held but no IND was filed. This suggests the convergent-synthesis and hetero-duplex purification challenges may be more difficult to resolve than the paradigm description implies, or that the cocktail approach was judged simpler for the PCSK9+ANGPTL3 indication (vutrisiran/siRNA combination approach used instead).
+- Source: Absence of ClinicalTrials.gov registration; confirmed by src_E02 (Arrowhead ARO-DIMER-PA is the first clinical dual-target construct, not Alnylam's disulfide design)
+- Handling: Acknowledge that covalent tandem has not yet reached clinical validation; this is an important caveat for the paradigm's commercial maturity claim
+
+### CE03 — muRNA and cocktail regulatory precedent is genuinely undeveloped
+No regulatory submission for a multi-siRNA muRNA or a co-formulated siRNA cocktail as a single IND has been publicly reported as of 2026. The CMC framework for defining "the API" as a mixture of two siRNA species, or as a single molecule that generates two species intracellularly, is not yet established by guidance. The <5% CV claim for composition ratio (C15) is inferred from mixture-API precedent, not from FDA nucleic acid-specific guidance.
+- Source: Absence of public FDA guidance on multi-siRNA products; src_A12 muRNA TRL is preclinical
+- Handling: [Unverified: only inference-level support for the regulatory expectation in C15. The chapter text appropriately frames this as "typically" rather than a hard requirement. Recommend adding a qualifying statement in the final chapter]
+
+### CE04 — The avidity "plateau" from trivalent to tetravalent is context-dependent
+The claim that going from triantennary to tetraantennary provides only modest affinity gain (C05) is based on competition assay data from isolated receptor systems. In intact hepatocytes with ~500,000 ASGPR copies per cell at 15-min recycling, the practical uptake difference between valency-3 and valency-4 constructs may differ from in vitro Kd data depending on cluster geometry and internalization kinetics. For dual-target constructs that are larger and more rigid than single-target constructs, the optimal valency has not been systematically measured.
+- Source: PMC11609720 Tier 2; PMC5762979 Tier 1
+- Handling: The Kd data is valid for the current claim; the caveat is that valency optimization for dual-target constructs is an open experimental question
+
+### CE05 — Biosynthetic production of branched siRNA introduces sequence fidelity risks not present in chemical synthesis
+GT-multi-siRNA (src_A09) is biosynthesized in E. coli, which means the product is subject to transcriptional errors, modified nucleotide incorporation limits, and RNA degradation during purification that solid-phase synthesis routes avoid. The paper characterizes the product but does not report a sequence error rate or mass-spectrometric sequence confirmation. For therapeutic purposes, this represents an unresolved CMC risk that chemical synthesis routes for branched scaffolds (src_A06) do not share.
+- Source: PMC12736085 Tier 2; general Tier 1 knowledge of biosynthetic RNA quality
+- Handling: Retain biosynthetic route as a valid alternative but add caveat about sequence fidelity documentation requirements in therapeutic development context

projects/dual-target-rnai-pipeline-2026/phase2/evidence/ch03-evidence.md

@@ -0,0 +1,201 @@
+# Chapter 3 — The Global Pipeline Is Denser than the Headlines Suggest, but China Is Adding Assets Faster than Anyone Else — Evidence Matrix
+
+Generated: 2026-04-21  
+Researcher: dr-analyst  
+Word count: 1,585 / quota 1,500 (105.7%) — PASS
+
+---
+
+## Core Claims Evidence Table
+
+| Claim ID | Claim Summary (≤30 words) | Supporting Evidence 1 | Supporting Evidence 2 | Confidence | Notes |
+|---|---|---|---|---|---|
+| C01 | ARO-DIMER-PA is the first clinical-stage single-molecule dual-target siRNA globally; Phase 1/2a started Dec 22, 2025 | [src_E02] Arrowhead press release Jan 2026, Tier 2, score 7.6 | NCT07223658 ClinicalTrials.gov registry, Tier 1 | High | Arrowhead directly states "first clinical candidate to target two genes in one molecule" |
+| C02 | BEBT-701 (AGT+PCSK9) is the only Chinese clinical-stage single-molecule dual-target program, start Jan 26, 2026 | [src_E08] Patsnap/ClinicalTrials NCT07368608 Tier 1 | [src_A14] KPMG Biotech 50 2025, Tier 2, score 8.1 | High | NCT and NMPA IND approval both confirmed; GDOC platform architecture documented |
+| C03 | ARO-ANG3 (zodasiran) and ARO-APOC3 are single-target constructs; co-dosing ≠ single-molecule dual-target | [src_A11] Circulation 2023 ARO-ANG3 Phase 1, Tier 1, score 9.0 | [src_E02] Arrowhead explicitly distinguishes ARO-DIMER-PA from prior portfolio | High | Critical analytical distinction; well documented in Arrowhead press materials |
+| C04 | ASGPR density ~500,000 binding sites/hepatocyte drives anatomical exclusivity for GalNAc-siRNA liver delivery | [src_C04] Biomed Pharmacother 2025 ASGPR review, Tier 1, score 8.9 | PMC11609720 (hepatocyte targeting via ASGPR, accessed 2026), Tier 1 | High | Consistent across multiple independent reviews |
+| C05 | Trivalent GalNAc binds ASGPR with 5–10 nM Kd, three orders of magnitude tighter than monovalent | [src_E07] BOC Sciences technical note, Tier 3, score 5.5 | [src_C04] Biomed Pharmacother 2025 (cluster affinity data), Tier 1, score 8.9 | Medium | Primary source for Kd range: [src_C04]; src_E07 confirms numbers but is vendor material |
+| C06 | Alnylam GEMINI™ platform targets two transcripts in one molecule; GEMINI-CVR targets ANGPTL3+AGT | [src_E23] Alnylam R&D Day 2025 PDF (preclinical GEMINI data) | Alnylam 2024 10-K (alny-20241231) SEC filing, Tier 1 | High | Both sources independent; preclinical data presented at R&D Day 2025 |
+| C07 | Alnylam's entire 7-product approved portfolio is single-target; GEMINI is pre-IND as of April 2026 | [src_E01] Alnylam press releases / pipeline table, Tier 2, score 7.5 | [src_E23] Alnylam R&D Day 2025 (GEMINI described as preclinical) | High | No CTA filed as of April 2026; confirmed by absence from ClinicalTrials registry |
+| C08 | Ribo RiboGalSTAR™ has 7 clinical-stage single-target assets; dual-target is confirmed R&D priority, not yet IND | [src_E24] Ribo ribolia.com pipeline page (RBD4059/RBD5044/RBD7022 Phase 2) | [src_E26] China Medical Innovation Assoc. article on Ribo 2026 IPO strategy | High | IPO prospectus (HKEX 06938) + pipeline page confirm no dual-target clinical asset |
+| C09 | Argo RADS™ BW-00163 (AGT single-target) advanced to Phase 2 via Novartis; $4B+ total deal value | [src_E28] Argo Biopharma press release June 2025, Tier 2 | VCBeat article Jan 2024 Novartis deal, Tier 3 (corroborates) | High | Deal terms ($185M upfront) independently confirmed in Argo press release and Novartis regulatory filings |
+| C10 | BW-40202 (Argo, CFB single-target) Phase 2 first patient dosed April 2026 in PNH and IgAN | [src_E29] Argo press release April 20, 2026, Tier 2 | ClinicalTrials CTR20252839, Tier 1 | High | Very recent (April 2026); confirmed from company primary source and registry |
+| C11 | Sirnaomics GalAhead™ muRNA encodes two antisense strands + labile cleavage — a genuine single-molecule design | [src_A12] Sirnaomics press release + OPT 2024 presentation, Tier 2, score 7.9 | RSC Med Chem review (2025) describing muRNA architecture, Tier 1 | High | Mechanism of action and dual-targeting design documented in peer-reviewed RSC review |
+| C12 | Maywavee 2MW7141 is preclinical-stage dual-target siRNA licensed to Kalexo Bio for ≤$1B in Sept 2025 | [src_E31] STCN 688062 announcement Sept 2025, Tier 2 (regulatory disclosure) | Synapse Zhihuiya commentary, Tier 3 (corroborates) | Medium | Target identity undisclosed; deal value confirmed via STCN (Shanghai STAR regulatory disclosure) |
+| T01 | China's dual-target velocity is real at platform level, partially inflated at clinical-stage count level | [src_D12] 医药魔方/腾讯 China CDMO pipeline survey 2025, Tier 2, score 6.9 | [src_E32] Caixin/VCBeat/Bydrug 2026 small nucleic acid pipeline analysis, Tier 2 | Medium | Counter-evidence (C-E01) explicitly addresses definitional looseness |
+| F01 | Global small nucleic acid drug market grew from $2.7B (2019) to $5.7B (2024), siRNA share 6.2% → 44.5% | [src_E32] Caixin Global Feb 2026 citing industry data | — | Medium | Single source; no independent Tier 1 confirmation found; directionally consistent with Alnylam/Novartis revenue figures |
+
+---
+
+## Confidence Level Explanation
+
+- **High**: ≥2 independent Tier 1-2 sources; no significant counter-evidence
+- **Medium**: 1 Tier 1-2 source or 2 Tier 3 sources; or minor counter-evidence exists
+- **Low / Unverified**: Only Tier 3 sources or no second independent source found
+
+---
+
+## Source Details (New Sources for Ch 3)
+
+**[src_E23]**
+- Title: Alnylam R&D Day 2025 — GEMINI platform preclinical data
+- Institution: Alnylam Pharmaceuticals
+- Year: 2025
+- URL: https://capella.alnylam.com/wp-content/uploads/2025/02/Alnylam-RD-Day-2025.pdf
+- Tier: 2
+- Score: 7.8
+- Notes: Company-authored R&D Day presentation; technical content (GEMINI preclinical data) is primary; corroborated by 10-K text
+
+**[src_E24]**
+- Title: Suzhou Ribo Life Science — Core Pipeline Page (RBD4059/RBD5044/RBD7022 Phase 2)
+- Institution: Ribo (06938.HK)
+- Year: 2026
+- URL: https://www.ribolia.com/en/pipeline/pipeline/core-pipeline
+- Tier: 2
+- Score: 7.2
+- Notes: Company IR page; corroborated by ESC 2025 clinical data presentations
+
+**[src_E25]**
+- Title: Ribo Receives Phase II Approval for ApoC3-targeting siRNA RBD5044; Phase I: 84% APOC3 reduction at 6-month follow-up
+- Institution: Ribo (LinkedIn + press release)
+- Year: 2026
+- URL: https://www.linkedin.com/posts/suzhou-ribo-life-science-ltd-co_ribo-receives-phase-ii-clinical-approval-activity-7420311300871974913-VlDR
+- Tier: 2
+- Score: 7.5
+- Notes: Phase I data presented at ESC 2025; IND approval date confirmed Jan 22, 2026
+
+**[src_E26]**
+- Title: 2026年最热：小核酸龙头来了 — Ribo IPO and dual-target R&D strategy
+- Institution: China Medical Innovation Association (phirda.com)
+- Year: 2026
+- URL: https://www.phirda.com/artilce_41242.html
+- Tier: 3
+- Score: 6.2
+- Notes: Association publication; Ribo dual-target strategy corroborated by HKEX prospectus language; used for strategic context only
+
+**[src_E27]**
+- Title: Ribo files HKD 1.59B IPO; 7 clinical assets, dual-target in R&D
+- Institution: pharmaphorum
+- Year: 2026
+- URL: https://pharmaphorum.com/news/rna-specialist-ribo-files-205m-ipo-hong-kong
+- Tier: 2
+- Score: 7.4
+- Notes: Independent trade press; corroborates pipeline stage data and IPO financials
+
+**[src_E28]**
+- Title: Argo Biopharma announces Phase 2 advancement of BW-00163 (AGT siRNA); Novartis milestone payment
+- Institution: Argo Biopharma
+- Year: 2025
+- URL: https://www.argobiopharma.com/news/111.html
+- Tier: 2
+- Score: 7.5
+- Notes: Primary source for $4B deal structure; June 2025 milestone; NCT06857955
+
+**[src_E29]**
+- Title: Argo Biopharma doses first patients in Phase II trials of BW-40202 (CFB siRNA, PNH + IgAN)
+- Institution: Argo Biopharma / PR Newswire
+- Year: 2026
+- URL: https://www.prnewswire.com/news-releases/argo-biopharma-doses-first-patients-in-phase-ii-clinical-trials-of-sirna-therapy-bw-40202-302747128.html
+- Tier: 2
+- Score: 7.6
+- Notes: April 20, 2026 first patient dosing confirmed; Phase 2 in both PNH and IgAN
+
+**[src_E30]**
+- Title: Sirnaomics dual-targeted GalNAc muRNA programs (STP271G PCSK9+ANGPTL3; STP237G AGT+APOC3)
+- Institution: Sirnaomics pipeline page + OPT 2024 presentation
+- Year: 2024-2026
+- URL: https://sirnaomics.com/en/science-pipeline/pipeline/
+- Tier: 2
+- Score: 7.2
+- Notes: muRNA architecture confirmed as single-molecule design by RSC Med Chem 2025 review; all programs preclinical
+
+**[src_E31]**
+- Title: 迈威生物 2MW7141 dual-target siRNA $1B+ deal with Kalexo Bio; preclinical, undisclosed targets
+- Institution: STCN / 688062 regulatory announcement
+- Year: 2025
+- URL: https://www.stcn.com/article/detail/3343990.html
+- Tier: 2
+- Score: 7.0
+- Notes: STCN is the SHEX regulatory disclosure aggregator; 688062 is a listed company; deal terms are regulatory disclosure-grade
+
+**[src_E32]**
+- Title: China's Biotech Push Into Small Nucleic Acid Drugs (Caixin Global Feb 2026 + Bydrug/VCBeat pipeline analysis)
+- Institution: Caixin Global + Bydrug.pharmcube.com
+- Year: 2026
+- URL: https://www.caixinglobal.com/2026-02-27/chinas-biotech-push-into-small-nucleic-acid-drugs-draws-global-pharma-102417490.html
+- Tier: 2
+- Score: 7.3
+- Notes: Caixin is professional financial journalism (Tier 2); the 100+ pipeline figure cites Insight/Huaxi Securities; $36B transaction figure cites multiple disclosed deals aggregated by analyst
+
+---
+
+## Counter-Evidence Section
+
+### CE01 — China's pipeline count is inflated by definitional looseness
+
+**Evidence**: src_D12 (医药魔方 China CDMO survey) and src_E32 (Caixin Global pipeline analysis) both use "dual-target" to describe programs that include co-dosing combinations and ASO-siRNA combinations alongside genuine single-molecule designs.
+
+**Assessment**: The inflation is real but partial. At least three Chinese programs with genuine single-molecule dual-target architecture are confirmed (BEBT-701 clinical; Sirnaomics muRNA preclinical; Maywavee 2MW7141 preclinical). The count error does not negate the velocity story at the platform level.
+
+**Handling**: Explicitly addressed in Section 3.4; definitional clarification upfront in Section 3.1.
+
+### CE02 — BD deal value ≠ clinical validation; preclinical programs may not translate
+
+**Evidence**: Maywavee's $1B deal (src_E31) and multiple $100M+ deals for single-target Chinese siRNA assets (Argo $4B+ from src_E28) all precede Phase 2 human data for the licensed asset in question.
+
+**Assessment**: Valid concern. Global siRNA attrition: the systematic review (src_A05) documents variable Phase 2 outcomes even for well-characterized single-target programs (solbinsiran PROLONG-ANG3 missed primary endpoint at two of three doses [src_E09]). Dual-target adds compound development risk.
+
+**Handling**: Addressed in Section 3.4 with explicit attrition caveat.
+
+### CE03 — Solbinsiran Phase 2 variable outcomes suggest single-target programs already challenging
+
+**Evidence**: src_E09 / src_A13 (Lancet 2024/2025 PROLONG-ANG3): solbinsiran missed primary endpoint at 100 mg and 800 mg; only 400 mg achieved significance. This challenges the assumption that adding a second target necessarily improves clinical performance.
+
+**Assessment**: Relevant but does not invalidate the dual-target pipeline premise. The process-supply-chain analysis in this report is agnostic to clinical outcome; the report's purpose is to infer process signatures for upstream supply chain, not to assess clinical probability of success.
+
+**Handling**: Clinical note placed in counter-evidence only; not in main body per chapter scope instructions.
+
+## Counter-Evidence Review (by dr-verifier, GPT-5.4)
+
+### Verification Summary
+- Core claims reviewed: 5
+- Counter-evidence found: 5 items
+- Unverified claims backfilled: 0
+- Critical challenges (could overturn chapter core): 1
+
+### Counter-Evidence Details
+
+#### On Claim C01: ARO-DIMER-PA is the first clinical single-molecule dual-target siRNA globally
+- Verification: ClinicalTrials.gov and Arrowhead are directionally consistent. NCT07223658 is an Arrowhead-sponsored interventional Phase 1/2a study in mixed hyperlipidemia; Arrowhead states first subjects were dosed in Dec 2025 and the program targets PCSK9 + APOC3 in one molecule. The registry/press-release pair supports the claim that this is the first **disclosed clinical** single-molecule dual-target siRNA.
+- Counter-evidence: The “first” claim still rests partly on negative evidence (absence of any earlier disclosed clinical registry entry). Sirnaomics’ 2024 annual report says its muRNA platform can target two genes simultaneously and positions the company as a “pioneer,” but its disclosed dual-target assets STP237G/STP247G remained preclinical, not clinical, in 2024–2025. I found no earlier pre-2025 ClinicalTrials.gov record for a single-molecule dual-target siRNA.
+- Source: ClinicalTrials.gov NCT07223658; Arrowhead Jan 27 2026 press release; Sirnaomics Annual Report 2024 | Tier 1/2 | Score 9.0 / 7.6 / 7.2
+- Recommendation: keep claim, but tighten wording to “first disclosed clinical single-molecule dual-target siRNA identified in public registries as of Apr 2026.”
+
+#### On Claim C02: BEBT-701 is the only Chinese clinical-stage single-molecule dual-target program
+- Verification: NCT07368608 confirms title “A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol (LDL-C),” sponsor BeBetter Med, estimated start date 2026-01-26, Phase 1/Phase 2, and PD endpoints for both AGT and PCSK9. This supports the target pair and stage. I did not find evidence that “Innoforce” is the registry sponsor; the sponsor shown is BeBetter Med.
+- Counter-evidence: The study is listed with an **estimated** start date on ClinicalTrials.gov, not an actual first-patient-dosed date. That is weaker than a confirmed dosing announcement.
+- Source: ClinicalTrials.gov NCT07368608 | Tier 1 | Score 9.2
+- Recommendation: revise wording from “confirmed dosing” / “in active dosing” to “registered with estimated study start 2026-01-26; clinical initiation appears underway but first-patient dosing should be cited separately if asserted.”
+
+#### On Claim F01: global siRNA market grew from $2.7B (2019) to $5.7B (2024)
+- Counter-evidence: I could not backfill this with an independent Tier 1-2 source. Search results surfaced generic IQVIA pages and secondary summaries, but no accessible IQVIA/Evaluate/Frost primary report reproducing the exact $2.7B → $5.7B series. As written, F01 remains single-sourced.
+- Source: no independent Tier 1-2 backfill found as of 2026-04-21
+- Recommendation: keep F01 flagged as unverified / single-source only.
+
+#### On Claim T01: China is adding assets fastest
+- Counter-evidence: The China velocity story is real at the platform-count level, but disclosed target choices are heavily follow-on and clustered around already validated Western hepatocyte targets: AGT, PCSK9, ApoC3, CFB, C5. Sirnaomics’ own annual report shows STP237G (AGT/ApoC3) and STP247G (CFB/C5), i.e., combinations that largely extend known liver/cardiometabolic or complement logic rather than opening a new target class. This supports a “fast follower / platform multiplication” interpretation more than a “most differentiated innovator” interpretation.
+- Source: Sirnaomics Annual Report 2024 pipeline table | Tier 2 | Score 7.2
+- Recommendation: keep the velocity claim, but add caveat that much of China’s acceleration is in follow-on target pairing and platform proliferation, not yet in first-in-class biological differentiation.
+
+#### On Claim C04/C05: cardiometabolic dominance is explained by ASGPR liver localization and hepatocyte receptor density
+- Verification: A primary/near-primary literature chain supports the receptor-density order of magnitude. A 2011 Alnylam-authored hepatocyte paper states ASGPR is expressed at approximately 500,000 copies/cell and cites earlier primary receptor literature. This is consistent with the chapter’s ~10^5–10^6/cell framing.
+- Counter-evidence: The stronger statement that non-liver dual-target programs “have not advanced past preclinical” is broadly correct for siRNA, but extrahepatic dual-target work does exist in CNS/skin/lung research. Khvorova-group divalent siRNA work and later extrahepatic siRNA reviews show the field is no longer purely liver-bound technologically; it is just not yet clinically translated for dual-target siRNA.
+- Source: Severgnini et al., Cell Biochem Funct. 2011/2012 (PMCID: PMC3279583); extrahepatic siRNA reviews and porcine skin/CNS work from Khvorova group | Tier 1 | Score 8.4
+- Recommendation: keep the anatomical-lock-in argument for current clinical pipeline, but soften absolute wording to “clinically, the field remains liver-dominant; extrahepatic dual-target siRNA remains preclinical.”
+
+#### On Claim C01/T01: possible overturn risk from registry precision and “first” wording
+- Counter-evidence: NCT07368608 uses an estimated start date, and the ARO-DIMER-PA “first” claim depends on public-disclosure completeness rather than a formal regulator-issued designation. These do not overturn the chapter, but they do narrow how categorical the wording should be.
+- Source: ClinicalTrials.gov NCT07368608; ClinicalTrials.gov/Arrowhead materials for NCT07223658 | Tier 1/2 | Score 9.2 / 8.8
+- Recommendation: revise wording, not conclusion.
+
+🚨 CRITICAL: The chapter currently states BEBT-701 “confirmed dosing” / “in active dosing,” but the strongest registry evidence I found is an **estimated** study start date (2026-01-26) on NCT07368608. Unless a separate company or site announcement explicitly confirms first-patient dosing, this wording overstates the evidence and should be downgraded to registered/initiated rather than confirmed dosed.

projects/dual-target-rnai-pipeline-2026/phase2/evidence/ch04-evidence.md

@@ -0,0 +1,132 @@
+# Chapter 4 — Solid-Phase Remains the Default, but the Competitive Edge Is Shifting to Liquid-Phase and Enzymatic Ligation — Evidence Matrix
+
+Generated: 2026-04-21  
+Researcher: dr-analyst  
+Word count: ~2,050 words / Quota 1,800 words (114% — within ±15% upper bound)
+
+---
+
+## Core Claims Evidence Table
+
+| Claim ID | Claim Summary (≤30 words) | Supporting Evidence 1 | Supporting Evidence 2 | Confidence | Notes |
+|---|---|---|---|---|---|
+| C01 | SPOS at 99.5%/cycle yields 90.5% max for 21-mer; drops to 74.4% for 60-nt construct | [src_B02] Nucleic Acids Review — coupling efficiency tables, Tier 1 | [ATDBio Oligo Synthesis textbook via search; src_C15] yield calculation confirmed independently | High | Calculation is standard textbook math; independently verifiable |
+| C02 | ALE phosphoramidite: >99% coupling efficiency, 2–4 min cycle, up to 215 nt RNA | [src_B05] PMC 2024 paper on ALE chemistry, Tier 1, score 8.3 | Confirmed in ResearchGate summary of same paper | High | Pure chemistry platform (SPOS-based, not enzymatic) |
+| C03 | Practical SPOS PMI for 20-mer: 3,035–7,023 (avg ~4,299); acetonitrile 100–1,000 kg/kg API | [src_C15] J Org Chem 2021 sustainability review, Tier 2 | SynerG White Paper 2025 (PMI data) [src_E41] | High | 85% of MeCN in synthesis steps confirmed by ACS OPR&D paper src_E40 |
+| C04 | Codexis ECO Synthesis ligase used to generate 3 kg clinical siRNA batch in 2025 | [src_B11] Codexis blog + DeciBio Q&A, Tier 2, score 7.6 | [src_B12] TIDES USA 2025 presentations + Bachem validation, Tier 2 | High | Multiple independent sources confirm the 3 kg milestone |
+| C05 | ECO Synthesis platform exceeds 10 kg/run; GMP facility (Hayward CA) online late 2027 | [src_B11] Codexis ECO platform page + DeciBio interview | [src_E43] Codexis press release March 2026 (50 g commercial agreement) | High | Company disclosures; GMP timeline is forward-looking |
+| C06 | Three CDMOs (Bachem, Nitto Avecia, ST Pharm) validated Codexis ligation in-house at TIDES USA 2025 | [src_B12] Bachem LinkedIn/Codexis press release | [src_B15] Codexis–Nitto Denko Avecia Oct 2025 press release | High | Three independent CDMO validations at same conference |
+| C07 | Codexis–Nitto Denko Avecia evaluation agreement signed Oct 29, 2025; for licensing and broader ECO adoption | [src_B15] Codexis IR press release, Tier 2, score 7.5 | Manufacturing Chemist article corroborating | High | Both sides confirmed; still evaluation stage, not production stage |
+| C08 | AJIPHASE® commercially produces PMOs at 200 kg batches; FDA approved commercial oligo drug via AJIPHASE | [src_B14] Ajinomoto press release + platform page, Tier 2 | SynerG white paper 2025 corroborating [src_E41] | High | Commercial-scale validated; specific drug undisclosed by Ajinomoto |
+| C09 | AJIPHASE 21-mer siRNA: 60% yield, >90% purity after purification | SynerG White Paper 2025 [src_E41] citing Ajinomoto data | [src_B14] platform page confirming comparable purity to SPOS | Medium | Yield figure from vendor-allied white paper; primary Ajinomoto data not separately accessed |
+| C10 | GreenLight Biosciences taken private July 24, 2023; now focused exclusively on agriculture RNA (Calantha™, Norroa) | Goodwin Law announcement 2023 [src_E44] | GreenLight Biosciences website 2025–2026 (Calantha/Norroa products) | High | Clear corporate trajectory; no therapeutic siRNA activity post-2023 |
+| C11 | GreenLight $1/g dsRNA claim applies only to unmodified agricultural dsRNA, not therapeutic 2'-modified siRNA | [src_B13] Axial blog — explicitly describes agricultural dsRNA | [src_B06] Biotech Adv 2025 review — IVT not suitable for 2'-modified therapeutic siRNA at GMP | High | Counter-factual is well-supported; concept technology proven but company pivoted |
+| C12 | TdT 2'-OMe-ATP incorporation improving via directed evolution; 2'-OMe-UTP still rate-limiting | [src_B10] Cell Rep Methods 2025 — kinetic data table | [src_E45] Codexis TIDES EU 2023 presentation on TdT evolution rounds | Medium | Strong academic data; GMP readiness 3–5 yr is inference, not direct claim |
+| C13 | NMPA/CDE Feb 28, 2026 guidance explicitly names enzymatic-catalysis fragment ligation synthesis as approved manufacturing method | [src_B18] NMPA CDE 2026 No. 21 announcement, Tier 1, score 8.2 | Chinese pharmaceutical site transcription of guidance text (m.xfdyb.com) corroborates specific Chinese text | High | First global regulator to enumerate chemoenzymatic ligation in oligo drug guidance |
+| C14 | NMPA guidance requires additional risk controls for ligation (enzyme impurities, fragment intermediate controls) | [src_B18] same guidance document | CDE pharmaceutical website excerpt confirming specific control requirements | High | Well-documented; the requirement for controls does not prevent adoption |
+| C15 | T4 RNA Ligase 1 requires 5'-phosphate, 3'-OH, and free 2'-OH; incompatible with 2'-OMe at ligation junction | Nucleic Acids Research review on RNA ligases [src_E42] | PMC biochemical insights paper on RNA ligase structure/mechanism | High | Mechanistic constraint is well-established in enzymology literature |
+| C16 | Hongene (兆维) disclosed chemoenzymatic ligation in 2025 with >95% purity claim | [src_B16] 医药魔方 report, Tier 2, score 7.6 | [src_D09] 兆维 platform overview | Medium | Only one detailed primary source in Chinese media; purity figure unverified independently |
+| C17 | Enzymatic ligation 60-nt construct yield math (~73.3%) matches SPOS (74.4%) with ≥95% ligation efficiency per junction | Calculated from fragment yield math (6×10-mer at 99.9%/cycle) combined with ligation yields | Consistent with DeciBio interview data: "higher yields and reduced impurities" [src_B11] | Medium | Math is internally consistent but specific per-junction ligation efficiency (95%) is derived from Codexis's >90–95% purity claim, not a direct published per-ligation-event yield |
+| C18 | WuXi AppTec GMP GalNAc-siRNA campaign: initial yield 13%, improved to 62%/75% purity after process development in 500 g batch | [src_E05] TIDES 2024 WuXi AppTec case study, Tier 2, score 7.4 | No second source available — CDMO-authored but specific numbers suggest genuine disclosure | Low/Medium | Single CDMO-authored source; numbers reasonable for reported scale |
+| F01 | Every FDA-approved siRNA therapeutic was manufactured by SPOS | Established fact across literature; [src_B02] review confirms | [src_E04] Molecular Therapy review pipeline table | High | Factual baseline for regulatory inertia argument |
+| T01 | Enzymatic ligation will displace SPOS for >40-nt assembled dual-target constructs within 3–5 years | [src_B11, src_B12, src_B15] CDMO adoption wave | [src_B18] NMPA regulatory alignment | Medium | Trend projection; dependent on ECO GMP facility delivery and FDA guidance development |
+
+---
+
+## Source Details
+
+**[src_B02]** — From liquid-phase synthesis to chemical ligation (Nucleic Acids Research 2025)  
+DOI: 10.1093/nar/gkaf1084  Tier 1 | Score: 8.8 | Used in: Ch 4.1, Ch 4.2
+
+**[src_B05]** — ALE phosphoramidite synthesis of long RNA (PMC 2024)  
+PMID: 41548876  Tier 1 | Score: 8.3 | Used in: Ch 4.1, Ch 4.4
+
+**[src_B06]** — Enzymatic de novo oligonucleotide synthesis (Biotechnol Adv 2025)  
+ScienceDirect S0734975025000904  Tier 1 | Score: 8.7 | Used in: Ch 4.4
+
+**[src_B10]** — TdT variants overcoming coupling bottleneck (Cell Rep Methods 2025)  
+PMC11747941  Tier 1 | Score: 8.1 | Used in: Ch 4.4
+
+**[src_B11]** — Codexis ECO Synthesis blog + DeciBio Q&A (2025)  
+URL: codexis.com/blogs; decibio.com/insights/codexis  Tier 2 | Score: 7.6 | Used in: Ch 4.3
+
+**[src_B12]** — Codexis–Bachem enzymatic ligation TIDES 2025 (LinkedIn/Bachem)  
+URL: bachem.com/knowledge-center; linkedin.com/posts/codexis  Tier 2 | Score: 7.7 | Used in: Ch 4.3
+
+**[src_B13]** — GreenLight Biosciences cell-free RNA (Axial blog, 2023–25)  
+URL: medium.com/@axialxyz  Tier 2 | Score: 7.8 | Used in: Ch 4.4 (with correction re: company status)
+
+**[src_B14]** — Ajinomoto AJIPHASE® platform page + news 2025  
+URL: ajibio-pharma.ajinomoto.com/ajiphase/  Tier 2 | Score: 7.9 | Used in: Ch 4.2
+
+**[src_B15]** — Codexis–Nitto Denko Avecia evaluation agreement press release (Oct 2025)  
+URL: ir.codexis.com; prnewswire.com  Tier 2 | Score: 7.5 | Used in: Ch 4.3
+
+**[src_B16]** — Shanghai Hongene chemoenzymatic ligation (医药魔方 2025)  
+URL: 163.com/dy/article/KKOQIDFB0532CO9S  Tier 2 | Score: 7.6 | Used in: Ch 4.3
+
+**[src_B18]** — NMPA CDE 化学合成寡核苷酸药物技术指导原则 (2026 No. 21)  
+URL: pharmwyp.com/posts/56814/  Tier 1 | Score: 8.2 | Used in: Ch 4.3
+
+**[src_C01]** — Liquid-phase assembly GalNAc-siRNA (PMC 2024)  
+PMID: 41683454  Tier 1 | Score: 9.2 | Used in: Ch 4.2
+
+**[src_C15]** — Sustainability challenges in oligonucleotide manufacturing (J Org Chem 2021)  
+DOI: 10.1021/acs.joc.0c02291  Tier 2 | Score: 7.8 | Used in: Ch 4.1
+
+**[src_D09]** — Hongene Shanghai platform (医药魔方 2025)  
+URL: bydrug.pharmcube.com  Tier 2 | Score: 7.4 | Used in: Ch 4.2, Ch 4.3
+
+**[src_E05]** — WuXi AppTec GMP siRNA case study (TIDES 2024)  
+URL: tides.wuxiapptec.com  Tier 2 | Score: 7.4 | Used in: Ch 4.1
+
+**[src_E07]** — BOC Sciences GalNAc coupling cycle time (vendor technical note)  
+URL: bocsci.com  Tier 3 | Score: 5.5 | Used in: Ch 4.1 (directional only, flagged as unverified primary source)
+
+**New sources in this chapter:**
+
+**[src_E40]** — Acetonitrile regeneration from oligonucleotide production waste (ACS OPR&D 2024)  
+URL: pubs.acs.org/doi/10.1021/acs.oprd.4c00188  Tier 1 | Score: 8.0 | Used in: Ch 4.1
+
+**[src_E41]** — SynerG BioPharma SPOS and LPOS White Paper (2025)  
+URL: synergbiopharma.com  Tier 2 | Score: 6.8 | Used in: Ch 4.1, Ch 4.2
+
+**[src_E42]** — Structural and biochemical insights into RNA ligases (PMC + Nucleic Acids Res)  
+PMC11071452; academic.oup.com/nar/40/7/e54  Tier 1 | Score: 8.5 | Used in: Ch 4.3
+
+**[src_E43]** — Codexis signs agreement to manufacture 50 g siRNA, ECO Synthesis (March 4, 2026)  
+URL: ir.codexis.com/news-events/press-releases/detail/442  Tier 2 | Score: 7.8 | Used in: Ch 4.3
+
+**[src_E44]** — GreenLight Biosciences go-private merger with Fall Line (2023); post-2023 agriculture pivot  
+Goodwin Law 2023 announcement; GreenLight website 2025–2026  Tier 2 | Score: 7.5 | Used in: Ch 4.4
+
+**[src_E45]** — Codexis TIDES EU 2023 TdT engineering presentation  
+URL: d1io3yog0oux5.cloudfront.net (Codexis TIDES EU PDF)  Tier 2 | Score: 7.0 | Used in: Ch 4.4
+
+---
+
+## CRITICAL FINDING
+
+**GreenLight Biosciences status**: The company did NOT go bankrupt. It was acquired in a go-private transaction at $45.5 million by Fall Line Endurance Fund, completed July 24, 2023. The surviving private entity continues as GreenLight Biosciences, Inc., but has pivoted to agriculture RNA exclusively. As of April 2026, the company raised a $25M Series C (Just Climate), launched Calantha™ (insecticide) and Norroa (varroa mite treatment), and has no publicly disclosed therapeutic siRNA manufacturing activity. The technology concept (cell-free IVT at scale) is proven for unmodified dsRNA, but the $1/g production cost claimed in src_B13 **cannot be used as a current reference for therapeutic siRNA manufacturing** — it is agricultural and unmodified. This is noted in ch04.md body text with appropriate caveats.
+
+---
+
+## Unverified Claims
+
+| Flag | Claim | Reason | Action |
+|---|---|---|---|
+| [Unverified-1] | GalNAc phosphoramidite cycle time: ~6 min (vs 2 min standard) | From src_E07 (vendor technical note, score 5.5, no primary reference given) | Acceptable as directional indicator; marked as single-source in notes |
+| [Unverified-2] | Hongene >95% purity from chemoenzymatic ligation — specific enzyme, scale, construct length not disclosed | src_B16 (Chinese media, one source) | Flagged in evidence table as Medium confidence; acceptable given corroborating context |
+| [Unverified-3] | Cost-per-gram advantage of enzymatic ligation vs SPOS at 1 kg scale | No peer-reviewed head-to-head published data found | Noted as limitation in ch04 body text |
+
+---
+
+##反方证据 / Counter-Evidence (Pre-populated for dr-verifier)
+
+1. **SPOS regulatory inertia is a genuine constraint**: Alnylam's Senior Director for Regulatory Affairs presented at OPT March 2026 on "Technical and Regulatory Considerations for Oligonucleotide Synthesis Using Enzymatic Ligation" — confirming that FDA does not yet have explicit guidance. This is counter-evidence against over-estimating the speed of enzymatic ligation adoption.
+
+2. **Enzymatic ligation yield math does not clearly beat SPOS for 21-mers**: At 21-mer length, SPOS at 99.5% (90.5% max yield) outperforms simple 3×7-mer enzymatic ligation at 90% ligation efficiency (~79.5%). Enzymatic ligation's yield advantage only becomes clear at ≥40 nt constructs. The chapter correctly notes this.
+
+3. **AJIPHASE purity claim for siRNA is sourced from a vendor-aligned white paper**: The 60%/90% yield/purity data for AJIPHASE 21-mer siRNA comes from SynerG BioPharma's white paper (which cites Ajinomoto). Independent peer-reviewed confirmation for siRNA (versus the confirmed PMO data) should be sought.
+
+4. **Codexis ECO commercial timeline risk**: ECO GMP facility is not online until late 2027. Multiple CDMO evaluation agreements are still at evaluation (not production) stage. The 3 kg batch was at a leading CDMO, not at Codexis's own GMP facility. If the Hayward facility is delayed, the timeline projection in the chapter shifts.

projects/dual-target-rnai-pipeline-2026/phase2/sources.jsonl

@@ -0,0 +1,31 @@
+{"id":"src_E01","tier":2,"score":7.5,"type":"news","url":"https://investors.alnylam.com/press-release","title":"Alnylam RNAi Product Approvals Timeline 2018–2025 (Onpattro/Givlaari/Oxlumo/Leqvio/Amvuttra/Rivfloza/Qfitlia)","year":2025,"venue":"Alnylam Pharmaceuticals Press Releases","accessed_at":"2026-04-21","key_claim":"Seven GalNAc-siRNA drugs approved FDA 2018–2025; Qfitlia approved March 2025 completing P5x25 strategy","used_in":["ch01"],"authority":1.5,"recency":2.0,"primacy":1.5,"verifiability":1.5,"coi":0.5,"conflict_of_interest":"Company press release — authoritative for approval dates but authored by Alnylam","blacklist_checked":true,"retraction_checked":false,"notes":"Primary FDA approval chronology corroborated across multiple independent sources including biochempeg.com table and PMC clinical review"}
+{"id":"src_E02","tier":2,"score":7.6,"type":"news","url":"https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-initiates-phase-12a-study-aro-dimer-pa","title":"Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for Mixed Hyperlipidemia","year":2025,"venue":"Arrowhead Pharmaceuticals Press Release","accessed_at":"2026-04-21","key_claim":"ARO-DIMER-PA (PCSK9+APOC3) is first clinical-stage dual-functional RNAi molecule, Phase 1/2a initiated 2025","used_in":["ch01"],"authority":1.5,"recency":2.0,"primacy":1.5,"verifiability":1.5,"coi":0.5,"conflict_of_interest":"Company-authored press release; clinical phase initiation fact is independently verifiable via ClinicalTrials.gov","blacklist_checked":true,"retraction_checked":false,"notes":"TRiM platform dual-target molecule; NHP preclinical data cited internally"}
+{"id":"src_E03","tier":3,"score":6.5,"type":"news","url":"https://biocytogen.com/blogs/dual-target-nucleic-acid-therapeutics-humanized-models","title":"Accelerating Dual-Target Small Nucleic Acid Therapeutics with Humanized Models","year":2025,"venue":"Biocytogen Blog","accessed_at":"2026-04-21","key_claim":"UK Biobank data: combined APOC3+PCSK9 protective alleles confer 10% lower CHD risk vs single allele (citing Wang et al. 2025)","used_in":["ch01"],"authority":1.0,"recency":2.0,"primacy":0.5,"verifiability":0.5,"coi":1.0,"conflict_of_interest":"Commercial vendor blog; Wang et al. 2025 primary citation not directly accessed","blacklist_checked":true,"retraction_checked":false,"notes":"The 10% CHD risk reduction figure requires primary source verification against Wang et al. 2025 UK Biobank publication"}
+{"id":"src_E04","tier":2,"score":7.8,"type":"journal","url":"https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(24)00324-X","title":"Development, opportunities, and challenges of siRNA nucleic acid drugs","year":2025,"venue":"Molecular Therapy Nucleic Acids","accessed_at":"2026-04-21","key_claim":"Six siRNA drugs commercially approved by 2025; clinical trial table includes complement C5 program cemdisiran in Phase 3","used_in":["ch01"],"authority":2.0,"recency":2.0,"primacy":1.0,"verifiability":1.5,"coi":1.0,"conflict_of_interest":"None disclosed","blacklist_checked":true,"retraction_checked":true,"notes":"Open access Cell/Elsevier review; good pipeline table for confirmation of Phase status"}
+{"id":"src_E05","tier":2,"score":7.4,"type":"report","url":"https://tides.wuxiapptec.com/wp-content/uploads/2024/07/Fast-Track-to-Phase-I-Two-siRNA-IND-CMC-Packages_final-approved.pdf","title":"Fast-Track to Phase I: Two siRNA IND CMC Packages Completed in 14 Months","year":2024,"venue":"TIDES Conference / WuXi AppTec","accessed_at":"2026-04-21","key_claim":"Standard GalNAc-siRNA GMP optimization: initial yield 13%/crude purity 18% improved to 62%/75% after process development; 500g GMP batch in 10 months","used_in":["ch01"],"authority":1.5,"recency":2.0,"primacy":1.5,"verifiability":1.5,"coi":0.5,"conflict_of_interest":"CDMO-authored case study; WuXi AppTec has commercial interest in favorable presentation","blacklist_checked":true,"retraction_checked":false,"notes":"Technical detail level suggests genuine process disclosure not purely promotional; specific numbers used in Ch01 for baseline yield quantification"}
+{"id":"src_E06","tier":1,"score":8.8,"type":"journal","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12899625/","doi":"10.3390/molecules31060897","title":"Refined Design and Liquid-Phase Assembly of GalNAc-siRNA Conjugates: Comparative Efficiency Validation in PCSK9 Targeting","year":2026,"venue":"Molecules (MDPI)","accessed_at":"2026-04-21","key_claim":"Commercial GalNAc-preloaded CPG supports have loading below 100 µmol/g hindering industrial-scale synthesis; liquid-phase synthesis enables gram-to-kg scale potential","used_in":["ch01"],"authority":2.0,"recency":2.0,"primacy":2.0,"verifiability":2.0,"coi":1.0,"conflict_of_interest":"None disclosed","blacklist_checked":true,"retraction_checked":true,"notes":"Same paper indexed as src_A03/src_B04/src_C01 in initial scan — used here specifically for CPG loading limitation quote; peer-reviewed primary synthesis paper"}
+{"id":"src_E07","tier":3,"score":5.5,"type":"news","url":"https://www.bocsci.com/research-area/formulating-sirna-for-liver-targeted-delivery-galnac-conjugation-tips.html","title":"GalNAc siRNA Formulation for Liver Targeting — Technical Overview","year":2025,"venue":"BOC Sciences Technical Notes","accessed_at":"2026-04-21","key_claim":"GalNAc cluster as phosphoramidite monomer extends coupling cycle time from 2 min to 6 min due to diffusion limitations in 500 Å CPG pores","used_in":["ch01"],"authority":1.0,"recency":2.0,"primacy":0.5,"verifiability":0.5,"coi":0.5,"conflict_of_interest":"Commercial vendor; cycle-time claim may derive from unpublished internal data","blacklist_checked":true,"retraction_checked":false,"notes":"Cycle-time figure flagged as requiring primary source verification; used only in Ch01 as a directional indicator with appropriate confidence level"}
+{"id":"src_E08","tier":3,"score":6.0,"type":"database","url":"https://synapse.patsnap.com/organization/e8cb014d0dbbc49f59602b29e212c16c","title":"BeBetter Med — Drug pipelines and Clinical Trials (Synapse/Patsnap)","year":2026,"venue":"Patsnap Synapse Database","accessed_at":"2026-04-21","key_claim":"BEBT-701 (AGT+PCSK9) NCT07368608 Phase 1/2 trial registered; start date January 26 2026; sponsor BeBetter Med","used_in":["ch01"],"authority":1.0,"recency":2.0,"primacy":1.0,"verifiability":1.5,"coi":1.0,"conflict_of_interest":"Database aggregator, no inherent conflict","blacklist_checked":true,"retraction_checked":false,"notes":"NCT number and start date confirmed from ClinicalTrials.gov registry via Synapse aggregation"}
+{"id":"src_E09","tier":1,"score":9.0,"type":"journal","url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00507-0/fulltext","doi":"10.1016/S0140-6736(25)00507-0","title":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3)","year":2025,"venue":"The Lancet","accessed_at":"2026-04-21","key_claim":"Solbinsiran Phase 2 PROLONG-ANG3: 205 patients, variable apoB reductions (significant only at 400 mg); 100 mg and 800 mg arms missed primary endpoint — illustrating variable single-target outcomes","used_in":["ch01"],"authority":3.0,"recency":2.0,"primacy":2.0,"verifiability":2.0,"coi":0.0,"conflict_of_interest":"Eli Lilly-sponsored trial; declared industry conflicts among investigators","blacklist_checked":true,"retraction_checked":true,"notes":"Primary counter-evidence for Section CE01; Lancet publication score elevated despite COI because the COI is declared and trial was randomized controlled"}
+{"id":"src_E10","tier":3,"score":6.0,"type":"news","url":"https://www.bioxconomy.com/modalities/dual-targeting-sirnas-could-treat-complex-genetic-diseases","title":"Dual-targeting siRNAs could treat complex genetic diseases","year":2024,"venue":"Bioxconomy","accessed_at":"2026-04-21","key_claim":"Dual-target siRNAs present doubled off-target risk surface; 'careful safety evaluation will be essential in future translational studies' (citing Sugimoto et al.)","used_in":["ch01"],"authority":1.0,"recency":2.0,"primacy":0.5,"verifiability":0.5,"coi":1.0,"conflict_of_interest":"Independent science journalism; Sugimoto primary citation not directly accessed","blacklist_checked":true,"retraction_checked":false,"notes":"Counter-evidence source CE02; primary Sugimoto publication should be located for stronger citation in Ch01 future revision"}
+{"id":"src_E23","tier":2,"score":7.8,"type":"report","url":"https://capella.alnylam.com/wp-content/uploads/2025/02/Alnylam-RD-Day-2025.pdf","title":"Alnylam R&D Day 2025 — GEMINI platform preclinical data (ANGPTL3+AGT dual siRNA single entity)","year":2025,"venue":"Alnylam Pharmaceuticals R&D Day","accessed_at":"2026-04-21","key_claim":"GEMINI combines two siRNAs in a single chemical entity; GEMINI-CVR targets ANGPTL3+AGT with biannual dosing goal; preclinical data show superior dual knockdown vs mixture","used_in":["ch03"],"authority":1.5,"recency":2.0,"primacy":1.5,"verifiability":1.5,"coi":0.5,"conflict_of_interest":"Company R&D Day; technical content primary; corroborated by 10-K SEC filing","blacklist_checked":true,"retraction_checked":false,"notes":"Alnylam 2024 10-K (alny-20241231) independently corroborates GEMINI platform description and pre-IND status"}
+{"id":"src_E24","tier":2,"score":7.2,"type":"database","url":"https://www.ribolia.com/en/pipeline/pipeline/core-pipeline","title":"Suzhou Ribo Life Science — Core Pipeline (RBD4059 Phase 2, RBD5044 Phase 2, RBD7022 Phase 2)","year":2026,"venue":"Ribo IR / HKEX 06938","accessed_at":"2026-04-21","key_claim":"7 clinical-stage single-target assets; dual-target in active R&D under RiboGalSTAR™; no dual-target IND as of April 2026","used_in":["ch03"],"authority":1.5,"recency":2.0,"primacy":1.5,"verifiability":1.0,"coi":0.5,"conflict_of_interest":"Company IR page; corroborated by ESC 2025 presentations and pharmaphorum independent coverage","blacklist_checked":true,"retraction_checked":false,"notes":"Ribo IPO raised HKD 1.59B on HKEX Jan 2026; pipeline page is real-time updated"}
+{"id":"src_E25","tier":2,"score":7.5,"type":"news","url":"https://www.ribolia.com/en/media-center/our-products-news/50","title":"Ribo ESC 2025 — RBD5044 Phase I: 84% APOC3 knockdown sustained at 6-month follow-up; RBD7022 Phase I: 75% PCSK9 max reduction at 6 months","year":2025,"venue":"Ribo Press Release / ESC 2025","accessed_at":"2026-04-21","key_claim":"RBD5044 single injection: 84% APOC3 knockdown sustained through 6-month follow-up; supports Q6M dosing; well-tolerated","used_in":["ch03"],"authority":1.5,"recency":2.0,"primacy":1.5,"verifiability":1.5,"coi":0.5,"conflict_of_interest":"Company press release; clinical data presented at peer-reviewed conference (ESC 2025)","blacklist_checked":true,"retraction_checked":false,"notes":"ESC 2025 presentation is independent conference review; multiple Ribo assets presented same day"}
+{"id":"src_E26","tier":3,"score":6.2,"type":"news","url":"https://www.phirda.com/artilce_41242.html","title":"2026最热：小核酸龙头来了 — Ribo IPO strategy and dual-target R&D roadmap","year":2026,"venue":"China Medical Innovation Association (phirda.com)","accessed_at":"2026-04-21","key_claim":"Ribo explicitly prioritizes dual-target and multi-target technology breakthroughs; RSC 2.0 modification system; RiboGalSTAR™ liver delivery","used_in":["ch03"],"authority":1.0,"recency":2.0,"primacy":0.5,"verifiability":0.5,"coi":0.5,"conflict_of_interest":"Association publication; corroborates HKEX prospectus language; dual-target R&D priority confirmed","blacklist_checked":true,"retraction_checked":false,"notes":"Used for strategic context only; Ribo HKEX prospectus is the primary source for dual-target R&D priority claim"}
+{"id":"src_E27","tier":2,"score":7.4,"type":"news","url":"https://pharmaphorum.com/news/rna-specialist-ribo-files-205m-ipo-hong-kong","title":"RNA specialist Ribo files $205m IPO in Hong Kong — 7 clinical assets, dual-target in R&D","year":2026,"venue":"pharmaphorum","accessed_at":"2026-04-21","key_claim":"Ribo HKD 1.59B IPO; 7 clinical-stage assets; Boehringer Ingelheim MASH + Qilu dyslipidaemia partnerships >$2B combined; RiboGalSTAR™ dual-target extension in development","used_in":["ch03"],"authority":1.5,"recency":2.0,"primacy":0.5,"verifiability":1.5,"coi":1.0,"conflict_of_interest":"Independent trade press (pharmaphorum); no conflict; corroborates HKEX prospectus data","blacklist_checked":true,"retraction_checked":false,"notes":"Pharmaphorum is Tier 2 trade media; independent confirmation of Ribo pipeline and partnership data"}
+{"id":"src_E28","tier":2,"score":7.5,"type":"news","url":"https://www.argobiopharma.com/news/111.html","title":"Argo Biopharma: BW-00163 (AGT siRNA) advances to Phase 2; Novartis milestone payment; $4B+ total deal value","year":2025,"venue":"Argo Biopharma Press Release","accessed_at":"2026-04-21","key_claim":"BW-00163 progressed to Phase 2 via Novartis June 2025; $185M upfront + $4B+ total potential from Jan 2024 deal for two cardiovascular assets","used_in":["ch03"],"authority":1.5,"recency":2.0,"primacy":1.5,"verifiability":1.5,"coi":0.5,"conflict_of_interest":"Company press release; deal terms independently referenced in VCBeat and Novartis regulatory filings","blacklist_checked":true,"retraction_checked":false,"notes":"NCT06857955 (BW-00163 Phase 2 Novartis-sponsored) independently registered on ClinicalTrials.gov"}
+{"id":"src_E29","tier":2,"score":7.6,"type":"news","url":"https://www.prnewswire.com/news-releases/argo-biopharma-doses-first-patients-in-phase-ii-clinical-trials-of-sirna-therapy-bw-40202-302747128.html","title":"Argo Biopharma doses first patients in Phase II trials of BW-40202 (CFB siRNA, PNH + IgAN)","year":2026,"venue":"PR Newswire / Argo Biopharma","accessed_at":"2026-04-21","key_claim":"First patient dosed April 20, 2026 in Phase II BW-40202 trials for PNH and IgAN; BW-40202 is single-target CFB siRNA; RADS™ platform","used_in":["ch03"],"authority":1.5,"recency":2.0,"primacy":1.5,"verifiability":1.5,"coi":0.5,"conflict_of_interest":"Company press release on PR Newswire; independently corroborated by CTR20252839 registry","blacklist_checked":true,"retraction_checked":false,"notes":"Very recent (April 20, 2026); confirmed in both NMPA ChiCTR registry and Australian IND registry"}
+{"id":"src_E30","tier":2,"score":7.2,"type":"database","url":"https://sirnaomics.com/en/science-pipeline/pipeline/","title":"Sirnaomics Pipeline — muRNA dual-target programs STP271G (PCSK9+ANGPTL3), STP237G (AGT+APOC3), STP247G (CFB+C5)","year":2026,"venue":"Sirnaomics (HKEX 2257)","accessed_at":"2026-04-21","key_claim":"Sirnaomics has 3+ preclinical muRNA dual-target programs; PDoV-GalNAc scaffold also preclinical; muRNA design confirmed as single-molecule by RSC Med Chem 2025","used_in":["ch03"],"authority":1.5,"recency":2.0,"primacy":1.5,"verifiability":1.0,"coi":0.5,"conflict_of_interest":"Company pipeline page; muRNA architecture independently described in RSC Medicinal Chemistry review 2025","blacklist_checked":true,"retraction_checked":false,"notes":"PDoV-GalNAc and GalAhead™ muRNA are distinct Sirnaomics scaffolds; both preclinical for dual-target programs"}
+{"id":"src_E31","tier":2,"score":7.0,"type":"news","url":"https://www.stcn.com/article/detail/3343990.html","title":"迈威生物 (688062) 2MW7141 dual-target siRNA licensed to Kalexo Bio; ≤$1B deal value","year":2025,"venue":"Securities Times (STCN) / Shanghai STAR Market regulatory disclosure","accessed_at":"2026-04-21","key_claim":"2MW7141 is preclinical-stage dual-target siRNA for lipid abnormalities; ≤$1B deal with Kalexo (Aditum Bio); target identity undisclosed; first-in-class non-LNP delivery claimed","used_in":["ch03"],"authority":1.5,"recency":2.0,"primacy":1.5,"verifiability":1.0,"coi":0.5,"conflict_of_interest":"STCN aggregates Shanghai STAR Market regulatory disclosures; 688062 is publicly listed company; deal terms are formal disclosure","blacklist_checked":true,"retraction_checked":false,"notes":"STCN (Securities Times) is official SHEX disclosure channel; deal value constitutes mandatory regulatory disclosure for listed company"}
+{"id":"src_E32","tier":2,"score":7.3,"type":"news","url":"https://www.caixinglobal.com/2026-02-27/chinas-biotech-push-into-small-nucleic-acid-drugs-draws-global-pharma-102417490.html","title":"China's Biotech Push Into Small Nucleic Acid Drugs Draws Global Pharma (Caixin Global Feb 2026)","year":2026,"venue":"Caixin Global","accessed_at":"2026-04-21","key_claim":"Over 100 Chinese small nucleic acid drug pipelines by Jan 2026 (Insight data); global siRNA market $2.7B (2019) to $5.7B (2024); >$36B in 2025 sector transactions","used_in":["ch03"],"authority":1.5,"recency":2.0,"primacy":0.5,"verifiability":1.5,"coi":1.0,"conflict_of_interest":"Caixin is independent financial journalism; data attributed to Huaxi Securities and Insight database","blacklist_checked":true,"retraction_checked":false,"notes":"Caixin is premium financial media with editorial standards; the 100+ pipeline figure should be treated as directional (definitionally broad)"}
+{"id":"src_E11","tier":1,"score":7.2,"type":"journal","url":"https://www.sciencedirect.com/science/article/abs/pii/S0168365914004118","doi":"10.1016/j.jconrel.2014.07.049","title":"Disulfide-Containing Parenteral Delivery Systems and Their Redox-Biological Fate","year":2014,"venue":"Journal of Controlled Release","accessed_at":"2026-04-21","key_claim":"Intracellular GSH 1–10 mM; extracellular plasma GSH ~2–20 µM; ~500-fold gradient drives selective intracellular disulfide cleavage for siRNA delivery","used_in":["ch02"],"authority":2.0,"recency":0.6,"primacy":2.0,"verifiability":1.5,"coi":1.0,"conflict_of_interest":"None disclosed; academic review","blacklist_checked":true,"retraction_checked":true,"notes":"Foundational redox biology review; mechanism unchanged since publication; score adjusted for age (-0.6 recency penalty for 12-year-old paper in stable-mechanism category)"}
+{"id":"src_E12","tier":2,"score":7.5,"type":"journal","url":"https://www.chromatographyonline.com/view/analysis-of-sirna-with-denaturing-and-non-denaturing-ion-pair-reversed-phase-liquid-chromatography-methods","title":"Analysis of siRNA with Denaturing and Non-Denaturing Ion-Pair Reversed-Phase Liquid Chromatography Methods","year":2023,"venue":"LCGC International","accessed_at":"2026-04-21","key_claim":"Denaturing IP-RPLC separates hetero-duplex, homo-duplex, and single-strand populations in dual-siRNA constructs; method validation requirements described","used_in":["ch02"],"authority":1.5,"recency":2.0,"primacy":1.5,"verifiability":1.5,"coi":1.0,"conflict_of_interest":"None disclosed; analytical methods article","blacklist_checked":true,"retraction_checked":false,"notes":"Professional analytical methods journal; specific siRNA duplex separation method validation described; supports hetero-duplex QC claim for covalent tandem paradigm"}
+{"id":"src_E13","tier":1,"score":8.6,"type":"journal","url":"https://pubs.rsc.org/en/content/articlehtml/2023/cs/d2cs00788f","doi":"10.1039/D2CS00788F","title":"Targeted delivery of oligonucleotides using multivalent protein-carbohydrate interactions","year":2023,"venue":"Chemical Society Reviews (RSC)","accessed_at":"2026-04-21","key_claim":"Alnylam triantennary GalNAc Kd = 2.3 nM for ASGPR; 10^6-fold affinity gain from mono to triantennary; tetraantennary only modest further improvement; cluster effect mechanism","used_in":["ch02"],"authority":2.5,"recency":2.0,"primacy":1.5,"verifiability":2.0,"coi":1.0,"conflict_of_interest":"None disclosed; independent academic review","blacklist_checked":true,"retraction_checked":true,"notes":"Chem Soc Rev high IF; comprehensive review of multivalent carbohydrate-ASGPR binding; Kd = 2.3 nM value confirmed from Nair et al. JACS 2014 primary data cited within"}
+{"id":"src_E14","tier":1,"score":7.5,"type":"regulatory","url":"https://www.ich.org/page/quality-guidelines","title":"ICH Q6A — Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and Drug Products (Chemical Substances)","year":1999,"venue":"ICH / FDA / EMA","accessed_at":"2026-04-21","key_claim":"Specifications framework for drug substance identity and purity; mixture-API composition ratio control requirements; <5% CV inference for fixed-composition mixture products","used_in":["ch02"],"authority":2.0,"recency":0.5,"primacy":2.0,"verifiability":2.0,"coi":1.0,"conflict_of_interest":"None; regulatory guidance","blacklist_checked":true,"retraction_checked":false,"notes":"Still-authoritative ICH guidance; specific <5% CV figure for siRNA cocktail composition is inferred not explicitly stated — flagged as unverified in evidence table C15; recommend FDA OPQ consultation"}
+{"id":"src_E15","tier":1,"score":8.3,"type":"journal","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5762979/","doi":"10.1016/j.omtn.2017.11.010","title":"Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression","year":2017,"venue":"Molecular Therapy Nucleic Acids","accessed_at":"2026-04-21","key_claim":"Triantennary GalNAc-ASGPR Kd ~2 nM; ASGPR receptor saturation documented at doses >5 mg/kg; in silico model parameters: Kd=2nM, kon=1e5 M-1s-1, ASGPR ~600 nM intrahepatic","used_in":["ch02"],"authority":2.0,"recency":1.0,"primacy":2.0,"verifiability":2.0,"coi":1.0,"conflict_of_interest":"Alnylam-affiliated authors; declared; data directly relevant and specific","blacklist_checked":true,"retraction_checked":true,"notes":"Key quantitative ASGPR saturation data; Kd value corroborates src_E13; saturation threshold at >5 mg/kg provides basis for cocktail receptor saturation counter-argument; COI declared and methodology sound"}
+{"id":"src_E40","tier":1,"score":8.0,"type":"journal","url":"https://pubs.acs.org/doi/10.1021/acs.oprd.4c00188","doi":"10.1021/acs.oprd.4c00188","title":"Acetonitrile Regeneration from Oligonucleotide Production Waste","year":2024,"venue":"Organic Process Research & Development (ACS)","accessed_at":"2026-04-21","key_claim":"Approximately 85% of total acetonitrile usage in SPOS is consumed during synthesis wash steps","used_in":["ch04"],"authority":2.0,"recency":2.0,"primacy":2.0,"verifiability":2.0,"coi":1.0,"conflict_of_interest":"None disclosed","blacklist_checked":true,"retraction_checked":false,"notes":"ACS OPR&D primary paper on solvent use in oligo manufacturing; 85% stat is key for PMI analysis"}
+{"id":"src_E41","tier":2,"score":6.8,"type":"report","url":"https://synergbiopharma.com/wp-content/uploads/2025/10/SynerG_SPOS-and-LPOS_whitepaper.pdf","title":"Solid-Phase Oligonucleotide Synthesis (SPOS) and Liquid-Phase Oligonucleotide Synthesis (LPOS): A Comparative Review","year":2025,"venue":"SynerG BioPharma White Paper","accessed_at":"2026-04-21","key_claim":"PMI for 20-mer therapeutic oligos: 3,035–7,023 (avg 4,299); MeCN consumption up to 1,000 kg/kg API; AJIPHASE 21-mer siRNA: 60% yield, >90% purity","used_in":["ch04"],"authority":1.5,"recency":2.0,"primacy":1.0,"verifiability":1.5,"coi":0.5,"conflict_of_interest":"CDMO-affiliated white paper; PMI data cites published sources; AJIPHASE claim cites Ajinomoto","blacklist_checked":true,"retraction_checked":false,"notes":"Useful aggregator of SPOS/LPOS comparative data; primary sources should be traced where possible"}
+{"id":"src_E42","tier":1,"score":8.5,"type":"journal","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11071452/","title":"Biochemical and structural insights into a 5' to 3' RNA ligase — T4 RNA Ligase 1 substrate requirements","year":2024,"venue":"PMC / Nucleic Acids Research","accessed_at":"2026-04-21","key_claim":"T4 RNA Ligase 1 requires 5'-phosphate, 3'-hydroxyl, and free 2'-hydroxyl; substrate incompatible with 2'-OMe at ligation junction in wild-type form","used_in":["ch04"],"authority":2.0,"recency":2.0,"primacy":2.0,"verifiability":2.0,"coi":1.0,"conflict_of_interest":"None disclosed","blacklist_checked":true,"retraction_checked":false,"notes":"Primary mechanistic constraint paper for T4 Rnl1; key for explaining why engineered ligases are required for 2'-modified siRNA ligation"}
+{"id":"src_E43","tier":2,"score":7.8,"type":"news","url":"https://ir.codexis.com/news-events/press-releases/detail/442/codexis-signs-agreement-to-manufacture-50-g-sirna-using-its-eco-synthesis-manufacturing-platform","title":"Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform","year":2026,"venue":"Codexis IR Press Release","accessed_at":"2026-04-21","key_claim":"Codexis agreed in March 2026 to manufacture 50 g siRNA for a cardiovascular indication preclinical program via ECO Synthesis; confirms commercial traction","used_in":["ch04"],"authority":1.5,"recency":2.0,"primacy":1.5,"verifiability":2.0,"coi":0.5,"conflict_of_interest":"Company press release; fact of agreement independently verifiable from IR filing","blacklist_checked":true,"retraction_checked":false,"notes":"March 4, 2026 announcement; confirms ECO Synthesis is at commercial engagement stage"}
+{"id":"src_E44","tier":2,"score":7.5,"type":"news","url":"https://www.globenewswire.com/news-release/2023/07/24/2709622/0/en/GreenLight-Announces-Completion-of-Merger-with-Fall-Line-Endurance-Fund.html","title":"GreenLight Announces Completion of Merger with Fall Line Endurance Fund — $45.5M go-private transaction, July 24, 2023","year":2023,"venue":"GlobeNewswire / Goodwin Law","accessed_at":"2026-04-21","key_claim":"GreenLight Biosciences Holdings taken private July 24, 2023 at $45.5M; surviving entity pivoted exclusively to agriculture RNA (Calantha, Norroa); therapeutic siRNA program discontinued","used_in":["ch04"],"authority":1.5,"recency":1.5,"primacy":1.5,"verifiability":2.0,"coi":1.0,"conflict_of_interest":"None — factual M&A announcement","blacklist_checked":true,"retraction_checked":false,"notes":"CRITICAL CORRECTION: GreenLight did NOT go bankrupt; it was acquired and pivoted to agriculture. The $1/g IVT cost claim applies to agricultural unmodified dsRNA only, not therapeutic siRNA"}
+{"id":"src_E45","tier":2,"score":7.0,"type":"report","url":"https://d1io3yog0oux5.cloudfront.net/_f07ef482839a89d64e69eb116fc3ecf6/codexis/db/1165/11842/pdf/CDXS+TIDES+EU+Presentation+November+2023.pdf","title":"Revolutionizing Nucleic Acid Synthesis with Engineered Enzymes — Codexis TIDES EU 2023 Presentation (TdT engineering)","year":2023,"venue":"Codexis / TIDES Europe Conference","accessed_at":"2026-04-21","key_claim":"Iterative TdT evolution showing progressive improvement in 2'-OMe and 2'-F modified NQP incorporation efficiency across multiple evolution rounds","used_in":["ch04"],"authority":1.5,"recency":1.5,"primacy":1.5,"verifiability":1.5,"coi":0.5,"conflict_of_interest":"Company presentation; data appears genuine process development disclosure","blacklist_checked":true,"retraction_checked":false,"notes":"2023 TIDES EU presentation; shows TdT engineering in progress for modified RNA; current status (2025-2026) per DeciBio Q&A suggests still not at GMP-ready stage for full alternating 2'-OMe/2'-F 21-mers"}